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Abstract 34 
Controversy exists regarding the potential association between taking calcium channel 35 
blockers (CCBs) and the development of breast cancer. As a positive association 36 
would have important public health implications due to the widespread use of CCBs, 37 
this study aimed to incorporate new evidence to determine whether an association is 38 
likely to exist. We searched MEDLINE, EMBASE and the Cochrane Library to 28 39 
June 2016 for relevant literature. References and citing articles were checked and 40 
authors contacted as necessary. Two authors independently selected articles and 41 
extracted data. Twenty-nine studies were reviewed; 26 were non-randomised studies 42 
(NRS). Meta-analysis of study data where adjustment for ‘confounding by indication’ 43 
was judged to be present suggests that an association, if any, is likely to be modest in 44 
magnitude (pooled odds/risk ratio 1.09 (95% confidence interval (CI) 1.03 – 1.15, I2 = 45 
0%, 8 sub-studies; pooled hazard ratio 0.99 (95% CI 0.94 – 1.03, I2 = 35%, 9 sub-46 
studies)). There are credible study data showing an increased relative risk with long-47 
term use of CCBs, but the results of our meta-analysis and of meta-regression of log 48 
relative risk against minimum follow-up time are mixed. The current summative 49 
evidence does not support a clear association between taking CCBs and developing 50 
breast cancer. However, uncertainty remains, especially for long-term use and any 51 
association might not be uniform between different populations and/or breast cancer 52 
sub-types. We thus recommend further NRS in settings where CCB use is highly 53 
prevalent and population-based cancer, prescription and health-registries exist, to 54 
resolve this continuing uncertainty. PROSPERO, CRD42015026712.  55 
 56 
Keywords: calcium channel blockers, breast neoplasms, dihydropyridines, 57 
amlodipine, nifedipine, verapamil.  58 




 In 2013 a large case-control study linked long-term calcium channel blocker 61 
(CCB) use with breast cancer.  62 
 Since then, research groups have conducted studies to confirm/refute this 63 
association.  64 
 Our systematic review and meta-analysis critically reviewed relevant studies 65 
to 2016.  66 
 While an association seems unlikely, there remains uncertainty for use beyond 67 
10 years.  68 
 We recommend further investigation of long-term use to provide further 69 
reassurance.  70 
  71 
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1. Introduction1 72 
Calcium channel blockers (CCBs) are considered first-line treatment for hypertension, 73 
with a common aim of preventing downstream morbidity and premature mortality (1). 74 
In Australia during 2015, amlodipine was the fourth most commonly dispensed drug 75 
in the community, with 41.35 doses prescribed/1000 population daily (equating to 76 
over 350 million doses annually) (2). Whether CCBs have a role in the development 77 
of breast cancer has been a topic of interest to many research groups (editorialised in 78 
(3)). With one in eight Australian women by age 85 years diagnosed with breast 79 
cancer, and 15,902 Australian women diagnosed with breast cancer in 2013, breast 80 
cancer is second only to lung cancer as the most common cause of death from cancer 81 
in Australian women (4, p. 86). One study found that in American women 58% of 82 
early stage breast cancer patients were prescribed an antihypertensive medication (5). 83 
Because of the widespread use of CCBs and the commonly preventive therapeutic 84 
aim, ongoing risk assessment is appropriate. 85 
 86 
The hypothesised mechanism for CCBs increasing the risk of developing cancer is 87 
through decreased influx of calcium inhibiting apoptosis. The plausibility of this 88 
hypothesis was reviewed by Mason (6), who considered studies showing CCB-related 89 
inhibited apoptosis of non-cancerous cells (7-10), and others showing the opposite 90 
effect (11-14). Despite inconclusive evidence supporting a biological mechanism for 91 
breast cancer potentiation by CCBs, observational data supporting an association has 92 
continued to emerge. Known risk factors for cancer, such as obesity (15, 16) and 93 
                                               
1 Abbreviations used in this paper: AHT = antihypertensive drug, CCB = calcium 
channel blocker, CI = confidence interval, HR = hazard ratio, NRS = non-randomised 
study, OR = odds ratio, PICOS = population, intervention, comparator, outcome, 
setting, RCT = randomised controlled trial, SIR = standardised incidence ratio. 
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excessive alcohol consumption (17, 18), may confound the association between CCBs 94 
and breast cancer, or conversely interact to potentiate breast cancer, in a way difficult 95 
to predict via pre-clinical studies or detect through randomised controlled trials 96 
(RCTs). 97 
  98 
As this remains a source of controversy, a critical review assessing whether there is an 99 
association is warranted. This study aimed to either: confirm whether an association 100 
between taking CCBs and developing breast cancer is plausible, or conclude that a 101 
definitive answer is not possible at this time and make measured recommendations for 102 
further research to resolve continuing uncertainty.  103 
2. Methods 104 
Cochrane guidelines formed the basis of this study design (19); the reporting follows 105 
the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement 106 
(20).  107 
2.1 Protocol and registration 108 
On 7 September 2015, a crude PubMed search was conducted: ‘calcium AND channel 109 
AND blockers AND breast AND cancer’. This search indicated that two meta-110 
analyses have recently been published on the same topic, though no comprehensive 111 
and critical systematic review was returned from this search (21, 22). Given the 112 
importance of critical appraisal, as well as meta-analysis of the literature, and that 113 
there has been progress in this area since 2013 when the searches for these meta-114 
analyses were conducted, we considered there was scope to expand upon existing 115 
meta-analyses. A study protocol including study eligibility criteria was registered on 116 
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PROSPERO on 6 October 2015 (Appendix A), at which time there were no other 117 
registered reviews on this topic (CRD42015026712) (23).  118 
2.2 Eligibility criteria 119 
Eligibility criteria followed the population, intervention, comparator, outcome, setting 120 
(PICOS) format.  121 
2.2.1 Inclusion criteria  122 
P: the general human population from any setting, or any specified subpopulation (not 123 
including studies utilising cell lines, even if human-derived). Even though breast 124 
cancer affects predominantly females, there was no restriction placed on sex for this 125 
criterion;  126 
I: taking a CCB (Anatomical Therapeutic Classification System: C08 (24)), of any 127 
sub-class (i.e. (non)-dihydropyridine) or release-type (i.e. immediate- or sustained-128 
release);  129 
C: persons not taking a CCB (i.e. taking another class/es of antihypertensive drug 130 
(AHT) or no AHT); 131 
O: development of newly diagnosed breast cancer of any type or level of severity, 132 
however diagnosed or assessed. If cancer overall was reported for a study, this could 133 
still be included as long as breast cancer as an outcome in the context of CCB as an 134 
exposure had a separate relative risk reported; 135 
S: any original research (therefore, not including editorials or commentary where no 136 
new data are generated or syntheses performed), regardless of quality.  137 
2.2.2 Exclusion criteria  138 
Systematic or narrative reviews, case studies, case reports or studies without a full-139 
text version in English were excluded.  140 
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2.3 Information sources and search strategy 141 
MEDLINE (via OVID), EMBASE (via OVID) and the Cochrane Library were 142 
searched from inception to 28 June 2016. Search terms (Appendix B), chosen in 143 
consultation with a specialist librarian, included Medical Subject Headings/EMTREE 144 
and free-text terms and were grouped into: <terms related to CCBs (e.g. “exp calcium 145 
channel blockers/”)> AND <terms relating to breast cancer (e.g. “exp breast 146 
neoplasms/”) > AND <limits to restrict to studies in humans only>. Unduplicated 147 
references of included studies and relevant meta-analyses (21, 22) were screened, 148 
along with unduplicated citing articles, identified via Web of Science on 28 June 149 
2016. We contacted the authors of eligible conference abstracts, requesting a copy of 150 
the conference poster or presentation slides.  151 
2.4 Study selection and data collection 152 
Two authors independently selected articles (CMW & JDH), assessing the 153 
title/abstract and then the full-text articles against each eligibility criterion in-turn. 154 
Data were extracted by three co-authors (CMW, n = 29, JDH, n = 7, EKC, n=22), 155 
using a pre-specified template (based on (25)). Disagreements in article selection or 156 
data extraction were resolved through discussion between the two relevant co-authors.  157 
2.5 Synthesis of results 158 
We performed a DerSimonian-Laird random effects meta-analysis (26). Studies were 159 
separated into: a) CCB versus no CCB, and; b) CCB versus another AHT, or CCB 160 
versus no CCB but with only hypertensive patients analysed, or CCB versus no CCB 161 
where adjustment was made for hypertension and/or use of other AHTs. Mutually 162 
exclusive sub-cohorts for which relative risks were reported within a single study, or 163 
where analyses were only performed separating by breast cancer type, or sub-164 
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analysed versus another AHT or in hypertensive patients only, were treated as 165 
separate studies. Where studies compared CCBs to no CCBs, adjusted for 166 
hypertension/other AHTs and sub-analysed for only those taking AHTs or with a 167 
diagnosis of hypertension, the main analysis was included in the CCB versus no CCB 168 
meta-analysis (i.e. a)) and the sub-analysis/es included in the CCB versus other AHT 169 
meta-analysis (i.e. b)). This meant that analysis/es from a given study most adjusted 170 
for ‘confounding by indication’ was included in the CCB versus other AHT meta-171 
analysis. As there was some question as the suitability of combining such diverse 172 
studies, we did not perform further meta-analysis for sub-type of CCB/breast cancer. 173 
Studies reporting risk and odds ratios were analysed together, as breast cancer was 174 
generally a rare outcome. Studies reporting standardised incidence ratios or hazard 175 
ratios were analysed separately to one another and to studies reporting a risk or an 176 
odds ratio, as these relative risk measurements communicate different information. 177 
The adjusted relative risks reported were used for the meta-analysis, with the standard 178 
error back calculated by the mean of the difference between the point estimate and the 179 
upper and lower 95% confidence intervals, divided through by 1.96. No studies were 180 
excluded based on quality, though this was subject to some sensitivity analysis (see 181 
‘risk of bias’ section below). We performed meta-regression of log-relative risk 182 
versus minimum follow-up time in single years, separating studies as described 183 
above. Finally, we repeated analyses for studies including female breast cancer only. 184 
Heterogeneity was described using the I2 statistic, where 0% indicates no inter-study 185 
heterogeneity up to 100% (27). Publication bias was explored through visual 186 
examination of Funnel plots and calculation of the Egger’s statistic (28). Analyses 187 
were performed using Stata SE (Version 13.1, College Station, Texas), using the 188 
metaan command for the meta-analyses (29).  189 
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 190 
2.6 Risk of bias  191 
The RTI Item Bank was used to qualitatively assess the risk of bias for both 192 
randomised and non-randomised studies (30). The Newcastle-Ottawa scale was used 193 
to assess the quality of non-randomised studies, with different criteria for (nested) 194 
case-control studies and cohort studies in the areas of selection (four possible stars), 195 
comparability (two possible stars), and exposure (three possible stars). In keeping 196 
with the authors of one of the 2014 meta-analyses (21), we considered seven or more 197 
stars to be ‘high quality’ (31). The quality of included randomised controlled trials 198 
was assessed as very low, low, moderate, or high, using the Grading of 199 
Recommendations, Assessment, Development and Evaluation criteria (32). For the 200 
meta-analysis some sensitivity analysis was performed removing low quality studies. 201 
Risk of bias and quality assessments were undertaken by one author (CMW).  202 
3. Results 203 
3.1 Study selection 204 
Database searching returned 2,099 unduplicated records of which 58 articles 205 
underwent full-text review. Twenty articles fulfilled the eligibility criteria (33-52). 206 
One conference abstract (53) was excluded after contacting the senior author for this 207 
study, who indicated that these data were to be re-analysed prior to writing up the 208 
study in full. A further 956 unduplicated articles were identified via reference and 209 
citation checking; nine of these fulfilled the eligibility criteria (54-62). For the three 210 
eligible records only available as conference abstracts (42, 49, 51), the authors sent a 211 
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copy of the presentation upon request. Figure 1 details article selection flow. 212 
Appendix C lists rejected articles undergoing full-text review.  213 
3.2 Study characteristics 214 
A summary of included study results is provided in Table 1, with full extracted data 215 
provided in Appendix D. Studies were published from 1996 through 2016 and 216 
included > 1.4 million participants (for some studies the exact participant number was 217 
not clear) of varying ages. Not all studies specified the sex of incident breast cancer, 218 
but the vast majority of studies (n=21) considered female breast cancer only (34-47, 219 
49-52, 57, 58, 61). For example, one study included women aged 55 to 74 years (46), 220 
whereas an earlier study had a mean age of 79 years (60).  The length of follow-up 221 
varied, with some studies conducting a discrete analysis for CCB use exceeding 10 222 
years (37, 45, 46, 49, 51). The majority of studies (27/29) used data from Europe or 223 
North America, with the exception of two recent studies from Taiwan (35, 44). 224 
Twenty-six were non-randomised studies (NRS), utilising nested case-control (33, 35, 225 
40, 54, 56), case-control (34, 36, 44-47, 61) or cohort designs (37-39, 41-43, 49-52, 226 
55, 58-60). The remainder were RCTs (48, 57, 62). Three sets of studies analysed the 227 
same or similar cohort over different time periods ((58) & (37), (38) & (50), (39, 52, 228 
59)). Three of the case-control analyses studied a population from he same area (36, 229 
45, 46). 230 
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Table 1. Summary of included studies (abbreviations not defined in table are defined below1).  231 
Study author(s) and 
year of publication  
Setting Study Design  Number of participants  Main results Notes, for more details see Appendix C.  




Study period  
1 January 1980 –  
31 December 2003. 
Nested case-control  
CCB (but not thiazide 
diuretic) versus 
thiazide diuretic (but 
not CCB) [ref] 
CCB any duration:  
92 cases; 927 controls.  
Thiazide:  
972 cases; 9213 controls. 
  




 Used population-based registries. 
 Total use CCB versus thiazide diuretic > 7.5 
years – aOR 0.73 (95% CI 0.43 – 1.23) 
Azoulay et al. 2012 
(33) 
United Kingdom  
Study period  
1 January 1995 –  
31 December 2010.  
Nested case-control  
CCB versus diuretics 
+/- beta-blockers [ref] 
CCB use:  
2,070 cases; 21,160 controls.  
Diuretics +/- beta-blockers: 
2,153 cases; 24,426 controls.  
aRR  
0.98 (95% CI 0.92 – 1.04)  
 
 Used UK General Practice Research 
Database (GPRD).  
 
Bergman et al. 2014 
(34) 
Sweden  
Study period  
1 January 2006 –  
31 December 2011. 
Case-control  
Continuous use (2006 
– 10), versus no 
continuous use [ref] 
CCB continuous use:  
148 cases; 719 controls.  
No continuous use: 
3,134 cases; 15,765 controls.  
aOR 1.1 (95% CI 0.9 – 
1.3)  
 Used population-based registries. 
 95% CI of aOR for duration-response 
analysis all crossed unity value of 1.  




Study period  
1 January 2001 – 31 
December 2011. 
Nested case-control  
CCB use versus never 
use [ref] 
Main cohort. 
Any CCB use:  
3,529 cases; 10,909 controls.  
No CCB use: 5,868 cases; 
26,679 controls.  
aOR 1.39 (95% CI 1.14 – 
1.69). 
 Used population-based registries. 
 For sub-cohort of AHT users, aOR = 1.21 
(95% CI 0.88 – 1.67). 
 For sub-cohort diagnosed with hypertension, 
aOR = 1.71 (95% CI 0.99 – 2.95). 
Davis & Mirick 2007 
(36) 
Seattle, United States 
Study interviews:  
March 2000 –  
December 2001.  
Case-control 
CCB ever user versus 
CCB never use [ref]  
CCB ever use:  
38 cases; 36 controls.  
CCB never use:  
509 cases; 560 controls.  
 
aOR 1.4 (95% CI 0.9 – 
2.4).  
 
 Questionnaire-based study utilising 
participants from a case-control study 
conducted five years previously. Cases 
originally diagnosed with breast cancer 
between November 1992 and March 1995. 
 No clear duration/recency-response trend.  
Devore  et al. 2015 
(37) 
United States  
Study period:  
Assessment of outcome 1 
June 1988 – 1 June 2012 
for Nurses’ Health Study 
(NHS) cohort;  
1 June 1989 – 1 June 
2011 for NHS II cohort.   
Cohort  
CCB current use 
versus past/never us 
[ref]  
NHS I –  
CCB current use: 640 
events/144,242 PYs  
Past/never use: 6,077 
events/1,634,906 PYs  
NHS II –  
CCB current use: 87 
events/47,431 PYs  
Past/never use: 3,025 
events/1,925,448 PYs  
NHS I  –  
aHR 1.07 (95% CI 0.99-
1.17) 
NHS II –  





 Questionnaire-based data collection, some 
of same cohort as earlier study by Michels et 
al. (58).  
 Restriction to hypertensive women only and 
assessment of consistency of use yielded 
aHR with 95% CIs crossing unity value of 1.  
 For NHS I, aHR of 1.36 (95% CI 1.09 – 
1.70) for oestrogen-receptor –ve breast 
cancer, though 95% CI for aHR for this 
analysis in NHS II crossed unity value.  
Fitzpatrick et al. 1997 
(38) 
United States 
Study period  
1989/90 – December 
1994 for original cohort; 
1992/93 – December 
Cohort  
CCB use versus no use 
[ref] 
CCB use:  
20 events/ 759 participants.  
No use:  
55 events/ 2,439 participants  
aHR 2.57 (95% CI 1.47 – 
4.49)  
 Outcome based on hospital records, 
exposure based on questionnaire.  
 aHR 2.91 (95% CI 1.41 – 6) when [ref] is 
users of other AHTs.  
 Higher than modal dose has stronger 
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Study author(s) and 
year of publication  
Setting Study Design  Number of participants  Main results Notes, for more details see Appendix C.  
1994 for African 
American cohort. 
 
association, though clear trend absent.  
 aHR 4.48 (95% CI 1.58 – 12.75) for CCB + 
oestrogen use, versus no use of either. 
 
Fryzek et al. 2006 
(39) 
North Jutland, Denmark  
Study period: 
1 January 1989 –  
31 December 2002. 
Cohort  
CCB ever use versus 
never use [ref] 
Number of events for CCB 
ever users/never users, not 
reported.  
aRR 0.80 (95% CI 0.59 – 
1.09).  
 Used population-based registries. 
 CCB exclusive use versus never use [ref] – 
aRR 1.19 (95% CI 0.87 – 1.65).  
 
González-Pérez 2004 
et al. (40) 
United Kingdom  
Study period  
January 1995 – December 
2001.   
Nested case-control 
CCB use (<1 year, 1-3 
years, > 3 years), past 
use) versus no use 
[ref]  
CCB use  
<1 year: 
63 cases; 377 controls  
1 – 3 years:  
66 cases; 419 controls  
> 3 years:  
128 cases; 703 controls  
Past use:  
118 cases; 657 controls 
< 1 year & 1 – 3 years: 
aOR 0.8 (95% CI 0.6 – 
1.1) 
> 3 years: aOR 1.0 (95% 
CI 0.6 – 1.2) 
Past use: aOR 0.9 (95% CI 
0.8 – 1.2)  
 Used the UK GPRD.  
 
Grimaldi-Bensouda 
2016 et al. (41) 
United Kingdom  
Study period: 
1996 – 2009. 
Cohort  
CCB use versus other 
AHT use [ref] 
CCB use: 1,397/457,417 
PYs   
Other AHT use [ref]: 1,194 
events/514,400 PYs   
aHR 0.95 (95% CI 0.87-
1.04) 
 Used population-based registries. 
 
Hole et al. 1998 (55) Glasgow, Scotland  
Study period: 
1 January 1980 –  
31 December 1995. 
Retrospective, cohort  
CCB use versus no use 
[ref] 
CCB use: 14 events 
observed; 12.86 expected.  
No use: 17 events observed; 
22.67 expected.  
Ratio of RRs – 1.45   Benchmarked against expected events from 
population-based registry  
 No use group also from blood pressure 
clinic, therefore likely on other AHTs.  
Jick et al. 1997 (56) United Kingdom 
Study period: based on 
outcome in 1995.   
Nested case-control 
CCB use versus beta-
blockers [ref], both +/- 
diuretics  
80 events amongst CCB 
users; events amongst beta-
blocker group not reported.  
aRR 1.32 (95% CI 0.72 – 
2.41)  
 Used the UK GPRD.  
 




versus no prescription 
[ref] 
General patient cohort 
Coronary angiography (CV) 
cohort  
GP group:  
aHR  1.71 (95% CI 1.20 – 
2.44)  
CV group:  
aHR 0.68 (95% CI 0.37 – 
1.25) 
 Used healthcare provider database. 
 Reported relative risks are from conference 
presentation and differ slightly from abstract 
(aHR point estimates of 1.58 and 0.51 
respectively).  
 Conference abstract and poster only, event 
numbers not reported, only relative risks.  
Largent et al. 2010 
(43) 
California, United States 
Study period:  
2000 – 31 December 
Prospective, cohort  
CCB regular use 
within 2 years versus 
CCB regular use:  
84 events/ 17,208 PYs 
No regular use:  
aRR 1.05 (95% CI 0.84 – 
1.31)  
 Outcome identified through population-
based cancer registry; exposure via 
questionnaire.  
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Study author(s) and 
year of publication  
Setting Study Design  Number of participants  Main results Notes, for more details see Appendix C.  
2006.   no regular use [ref]  1,630 events/448,175 PYs 




1 January 1998 – 31 
December 2011. 
Case-control 
CCB use versus no use 
[ref]  
CCB use: 3,411 cases; 9,290 
controls  
CCB never use: 3,052 cases; 
9,697 controls 
aOR 1.09 (95% CI 1.03 – 
1.16)  
 Used population-based insurance database.  
 Study included only hypertensive patients. 
 Evidence of a duration-response effect, 




Li et al. 2003 (45) Seattle – Puget Sound, 
United States 
Study period: outcomes 
from 1 April 1997 – 
 31 May 1999.  
 
Case-control 
CCB ever use versus 
never use of AHTs 
[ref]  
CCB use:  
149 cases; 141 controls. 
Never use:  
446 cases; 490 controls.  
aOR 1.2 (95% CI 0.9 – 
1.5)  
 Outcome data via population-based registry, 
exposure information via participant 
interviews.  
 Evidence of association with use of 
immediate-release CCBs and breast cancer.  
 No association overall (lower 95% CI of OR 
crosses unity) in sub-analysis restricting to 
ever users of AHTs.  
Li et al. 2013 (46) Greater Seattle, United 
States  
Study period:  
Outcomes 1 January 2000 
– 31 December 2008. 
Case-control 
Current CCB use 
versus never use [ref]  
Invasive ductal: 
CCB use:  
94 cases; 74 controls  
Never use:  
477 cases; 456 controls 
Invasive Lobular: 
CCB use:  
102 cases; 74 controls 
Never Use:  
556 cases; 456 controls  
Invasive ductal: 
aOR 1.3 (95% CI 0.9 – 
1.8) 
Invasive Lobular: 
aOR 1.3 (95% CI 0.9 – 
1.8)  
 Outcome data via population-based registry, 
exposure data via participant interview.  
 Evidence of duration-response relationship, 
especially with use ≥ 10 years: aOR 2.4 
(95% CI 1.2 – 4.9) for invasive ductal and 
2.6 (95% CI 1.3 – 5.3) for invasive lobular 
breast cancer. Also the case when analysis 
restricted to women using AHTs only and 
when separating into subclasses 
(non/dihydropyridine, long/short acting). 
 For use ≥ 10 years oestrogen receptor-
positive breast cancer invasive ductal aOR 
2.3 (95% CI 1.1 – 4.8) invasive lobular 
aOR 2.6 (95% CI 1.3 – 5.2), oestrogen 
receptor-negative  invasive ductal aOR 3.1 
(1.1 – 8.8), invasive lobular not reported.   
Lindholm et al. 2001 
(57) 
Sweden  
Recruitment from 1 
September 1992 – 31 
December 1998, with 
mean 5 years follow-up.  
 
Randomised, 
controlled trial  
CCB (felodipine or 
isradipine, both 2.5 – 
5mg daily) versus 
expected incidence for 
Swedish population   
19 cases observed; 22.54 
expected.  
Standardised incidence 
ratio (SIR):  
0.84 (95% CI 0.51 – 1.32)  
 Note previous history of breast cancer was 
not an exclusion criterion for this trial, with 
authors conducting a sub-analysis to exclude 
these participants yielding similar results 
(data not shown).  
 SIRs adjusted for age, sex and calendar year.  
Meier et al. 2000 (47) United Kingdom  Case-control CCB use:  aOR 1.0 (95% CI 0.8 –  Used the UK GPRD  
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Study author(s) and 
year of publication  
Setting Study Design  Number of participants  Main results Notes, for more details see Appendix C.  
Study period: outcomes 1 
January 1992 – 30 
September 1997. 
CCB use versus use of 
neither CCB, ACEI, or 
beta-blocker [ref] 
190 cases; 735 controls  
No CCB/ACEI/beta-blocker: 
2,567 cases; 9,745 controls  
1.1)   Duration-response analysis yielded aOR of: 
1.0 (95% CI 0.8 – 1.3) for 1 – 2 years; 1.0 
(95% CI 0.6 – 1.6) for 3 – 4 years and; 0.9 
(95% CI 0.7 – 1.2) for ≥5 years.  
 CCB subclass analysis, all 95% CI crossed 
unity value of 1.  
Michels et al. 1998 
(58) 
United States  
Study period:  
1988 – 1 May 1994. 
Prospective, cohort  
CCB use versus no use 
[ref] 
CCB use:  
51 events/ 11,807 PYs  
No use:  
304 events/ 82, 524 PYs  
aRR 1.07 (95% CI 0.78 – 
1.48)  
 Questionnaire-based study, some of the 
same cohort as later study by Devore et al. 
(37).  
Olsen et al. 1997 (59) North Jutland, Denmark  
Study period:  1 January 






32 cases observed; 40.3 
expected  
SIR 0.8 (95% CI 0.5 – 1.1)   Used population-based registries.  
 
Pahor et al. 1996 (60) United States  
Study period:  
1988 – 31 December 
1992.  
Prospective, cohort  
CCB use versus no use 
[ref]  
CCB use: 31 events 
 
aHR 1.65 (95% CI 0.49 – 
5.55)  
 Outcome/exposure assigned via interview, 
outcome confirmed against medical records.   
Poole-Wilson et al. 
2006 (48) 
Nineteen countries  Randomised 
controlled, trial  
Nifedipine GITS 
versus placebo [ref] 
Nifedipine GITs: 16 events/ 
3,655 patients for rate = 0.09 
Placebo: 8 events/3,654 
patients for rate of 0.04 
HR ~ 2.25, 95% CIs not 
reported though cross 
‘unity’ value of 1.  
 
Raebel et al. 2015 
(49) 2 
United States 
Study period:  
1997 to 30 April 2013 
Retrospective, cohort 
For conference 
abstract: CCB use > 1 
year versus CCB use < 
1 year [ref] 
For presentation:  
CCB versus ACEI use 
[ref] 
29,830 taking a CCB,  
Amongst CCB group, 572 
(1.9%) with breast cancer.  
From abstract:  
At 9 years, aHR 1.09 (95% 
CI 0.6 – 2) 
At 12 years, aHR 0.88 
(95% CI 0.28-2.78). 
From presentation:  
Cox Regression  
aHR 1.02 (95% CI 0.93-
1.12)  
Discrete time survival  
aHR 0.91  (95% CI 0.83-
1.00)  
 
Rosenberg et al. 1998 
(61) 
United States  
Study period:  
1983 – 1996.  
Case-control 
CCB use versus never 
use [ref]  
CCB use: 92 cases; unclear 
how many controls.  
Never use: unclear number 
of cases/controls 
aRR 1.1 (95% CI 0.8 – 
1.4).  
 Hospital-based controls used. Outcome data 
from discharge summaries/pathology 
reports; exposure data via interview.  
Sajadieh et al. 1999 Denmark  Randomised 2 cases observed; 2.5 SIR 0.4 (95% CI 0.1 – 2.9)   SIRs adjusted for age, sex and calendar year.  
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Study author(s) and 
year of publication  
Setting Study Design  Number of participants  Main results Notes, for more details see Appendix C.  
(62) Study period 1985 – 31 
December 1993.  
 
controlled, trial 
Verapamil use versus 
Danish population 
[ref]  
expected   SIR for placebo group (1 observed; 2.5 
expected) of 0.4 (95% CI 0.01 – 2.2)  
Saltzman et al. 2013 
(50) 
United States 
Study period 1989/90 – 
 31 December 2001 for 
original cohort; 1992/93 – 
31 December 2001 for 
African American cohort. 
Prospective, cohort 
CCB ‘ever use’ versus 
never use of AHTs 
[ref]  
CCB use: 55 events/9,916 
PYs  
Never use of AHTs: 69 
cases/ 14,081 PYs  
aHR 1.1 (95% CI 0.7 – 
1.6)  
 Outcome assigned via population-based 
registry, exposure via interview and label 
checking.  
 For use in past 2 years, aHR 1.6 (95% CI 1.0 
– 2.5) for all types of CCB; 2.4 (95% CI 1.3 
– 4.5) for immediate-release and 1.4 (95% 
CI 0.8 – 2.3) for sustained-release.  
Soldera et al. 2015 
(51) 2, 3  
United Kingdom  
Study period: to 31 
December 2010. 
Cohort 
CCB versus use of 
other AHTs [ref]  
CCB use:  
1,518 events/491,768 PYs  
Other AHTs:  
3,002 events/1,075,336 PYs  
aHR 0.98 (95% 0.92 – 
1.04)  
 Used UK Clinical Practice Research Data 
link.  
 Duration-response analysis (from 
presentation): <5 years, aHR 0.96 (95% CI 
0.90 – 1.03); 5 – 10 years, 1.05 (95% CI 0.9 
– 1.22); > 10 years, 0.61 (95% CI 0.32 – 
1.20)  
Sorensen et al. 2000 
(52) 
North Jutland, Denmark 
Study period: 1 January 





CCB prescription (>2) 
versus Danish 
Population [ref]  
84 cases observed; 86.7 
cases expected  
SIR 0.97 (95% CI 0.77 – 
1.20)  
 Used population-based registries.  
1. Abbreviations: ACEI = Angiotensin-converting enzyme Inhibitor, AHT = antihypertensive drug(s), aOR = adjusted odds ratio, aHR = adjusted hazard ratio, aRR = ad justed relative risk, CCB = calcium channel blocker, 232 
CI = confidence interval, GITS = gastro-intestinal therapeutic system, HRT = hormone replacement therapy, NSAIDs = non-steroidal anti-inflammatories, PY = person-year. 233 
2. Available as a conference abstract only and author-forwarded presentation only. 234 
3. Full paper indexed after the latest database search update for this review (63); the main results are unchanged from the abstract. 235 
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While some studies specifically focused on the risk of breast cancer associated with CCB use 236 
(34, 38, 42, 47, 49, 51), the remainder either explored the risk of breast cancer or cancer 237 
overall associated with AHTs, or the risk of cancer overall associated with CCBs. Older 238 
studies tended to include more patients taking immediate-release/short-acting CCBs, as 239 
prescribing trends changed to include more sustained-release/longer-acting CCBs in newer 240 
studies. Data collection sources included population-based registries (e.g. UK General 241 
Practice Research Database (33, 40, 47, 56)), or interview/questionnaires.  The choice of 242 
comparator group was generally non-users of CCBs. For some studies the reference group 243 
was another type/s of AHT (e.g. relative to thiazide diuretics in (54)).  In others, hypertension 244 
or use of AHTs was adjusted for in the analysis (40) and/or a sub-analysis was conducted 245 
restricting to only participants with hypertension and/or taking AHTs (35, 37, 38, 45, 46, 50).  246 
3.3 Results of individual studies 247 
The majority of included studies found no association between CCB use and breast cancer, 248 
beyond that which could be explained through chance (33-35, 39-41, 43, 47-49, 51, 52, 54-249 
62). In contrast, the findings of eight studies suggested a positive association between CCB 250 
use and breast cancer, to varying degrees (36-38, 42, 44-46, 50). Those with earlier study 251 
periods included mainly immediate-release/ short-acting CCBs that are no longer widely used 252 
in contemporary practice (36, 38, 45). Two more recent studies found an association for one 253 
sub-cohort within the analysis, which could not be reproduced for other sub-cohorts in that 254 
same study (37, 42). Analysis of data from the Cardiovascular Health Study suggests that 255 
recent use of CCBs, particularly immediate-release CCBs, may be associated with an 256 
increased rate of breast cancer relative to no AHT use (50). The only data from outside North 257 
America and Europe were from Taiwan, with the two studies covering a similar population 258 
producing conflicting findings, one finding an association (44) while the other did not (35). 259 
 260 
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 Authors of a recent study from Seattle reported an adjusted odds ratio (OR) for developing 261 
invasive ductal or lobular cancer respectively of 2.4 and 2.6, for use of CCBs for ≥10 years 262 
relative to never use (46), an association which remained when restricting to only users of 263 
AHTs.  264 
3.4 Synthesis of results 265 
Two studies were excluded from the meta-analysis as standard errors could not be calculated 266 
(48, 55). The pooled odds/risk ratio for the CCB versus no CCB was 1.14 (95% CI 1.04 – 267 
1.25, I2 = 15%, n = 8 studies/sub-studies (34-36, 45-47, 61), the same for female only 268 
studies); the combined hazard ratio was 1.02 (95% CI 0.88 – 1.17, I2 = 49%, n = 9 269 
studies/sub-studies (37-39, 42, 43, 50, 60): 1.02 (95% CI 0.87 – 1.17) for female only 270 
studies), and; the combined SIR was 0.90 (95% CI 0.74 – 1.05, I2 = 0%, n = 4 studies (52, 57, 271 
59, 62): 0.94 (95% CI 0.75 – 1.13 for female only). For the CCB versus other AHT meta-272 
analyses (Figures 2 and 3) the pooled odds/risk ratio was 1.09 (95% CI 1.03 – 1.15, I2 = 0: 273 
1.10 (95% CI 1.04 – 1.16) for female only studies) and the pooled hazard ratio was 0.99 274 
(95% CI 0.94 – 1.03, I2 = 35%: 0.99 (95% CI 0.94 – 1.05) for female only studies).  There 275 
was an inconsistent duration-response relationship for the CCB versus other AHT meta-276 
regression. The log relative risk against minimum follow-up time for log odds/risk ratio had a 277 
regression coefficient 0.047 (95% CI 0.007 – 0.086, p = 0.02, 5 studies/sub-studies (35, 40, 278 
45, 46, 54): 0.06 for female only studies), whilst for log hazard ratio, only one study was 279 
included (51), and no duration-response effect was seen (regression coefficient = 0.006, 95% 280 
CI -0.024 – 0.036, p = 0.703: 0.006 for female only studies). Visual examination of funnel 281 
plots suggested some asymmetry, as higher positive relative risk estimates tended to a higher 282 
standard error. The Egger’s statistic for CCB versus no CCBs with odds/risk ratios supported 283 
this (bias regression coefficient, 1.82, 95% CI 0.21 – 3.43, p = 0.033), while there was only 284 
weak quantitative evidence of potential reporting bias for the other meta-analyses.  285 
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3.5 Risk of bias  286 
All risk of bias assessments are provided in Appendix E. Overall, the risk of selection bias 287 
arising due to factors such as differential follow-up or different selection criteria for 288 
compared groups was assessed as low. Recall bias was more of an issue for studies using 289 
questionnaires/interviewers to collect data, than for studies using population-based registries. 290 
In some cases, aids were used to reduce the risk of misclassification such as using tablet 291 
bottles as a visual aid (e.g. (46)) and several studies used more objective measures to assign 292 
outcome (e.g. checking health records in (60)). The risk of ‘confounding by indication’ was 293 
reduced when only hypertensive patients were included, when analyses were adjusted for or 294 
conducted separately for women using AHTs and/or with hypertension, but this did not 295 
always occur. Relatively few studies accounted for latency in development of cancer, where 296 
exposure would be expected to precede outcome, though this was explored in several cases 297 
via duration-response analysis.  298 
 299 
The quality assessments detailed in Appendix F indicated that four of the studies were of 300 
‘low quality’ (38, 43, 58, 61). Sensitivity analysis via removing these studies from the meta-301 
analysis did not change the pooled risk ratios reported above markedly. The amended pooled 302 
odds/risk ratio for the CCB versus no CCB was 1.16 (95% CI 1.04 – 1.29, I2 = 27%), while 303 
the combined hazard ratio was 1.02 (95% CI 0.84 – 1.20, I2 = 55%). For the pooled SIR and 304 
the CCB versus other AHT meta-analyses the results were unchanged. 305 
4. Discussion 306 
This review is unable to definitively refute an association between taking CCBs and 307 
developing breast cancer, especially for use beyond 10 years. This was a thorough systematic 308 
review, in which data have been analysed quantitatively and interpreted taking study biases 309 
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into account. Thus while a definitive answer to the study question was not made possible by 310 
the published literature to date, our study does comprehensively assess the present ‘state of 311 
play’ for this question and does provide some reassurance that an association with short-term 312 
use seems reasonably unlikely. In highlighting continuing uncertainty, we recommend the 313 
controversy be resolved by further investigation through population-based NRS. It is 314 
reassuring that the majority of the 29 reviewed studies found no important association. 315 
However, the strong positive association (adjusted odds ratio >2 for use beyond ten years) 316 
and that some duration-response relationship is shown are noteworthy in one recent study 317 
(46). This study had differential response rates (80% for cases, 69% for controls), relatively 318 
small case numbers and the finding has not yet been subsequently clearly replicated 319 
elsewhere ((35, 37, 49, 51) and subsequent to database searching (64)). Our meta-analysis of 320 
study data where an attempt was made to correct for ‘confounding by indication’ suggests 321 
that an association, if any, is much lower in magnitude. The pooled odds/risk ratio of 1.09 in 322 
our meta-analysis is largely attributable to a single study (weighting of 82% (44)) and the 323 
pooling of hazard ratios suggests no association exists. Assessing the result had this single 324 
study not been included yields a pooled risk ratio closer to unity (1.08, 95% CI 0.95 – 1.22, I2 325 
= 0%), though it should be noted that this study seemed to have a reasonably low risk of bias 326 
(see Appendix F).  327 
  328 
Two meta-analyses on this topic were published during 2014 (21, 22). One group (21) 329 
reported a pooled OR of 1.11 (95% CI 0.93 to 1.33) for taking CCBs and developing breast 330 
cancer, with a pooled OR of 1.88 (95% CI 1.37 to 2.60) for immediate-release CCBs. 331 
Another group (22) concluded that long-term use beyond 10 years “appears to have a 332 
significant relationship with breast cancer”, based on pooling data from two trials (46, 50). 333 
However, the Forest Plot does not match the pooled estimate reported in the text (22). We 334 
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have combined studies with comparable outcome measures, and have focused the 335 
interpretation of the results on studies where there was an attempt to address ‘confounding by 336 
indication’, and have refrained from sub-analysis by CCB or breast cancer subtype, as 337 
conservative use of meta-analysis seems appropriate to the relatively methodologically 338 
disparate studies included in this review. It would be interesting to see if any association 339 
differs between oestrogen receptor-positive and –negative breast cancer, this was explored in 340 
some studies (37, 46). Devore and colleagues (37) report a possible positive association 341 
between CCBs and oestrogen receptor-negative breast cancer, while Li and colleagues (46) 342 
found the positive association in their study was not affected by oestrogen-receptor status 343 
(Table 1). However, there is little value in meta-analysing these two studies, especially as 344 
they report different relative risk measures. The larger number of studies included in our 345 
review relative to previous meta-analyses is attributable to wider eligibility criteria, and that 346 
several studies have been published subsequent to the earlier reviews being conducted. Since 347 
these reviews were published, there has been further data emerging with longer-term follow-348 
up (34, 35, 37, 41, 42, 44, 49, 51) and subsequent to database searching (64, 65), notably 349 
including data from outside North America and Europe. This was partly in response to the 350 
2013 study by Li et al (46); it is thus timely to reassess the literature to check if the likely risk 351 
has moved toward providing a more unequivocal answer to this controversy. While the 352 
authors of a previous meta-analysis concluded that, “there is no evidence that CCB use is 353 
associated with an increased risk of breast cancer”, the meta-analysis approach combined 354 
studies with comparators of no CCB use of other AHTs, and also combined different 355 
measures of relative risk (21). The approach we have taken in our meta-analysis takes 356 
advantage of the now greater number of available, relevant studies, to combine those that are 357 
reasonably comparable, amongst a group of relatively heterogeneous studies. The results 358 
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indicate that, especially for long-term use, we cannot confidently rule out an association at 359 
this time.  360 
 361 
Risk of bias and the likelihood of a causal link affect that importance of remaining 362 
uncertainty highlighted by our review. Studies using questionnaires (e.g. (36, 38)) had a 363 
higher risk of misclassification; earlier work by Beiderbeck and colleagues (66) found that 364 
this could be differential and markedly affect reported relative risks. While population-based 365 
registries were less susceptible to misclassification bias, two drawbacks are that potential 366 
confounders are limited by data stored on the registries, and that collecting a prescription 367 
from a pharmacy does not necessarily indicate taking it, though the importance of the latter is 368 
less for studies requiring records of ≥ 1 prescription (e.g. (54)). Competing mortality risks 369 
through people prescribed CCBs dying of non-cancer causes more often that those not taking 370 
CCBs, are not formally factored in to the reviewed analyses, though one group does discuss 371 
the possible effect on interpretation (35). This is worth exploring in future studies. Exclusion 372 
of patients with cancer reduces the risk of reverse causality (i.e. breast cancer leading to 373 
hypertension and subsequent prescription of a CCB) or of breast cancer developing prior to 374 
CCBs being taken. However, the few studies which allowed for a ‘latent period’ did so for ~ 375 
one year, and in most cases follow-up was relatively short (< 10 years) (38-40, 44, 51). 376 
Mason (6) concludes that a CCB-mediated decrease in apoptosis leading to a higher risk of 377 
carcinogenesis is unlikely. The lack of a clear biological mechanism is consistent with the 378 
majority of epidemiological studies showing no association. The majority of data are from 379 
North America or Europe, excepting two recent studies from Taiwan (35, 44), which 380 
produced conflicting results. Zhu and colleagues (67) discuss that social and biological 381 
differences between African-Americans and Caucasian Americans may affect the association 382 
between CCBs and breast cancer, and there may also be differences for Asian populations.   383 
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  384 
This review had several limitations. Whilst the selection criteria for the review were broad, 385 
they did not allow inclusion of data from papers looking at cancer and CCBs, where either 386 
breast cancer was not isolated as an outcome, or CCBs as the exposure (68-74). It is possible 387 
that this may have also led to some RCTs being omitted, though reviewing references of a 388 
recent systematic review and meta-analysis of relevant RCTs indicates that no eligible studies 389 
were missed (75). That long-term drug effects often emerge beyond the length of a typical 390 
RCT has also been demonstrated for the potential inverse association between low-dose 391 
aspirin and colorectal cancer (76), highlighting the important role of well-designed 392 
observational studies as part of effective post-marketing surveillance. Subsequent to database 393 
searching, a study from Puerto Rico corroborates a lack of association with long-term use 394 
(64), while a study from Spain indicates that use of CCBs beyond five years may be 395 
associated with developing breast cancer, especially for overweight or postmenopausal 396 
women (65). Incorporation of these data into the meta-analyses does not materially change 397 
the results. Finally, during the timeframe over which included studies were published there 398 
have been marked changes to hypertension and breast cancer epidemiology. If CCBs were 399 
independently associated with incident breast cancer, we would expect this to appear over 400 
time, notwithstanding the increasing proportion of longer acting CCBs over time. Thus to 401 
choose a time cut off to include studies appears somewhat arbitrary. For this reason we have 402 
included all studies fulfilling the eligibility criteria, regardless of the date of publication. That 403 
only three of the 17 sub studies where an attempt was made to correct for ‘confounding by 404 
indication’ were published prior to 2003 also limits the temporal impact on interpretation of 405 
the pooled data for the meta-analysis. 406 
 407 
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In view of continuing controversy, especially for any association between long-term CCB use 408 
and breast cancer, we recommend further NRS using population-based cancer, prescription 409 
and health data registries, where these are available in settings where CCB use is prevalent. 410 
These studies should include assessment of use beyond 10 years and adjust for important 411 
confounders.  412 
  413 
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Figure 2. Forest plot of pooled odds/risk ratio of breast cancer diagnosis for CCB 
versus other antihypertensive* 
 
*Versus another antihypertensive drug or only amongst hypertensive patients, or with 
adjustment for hypertension/use of other antihypertensive drugs.  The size of the box is 
proportionate to study weighting in the meta-analysis (inversely proportionate to the standard 
error), the horizontal lines indicates 95% confidence intervals (CI), and the diamond shows 
the pooled risk/odds ratio (1.09). Some 95% CIs differ slightly from original study due to 
rounding. AHT = antihypertensive drug, D = invasive ductal, HTN = patients with 
hypertension only, L = invasive lobular. Included study full references (35, 44-46, 54, 56) 
Figure 3. Forest plot of pooled hazard ratio of breast cancer diagnosis for CCB 
versus other antihypertensive*.  
 





*Versus another antihypertensive drug or only amongst hypertensive patients, or with 
adjustment for hypertension/use of other antihypertensive drugs.  The size of the box is 
proportionate to study weighting in the meta-analysis (inversely proportionate to the standard 
error), the horizontal lines indicates 95% confidence intervals (CI), and the diamond shows 
the pooled hazard ratio (0.99). Some 95% CIs differ slightly from original study due to 
rounding. B = Bensouda, DTS = discrete time survival, H = patients with hypertension only, 
N = Nurses’ Health Study. Included study full references (33, 37, 38, 41, 49, 51, 58)).   
  




Appendix A. Prospero protocol.  
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015026712  
  




Appendix B. Database search strategies  
MEDLINE 
1. exp Calcium Channel Blockers/ 
2. "calcium channel block$".af. 
3. CCB$.af. 
4. "calcium antagonist$".af. 
5. exp Dihydropyridines/ or dihydropyridine$.af. 
6. exp Amlodipine/ or amlodipine.af. 
7. clevidipine.af. 
8. exp Diltiazem/ or diltiazem.af. 
9. exp Felodipine/ or felodipine.af. 
10. lercanidipine.af. 
11. exp Nifedipine/ or nifedipine.af. 
12. exp Nimodipine/ or nimodipine.af. 
13. exp Verapamil/ or verapamil.af. 
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. exp Breast Neoplasms/ 
16. (breast adj6 neoplasm$).af. 
17. (breast adj6 cancer$).af. 
18. (breast adj6 carcinoma$).af. 
19. (breast adj6 tumour$).af. 
20. (breast adj6 tumor$).af. 
21. 15 or 16 or 17 or 18 or 19 or 20 
22. 14 and 21 
23. exp animals/ not humans/ 










1. exp calcium channel blocking agent/ 
2. "calcium channel block$".af. 
3. CCB$.af. 
4. "calcium antagonist$".af. 
5. exp dihydropyridine derivative/ or dihydropyridine$.af. 
6. exp amlodipine/ or amlodipine.af. 
7. exp clevidipine/ or clevidipine.af. 
8. exp diltiazem/ or diltiazem.af. 
9. exp felodipine/ or felodipine.af. 
10. exp lercanidipine/ or lercanidipine.af. 
11. exp nifedipine/ or nifedipine.af. 
12. exp nimodipine/ or nimodipine.af. 
13. exp verapamil/ or verapamil.af. 
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. exp breast cancer/ 
16. exp breast tumor/ 
17. exp breast carcinoma/ 
18. (breast adj6 cancer$).af. 
19. (breast adj6 neoplasm$).af. 
20. (breast adj6 carcinoma$).af. 
21. (breast adj6 tumour$).af. 
22. (breast adj6 tumor$).af. 
23. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 
24. 14 and 23 
25. animal/ 
26. exp animal experiment/ 
27. nonhuman/ 
28. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs 
or cat or cats or bovine or sheep).ti,ab,sh.   
29. 25 or 26 or 27 or 28 
30. exp human/ 
31. human experiment/ 
32. 30 or 31 
33. 29 not (29 and 32) 
34. 24 not 33 
 




Cochrane Library  
 
#1 MeSH descriptor: [Calcium Channel Blockers] explode all trees 
#2 calcium NEXT channel NEXT block*  
#3 CCB* 
#4 calcium NEXT antagonist*  
#5 MeSH descriptor: [Dihydropyridines] explode all trees 
#6 dihydropyridine*  
#7 MeSH descriptor: [Amlodipine] explode all trees 
#8 amlodipine  
#9 clevidipine  
#10 MeSH descriptor: [Diltiazem] explode all trees 
#11 diltiazem  
#12 MeSH descriptor: [Felodipine] explode all trees 
#13 felodipine  
#14 lercanidipine  
#15 MeSH descriptor: [Nifedipine] explode all trees 
#16 nifedipine  
#17 MeSH descriptor: [Nimodipine] explode all trees 
#18 nimodipine  
#19 MeSH descriptor: [Verapamil] explode all trees 
#20 verapamil  
#21 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 #14 or 
#15 or #16 or #17 or #18 or #19 or #20  
#22 MeSH descriptor: [Breast Neoplasms] explode all trees 
#23 breast NEAR neoplasm*  
#24 breast NEAR cancer*  
#25 breast NEAR carcinoma*  
#26 breast NEAR tumour*  
#27 breast NEAR tumor*  
#28 #22 or #23 or #24 or #25 or #26 or #27  
#29 #21 and #28  
  




Appendix C.  Rejected articles undergoing full-text review 
N = 94.  
 
Rejected under intervention criterion  
 
From database searching, n = 5 
 
 Minerva. BMJ. 1993;307(6903):574. 
 
 Safety and efficacy issues. WHO Drug Information. 2013;27(3):218-26. 
 
 Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast 
cancer mortality: A population-based study. J Clin Oncol. 2011;29(19):2635-44. 
 
 DeMaria AN, Ben-Yehuda O, Feld GK, Ginsburg GS, Greenberg BH, Lew WYW, et al. 
Highlights of the Year in JACC 2006. J Am Coll Cardiol. 2007;49(4):509-27. 
 
 Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: A 
case-control study. Acta Diabetologica. 2009;46(4):279-84. 
 
From other sources, n = 17 
 
 Assimes TL, Suissa S. Age at incident treatment of hypertension and risk of cancer: a 
population study. Cancer Causes Control. 2009; 20: 1811-20.  
 
 Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Cancer risk in association with 
Parkinson disease: A population-based study. Parkinsonism Relat Disord. 2010;16(3):186-90. 
 
 Beji NK, Reis N. Risk factors for breast cancer in Turkish women: a hospital-based case-
control study. Eur J Cancer Care. 2007; 16(2): 178-84.  
 
 Bhaskaran K, Douglas I, Evans S, van ST, Smeeth L. Angiotensn receptor blockers and risk 
of cancer: cohort study among people receiving antihypertensive drugs in UK General 
Practice Research Database. BMJ. 2012; 344: e2697.  
 
 Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, et al. Reduced Risk 
of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins. Cancer 
Invest. 2011;29(9):585-93. 
 
 Chang PY, Huang WY, Lin CL, Huang TC, Wu YY, Chen JH, et al. Propranolol Reduces 
Cancer Risk A Population-Based Cohort Study. Medicine. 2015;94(27). 
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Appendix D.  Data extracted from included studies (number next to publication year is the study reference on the main 
paper).  
 
Author(s) and year of publication 
(Reference number on manuscript) 
Assimes et al. 2008 (54) 
Objectives  To examine the relationship between the use of antihypertensive drugs and cancer 
outcomes.  
Methods   
Study design  Nested case-control study.  
Setting  Saskatchewan Province, Canada.  
Study period 1 January 1980 through 31 December 2003. 
Participants  Cohort formed from users of AHTs, defined by ≥3 prescriptions in one calendar year 
between 1 January 1980 and 30 June 1987. Follow-up from date of third dispensing in 
one year through cancer diagnosis, service termination or 31 December 2003, whichever 
arrived first.  
Cases: ≥1 cancer diagnosis, excluding non-melanoma skin cancer and in situ cervical 
cancer. Date of diagnosis considered as ‘index date’.  
Controls (10: 1 case): selected from province-level database, no diagnosis of cancer 
from 1967, matched to cases on entry into cohort, gender and age (+/- 3 years). 
Excluded if dispensing history for <2 years (modified if entry to cohort after 1 January 
1982).   
Variables  Outcome(s): Primary outcomes: all 35-cancer sites combined, four most common 
cancers (colorectal, breast, lung, prostate) and kidney.  
Secondary outcomes: other grouped categories (e.g. “head and neck” included lip, oral 
cavity, head & neck, larynx, thyroid). Only first cancer within study period considered.  
Exposure(s): Exposure to CCB, beta-blocker or ACEI/ATRA, relative to thiazide 
diuretic use.  
Potential confounder(s): “common pre-morbid conditions”. 
Potential effect modifier(s): Nil stated.  
Data sources/measurement  Exposure, outcome and covariate data collected via population-based prescription, cancer 
and health registries.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
Conditional logistic regression. Prescription database did not collect individual data from 
1 July 1987 to 31 December 1998, so data imputed during this time. 
CCB use relative to thiazide (but not CCB use), adjusted for age, ‘comorbid conditions’, 




missing data.  use of other AHTs except for potassium-sparing diuretics.  
Duration-response analysis also conducted for <2.5 years, 2.5 to ≤7.5 years, and >7.5 
years).  
Results  
Number of participants  Total cohort: 77,887 patients: 11,697 cases matched to 116,970 controls.  
Total use of any duration:  
CCB, but not thiazide: 92 cases; 927 controls 
Thiazide, but not CCB [ref]: 972 cases; 9213 controls 
Total use > 7.5 years: 
CCB group: 16 cases; 210 controls.  
Thiazide group [ref]: 316 cases; 2920 controls. 
Description of study group For total cohort: mean age 71.8 (SD 10.6 years) for cases; 71.7 (SD 10.6) for controls. 
Male ~ 53%. Mean duration of AHT use: 3.6 to 5.7 years. A subgroup exposed to long-
term AHT (mean duration 9.7 – 11.4 years, range 7.5 – 23.1 years).  
Outcome(s) overall  Breast cancer cases = 1623 (14% of total incident cancer cases in this study).  
Main results  Total use of any duration:   
aOR 0.96 (95% CI 0.76-1.22).  
Total use > 7.5 years: 
For aOR 0.73 (95% CI 0.43-1.23)  
Other analyses  Nil relevant  
Discussion   
Limitations (author reported) 1) Fewer participants on CCBs and ACEI/ATRAs than expected, even fewer on these 
exclusively.  
2) Some misclassification of exposure as prescription database offline for 18 months of 
the study period, though the authors did attempt to adjust for this in their analysis.  
3) Analysis not adjusted for smoking, BMI, family history.  
4) Could not adjust for use of potassium-sparing diuretics (showed co-linearity with 
thiazide diuretic use). Authors stated “we are not aware of any published studies to date 
that provide compelling evidence that potassium sparing diuretics are carcinogenic at the 
population level.” 
5) Dispensing used as surrogate for ‘taking’, potential for bias resulting from this. 
6) Evidence provided for indirect carcinogenic effects of antihypertensives, not specific 
genotoxic or carcinogenic effects (this would require a different study design).  
Interpretation  No author interpretation for breast cancer specifically, however authors stated “we found 
no association between the risk of cancer from all sites combined and the use of CCBs 
but not thiazide diuretics” 
Generalisability  Generalisability not specifically mentioned, however authors commented: “Assuming 
thiazide diuretics are not carcinogenic, our findings provide important reassurance to 




patients that the long-term use of commonly prescribed classes of antihypertensive drugs 
does not promote or initiate cancer.” 
Funding  Operating grant from the Canadian Institutes of Health Research. Dr. Assimes supported 
by a training bursary from Fonds de la Research en santé du Quebec and Dr. Suissa is a 
recipient of the Distinguished Investigator Award from the CIHR.  
Phamacoepidemiology Unit is funded by an Equipé grant from the FRSQ.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, aOR = adjusted odds ratio, ATRA = angiotensin II receptor antagonist, BMI 
= body mass index, CCB = calcium channel blocker, CI = confidence interval.  
  





Author(s) and year of publication 
(Reference number on manuscript) 
Azoulay et al. 2012 (33) 
Objectives  “…to determine whether angiotensin receptor blockers are associated with an overall 
increased risk of the four most common cancers, namely, lung, colorectal, breast and 
prostate cancers…”.   
Primary objective = these cancers combined. 
Secondary objective = these cancers individually.  
Methods   
Study design  Retrospective cohort design, from which a nested case-control study was performed.  
Setting  United Kingdom.  
Study period from 1 January 1995 through 31 December 2010.  
Participants  Cohort formed from patients prescribed an AHT from 1 January 1995 through 31 
December 2008. Need to have ≥ 2 years of health records from date of cohort entry, 
if this was not the case, date moved forward to first prescription preceded by at least 
2 years of database records Follow-up from entry into cohort through to first 
diagnosis of cancer, death from any course, end of registration with general practice 
at entry, or the 31 December 2010, whichever arrived first.  
Cases patients diagnosed with study cancer. Date of diagnosis assigned as ‘index 
date’.   
Controls (up to 10: 1 case): randomly selected, matched base of age (via year of 
birth), sex, calendar year of cohort entry, prevalent user status (prescription of AHT 
during 2-year period prior to cohort entry), and duration of follow-up.  
Excluded if history of any of the four study cancers prior to entry into cohort, or if 
AHT use started within year of ‘index date’ (to account for latency).   
  
Variables  Outcome(s): Primary outcome: all four cancers combined. Secondary outcome: four 
cancers (lung, colorectal, prostate, breast) individually.  
Exposure(s): prescription of an AHT. Grouped into ever use of mutually exclusive 
groups: 1) ARBs; 2) ACEIs; 3) CCBs; 4) other antihypertensives and; 5) beta-
blockers/diuretics [ref].  
Pre-specified potential confounder(s): excessive alcohol use, smoking status, BMI, 
HTN, CHF, CHD, diabetes, previous cancer (other than non-melanoma skin cancer 
or those under study), ever use of aspirin, other NSAIDs or statins. For breast cancer-
specific analysis, further adjustment for oophorectomy, use of HRT and prior use of 
oral contraceptives.  
Pre-specified potential effect modifier(s): not specifically mentioned.  
Data sources/measurement  Used UK General Practice Research Database (GPRD) for outcome, exposure and 




covariate data. Covariate data measured at any time from at least 2 years prior to 
cohort entry, up until 1 year prior to index date).  
Statistical methods, methods for controlling 
for confounders/effect modifiers, methods 
for dealing with missing data.  
Conditional logistic regression with adjustment for excessive alcohol use, BMI, 
smoking, diabetes, previous cancer, ever use of aspirin, statins, or NSAIDs, 
oophorectomy, use of HRT, and prior use of oral contraceptives.  
Results  
Number of participants Total cohort: 1,165,781: 41,059 cases matched to 410,167 controls.  
Ever use of CCBs versus diuretics +/- beta-blockers [ref]:  
Cases: 2,070 
Controls: 21,160 
Description of study group (age, gender, 
other demographic data provided) 
Mean age at cohort entry 63.4 years (SD 14.6), and 72.4 years for both cases and 
controls are index date. Cases and controls were followed for a mean of 5.5 (SD 3.3 
years), 53% of cases and controls were male. Smoking 56.7% for cases, 49% for 
controls.49.4% of cases and 48.5% of controls taking a CCB (+/- other 
antihypertensive(s)).  
Outcome(s) overall  Of 41,059 cases, 11,312 (27.5%) had breast cancer.  
Main results  aRR 0.98 (95% CI 0.92 – 1.04).  
Other analyses  Nil relevant  
Discussion   
Limitations (author reported) 1) Relying on prescription data may not link directly with compliance, therefore 
misclassification bias toward the null possible.   
2) Lack of information in GPRD regarding occupational exposures, race, and family 
history.  
3) Could not assess for confounding secondary to differing levels of hypertension 
control.  
Interpretation  No specific commentary regarding association between CCB and breast cancer,  
Generalisability  Not mentioned specifically, though assembly of a ~ 1.2 million person cohort is cited 
as a strength of the study.  
Funding  Grants from the Canadian Institutes of Health Research, Boehringer-Ingelheim, and 
the Canadian Foundation for Innovation.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, ARB = angiotensin II receptor blocker, aRR = adjusted relative-risk, BMI = 
body mass index, CCB = calcium channel blocker, CHD = coronary heart disease, CHF = congestive cardiac failure, CI = confidence interval, HRT = hormone replacement 
therapy, HTN = hypertension, IHD = ischaemic heart disease, NSAID = non-steroidal anti-inflammatory drug, SD = standard deviation.  
 
  




Author(s) and year of publication (Reference 
number on manuscript) 
Bergman et al. 2014 (34) 
Objectives  To replicate the study by Li et al. (2013, ref 43) by using population registries with 
high coverage.  
Methods   
Study design  Case-control study  
Setting  Sweden  
Study period 1 January 2006 through 31 December 2011.  
Participants   Cases: women receiving a diagnosis of breast cancer for the first time in 2011.  
Controls (1: 5 controls): sourced from the Swedish Population Registry, matched 
by age, could not have malignant or benign breast tumour or breast cancer in situ 
before 2011.  
Variables  Outcome(s): new diagnosis of breast cancer.  
Exposure(s): use of CCBs between 1 January 2006 and 31 December 2011. 
Defined as >3 prescriptions during a year.  
Potential confounder(s): age, educational level, location of residence, and history 
of cancer at sites other than the breast.  
Potential effect modifier(s):  
Data sources/ measurement   Swedish Cancer Register for outcome, Swedish Population Registry, National 
Registry on Prescription Drugs for exposure. 
Statistical methods, methods for controlling for 
confounders/effect modifiers, methods for 
dealing with missing data.  
Logistic regression adjusted for above listed confounders. Dose-duration analysis 
performed.  
Results  
Number of participants  19,766 total: 3,461 cases; 17,363 controls.  
Continuous use of CCBs over 5 years: 
148 cases; 719 controls.  
No continuous use of CCBs [ref]:  
3,314 cases; 15,765 controls.   
Description of study group Age range 55 to 74 years.   
Outcome(s) overall   
  
Main results  aOR1.1 (95% CI 0.9-1.3)  
Other analyses  For use in 2010 only: aOR 0.9 (95% CI 0.7-1.3) 
For use in 2009-10: aOR 1.1 (95% CI 0.8-1.5) 
For use in 2008-10: aOR 1.0 (95% CI 0.7-1.5) 
For use in 2007-10: aOR 1.1 (95% CI 0.8-1.6) 
Discussion   




Limitations (author reported) None reported  
Interpretation  5 years of exposure to CCBs did not increase the odds of developing breast cancer. 
However, as the Li et al. (2013, ref 43) paper showed that long-term use (≥10 
years) was associated with breast cancer, plan for continue surveillance.  
Generalisability  Not discussed.  
Funding  No specific funding mentioned, undertaken by staff of the National Board of Health 
and Welfare in Sweden, Stockholm, Sweden.  
Abbreviations: aOR = adjusted odds ratio CCB = calcium channel blocker, CI = confidence interval.  
  




Author(s) and year of publication 
(Reference number on manuscript) 
Chang et al. 2016 (35) 
Objectives  “…to investigate the association of long-term use of antihypertensive agents with incident 
breast cancer among women aged 55 years or older…” 
Methods   
Study design  Nested case-control study.   
Setting  Taiwan 
Study period 1 January 2001 through 31 December 2011.  
Participants   Cohorts Women aged 55 to 100 years in 2001, without any prescription for ACEIs or 
ARBs, alpha-blockers, beta-blockers, CCBs or other antihypertensive agent, or a diagnosis 
of incident cancer before study commencement. Separate cohorts included women 
prescribed ACEIs, ARBs, beta-blockers, CCBs and diuretics) and having a diagnosis of 
hypertension were also assembled. 
Cases: first diagnosis of breast cancer. The date of first breast cancer diagnosis was defined 
as the index date. 
Controls: For original cohort, from each case identified up to 4 age (5-year grouping) 
follow-up duration matched controls were selected from the cohort.  
For separate cohorts prescribed AHTs, from each case up to 4 age-matched (1-year 
grouping) and follow-up duration controls were identified for each cohort.  
Excluded: women not receiving a continuous insurance coverage in 2000. 
Variables  Outcome(s): first diagnosis of breast cancer 
Exposure(s): prescription of ACEIs or ARB, dihydropyridine CCB (non-dihydropyridine 
were excluded), or beta-blockers prior to breast cancer occurrence.  
Potential confounder(s): other medical conditions (e.g. diabetes, hypertension), other 
medicines (e.g. diuretics, insulin), and socioeconomic status.  
Potential effect modifier(s): Nil specified. 
Data sources/measurement  Outcome sourced for Taiwan’s National Cancer Registry. Exposure from Taiwan’s National 
Health Insurance (approximately 99% population coverage), specifically from the outpatient 
pharmacy prescription database, Insurance database also used to collect covariate medical, 
prescription, and diagnostic data.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
 Conditional logistic regression, for each cohort CCB use relative to non-use [ref].  
Adjustment for study drugs and with potential covariates added into model stepwise and 
retained if p<0.1 for model entry and >0.05 for removal.  
Stratification by duration of use: current, recent (from drug discontinuation to cancer 
diagnosis < 6 months) and past use (if ≥ 6 months had passed), and use for:  ≤ 2 years, > 2-4 
years, >4-6 years, > 8 years.  
 
In final model adjustment for: study drugs (ACEIs/ARBs, beta-blockers, dihydropyridine 




CCBs) socioeconomic status, diabetes mellitus, ischaemic heart disease, myocardial 
infarction, heart failure, cerebrovascular disease, chronic kidney disease, chronic liver 
disease, chronic lung disease, depression, Charlson’s index, diuretics, human insulin, statin, 
fibrates, aspirin, HRT, number of lipid measurements, number of mammography, number of 
outpatient visits, number of hospitalisations, length of hospital admissions more than 7 days. 
Results  
Number of participants  Original cohort = 794,533.   
Cohort taking AHTs = 178,412.  
Cohort with hypertension diagnosis = 114,971.  
Description of study group Overall, mean age 62.70 for both cases and controls, median follow-up of 9.9 years, 16.8% 
of cohort died and 0.19% were lost to follow-up.  
Outcome(s) overall  For overall cohort:  
Any CCB use: 3,529 cases and 10,909 controls. 
No use of CCBs [ref]: 5,868 cases and 26,679 controls.  
For cohort taking an AHT:  
Any CCB use: 1,260 cases and 4,534 controls. 
No use of CCBs [ref]: 816 cases and 3,770.  
For cohort with diagnosis of hypertension: 
Any CCB use: 950 cases and 3,595 controls. 
No use of CCBs [ref]: 356 cases and 1,629 controls. 
Main results   For overall cohort: adjusted OR (aOR) for any use versus no use [ref]: 1.39 (95% CI 1.14 – 
1.69).  
For cohort taking an AHT: aOR for any use versus no use [ref]: 1.21 (95% CI 0.88 – 1.67).  
For cohort with diagnosis of hypertension: aOR for any use versus no use [ref]: 1.71 (95% 
CI 0.99 – 2.95).  
 
Other analyses  CCB use by duration relative to non-user (including no medication user):  
≤2 years      (cases 2,906 control 8,662)    aOR   1.28 (95% CI 1.05-1.57) 
>2-4 years (cases  369 control 1,379)        aOR  1.37 (95% CI 1.05-1.79) 
>4-6 years  (cases  174 control 599)          aOR  1.43 (95% CI 1.02-2.01) 
>6-8 years  (cases  67 control 228)            aOR   1.39 (95% CI 0.84-2.29) 
>8 years      (cases  13 control 41)             aOR   1.38 (95% CI 0.48-4.01) 
 
Duration-response analysis shows no association for cohort with AHT use or diagnosis of 
hypertension.  
Discussion   
Limitations (author reported)  Possible residual confounding for covariates not considered in the model (especially 
smoking), small cases numbers for 8-10 years of use may have limited power of study for 




this subgroup, non-dihydropyridine CCBs, diuretics, aldosterone receptor antagonists not 
included due to limited time scale of use in Taiwan, different comorbidity patterns might 
affect results (e.g. beta-blockers use in heart failure) and no formal competing risks analysis.  
Interpretation  “…our study results did not suggest a causal relationship between long-term use of any 
AHT (dihydropyridine CCBs and others) and the risk of breast cancer”. The authors 
attribute risk in the larger cohort to confounding by indication. “…physicians should not 
sacrifice the long-term cardiovascular benefits of AHTs just for fear of uncertain breast 
cancer risk…”. 
Generalisability  Not discussed.  
Funding  Not mentioned.  
Abbreviations: ACEIs = angiotensin-converting enzyme inhibitors, AHTs = antihypertensive drugs, ARBs = angiotensin II receptor blockers, CCB = calcium channel 
blockers, CI = confidence interval, OR = odds ratio. 
 
  




Author(s) and year of publication 
(Reference number on manuscript) 
Davis & Mirick 2007 (36) 
Objectives  “To investigate whether the use of commonly prescribed medications, primarily 
antihypertensives and antidepressants, is associated with an increased risk of cancer”  
Methods   
Study design  Case-control study (re-analysis of cases/controls from a study conducted 5 years previous).   
Setting  Seattle, Metropolitan Area.  
Study interviews, March 2000 through December 2001. Cases originally diagnosed with 
breast cancer between November 1992 and March 1995.  
Participants  Cases were women aged 20-74 at time of diagnosis; date of diagnosed defined as the 
‘index date’.  
Controls originally identified by random-digit dialling and frequency-matched to cases by 
5-year age groups.  
Variables  Outcome(s): newly diagnosed breast cancer, with sub-analysis including localised breast 
cancer only.  
Exposure(s): taking CCBs (antidepressants, NSAIDS and beta-blockers also assessed in 
the study). If participants recalled taking a medication, they were asked about “regular 
use” defined as use 4 days/week for > 6 months in the 10 years prior to diagnosis, duration 
of regular use (e.g. < 5 years versus 5-10 years), and recency of regular use (e.g. 2 years 
since diagnosis). 
Potential confounder(s): parity, age at first pregnancy, mother/sister breast cancer, early 
double oophorectomy, combined oral contraceptive use, ever upper-gastrointestinal series, 
ever smoker, mother/sister breast cancer < 45 years, alcohol intake (if premenopausal), 
HRT (if postmenopausal).  
Potential effect modifier(s): none mentioned 
Data collection/measurement  Questionnaire sent out one week prior to telephone interview. Cases asked about 
exposure/covariate information from 10 years prior to their diagnosis, controls from 10 
years prior to corresponding index date.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Logistic regression conditional on 5-year age strata and adjusted for confounders listed 
above.   
Results  
Number of participants In original study: 813 of eligible cases agreed to participate (of 1,039, 78%), for this study 
600 (74% of those agreeing before, 58% of those eligible initially agreed to participate, 
89% of the original cohort still alive).  
In original study: 793 (of 1,053, 75%) of controls agreed to participate. For this study 600 
(76% of those agreeing before, 57% of original, 85% of the original study cohort still 





CCB ever users: 
38 cases; 36 controls.  
CCB never users [ref]:  
509 cases; 560 controls.  
Description of study group  Assume age range 25 through 83 years of age, though age range not specifically reported. 
Of 597 (of 600) cases reported on, 71% had localised disease, 28% had regional, 0.5% had 
distant disease).  
Outcome(s) overall  7% of cases were ever users of CCBs; 6% of controls were ever regular users of CCBs.  
Main results Ever use of CCBs versus never use:  
aOR 1.4 (95% CI 0.9-2.4). 
Other analyses  CCB use <5 years (relative to never use):  
aOR 1.7 (95% CI 0.9-3.0) 
CCB use 5-10 years (relative to never use):  
aOR 1.0 (95% CI 0.4-2.3)  
Use > 2 years prior to diagnosis (relative to never use): 
aOR 2.1 (95% CI 0.7-6.6) 
Use within 2 years of diagnosis (relative to never use):  
aOR 1.3 (95% CI 0.8-2.3) 
For localised disease only  
Ever use of CCBs (relative to never use) 
aOR 1.7 (95% CI 1.0-2.8) 
CCB use <5 years (relative to never user):  
aOR 2.0 (95% CI 1.1-3.8) 
CCB use 5-10 years (relative to never use) 
aOR 1.0 (95% CI 0.4-2.6) 
Use > 2 years prior to diagnosis (relative to never use): 
aOR 1.7 (95% CI 0.5-6.2) 
Use within 2 years of diagnosis (relative to never use):  
aOR 1.3 (95% CI 0.9-2.9) 
Discussion   
Limitations (author reported) 1) Because participants contacted 5-8 years after initial study and asked about their 
medication use 10 years before diagnosis, recall necessary for 5 to 18 years in the 
past.  
2) Small numbers recalling medication use in each class.  
3) Limited to cases that survived for ≥ 5 years, therefore bias introduced by some 
having died in the interim and potential for different patterns of medication use.  
Interpretation  “In conclusion, the results of this population-based study supports previous findings that 




calcium channel blocker use may be associated with a modest increase in breast cancer 
risk…”.  
Generalisability  No mention of generalisability.  
Funding  Grant from the National Cancer Institute (R01 CA81614).  
Abbreviations: aOR = adjusted odds ratio, CCB = calcium channel blocker, CI = confidence interval, HRT = hormone replacement therapy, NSAID = non-steroidal anti-
inflammatory drug.  
 
  




Author(s) and year of publication 
(Reference number on manuscript) 
Devore et al. 2015 (37) 
Objectives  “…to evaluate whether antihypertensive medication use, including long-term use, is 
associated with breast cancer incidence in women”.  
Methods   
Study design  Cohort study, follow up to previous study by Michels et al. (ref, 55)  
Setting  United States  
Study period, assessment of outcome from 1 June 1988 through 1 June 2012 for Nurses’ 
Health Study (NHS) cohort, from 1 June 1989 through 1 June 2011 for NHS.   
Participants  NHS cohort female nurses aged 30 to 55 years enrolled in 1976, NHS II female nurses aged 
between 25 and 42 enrolled in 1989. Follow-up from baseline to end of follow-up period, 
diagnosis of breast cancer, death, loss to follow-up, whichever occurred first. 
Cohort members’ eligible if returning questionnaires. Participants with incident breast cancer, 
other cancer types (excluding non-melanoma skin cancer) or who did not report height at 
baseline, were all excluded.  
Variables  Outcome(s): Incident breast cancer.  
Exposure(s): AHT use, CCBs one of the classes analysed.   
Potential confounder(s): BMI, height, combined oral contraceptive use, menopausal status, 
HRT for postmenopausal women, age at first birth, age at menarche, history of breast cancer, 
benign breast disease, ethanol intake, physical activity, smoking history, shift work history, 
aspirin use, and concomitant use of other AHTs.  
Potential effect modifier(s): None specifically mentioned.  
Data collection/measurement  Data collection via biennial questionnaire asking about health conditions, medications and 
lifestyle factors. Death registries checked at each questionnaire cycle to assess if non-
responders have died.  
Outcome data via self-report on biennial questionnaire, ideally confirmed by examining 
medical records, phone conversation or with written confirmation. Death via national death 
index. 
Exposure to CCBs assessed in 1988, 1994, and then every two-years thereafter for NHS, 
from 2001 onwards for NHS II. If data not collected in a questionnaire round, responses from 
previous questionnaire carried forward. For NHS II, data imputed back to 1989 based on 
responses in 2001.  
Covariate data collected at baseline and updated at each questionnaire cycle, missing 
indicators used where data were missing.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
 Cox proportional hazards adjusting for confounders above except for aspirin and concomitant 
AHT use, as these did not made a difference to generated HRs. Initially, all eligible cohort 
members included, then only including women with diagnosis of hypertension, then based on 
consistency of use, finally stratifying model by oestrogen-receptor status.  





Number of participants In NHS 95,501 women eligible; in NHS II 115,140 women eligible.  
 
Description of study group  Results state that demographic data similar for most demographic characteristics for current 
versus past/never users of AHTs, however current users tended to be older, have higher BMI, 
lower physical activity levels and less regular use of aspirin. 
Outcome(s) overall  Overall 10,012 cases of breast cancer (6,718 in NHS; 3,294 in NHS II).  
NHS cohort:  
Current CCB use: 640 events/144,242 PYs 
Never/past CCB use [ref]: 6,077 events/1,634,906 PYs 
NHS II cohort 
Current CCB use: 87 events/47,431 PYs 
Never/past CCB use [ref]: 3,025 events/ 1,925,448 PYs 
Main results  Results are for multi-variable adjusted model. 
Current CCB use versus never/past use [ref]  
NHS cohort:  
aHR 1.07 (95% CI 0.99-1.17)  
NHS II cohort: 
aHR 0.97 (95% CI 0.78-1.20)  
Analysis restricted to women with hypertension only, current CCB use versus never/past use 
[ref]  
NHS cohort:  
aHR 1.10 (95% CI 1.00-1.20)  
NHS II cohort: 
aHR 0.99 (95% CI 0.76-1.30) 
For consistent CCB use, incosistent CCB use, both versus never use [ref] 
NHS cohort:  
Inconsistent use – aHR 0.95 (95% CI 0.87 – 1.04) 
aHR 1.10 (95% CI 1.00-1.20)  
Consistent use – aHR 1.06 (95% CI 0.97 – 1.16) 
NHS II cohort: 
Inconsistent use – aHR 0.75 (95% CI 0.56 – 1.01)  
Consistent use –aHR 0.92 (95% CI 0.69 – 1.24)  
Duration response analysis (consistent use for 2-4, 6-8, 10-14, ≥16 years): 
95% CI for aHRs all cross the unity value of HR = 1, exact values not reported here, see Table 
4 in the Devore et al. study (ref, 30).   
Other analyses  CCB current use versus never/past users stratified for oestrogen-receptor status 
NHS  









Oestrogen receptor-negative  
aHR 1.20 (95% CI 0.75 – 1.93) 
Oestrogen receptor-positive 
Not reported 
Discussion   
Limitations (author reported) 1) Observational study, thus risk of confounders not accounted for. However, many 
potential confounders included in multi-variable analysis.  
2) Self-report for exposure, thus risk of misclassification.  
3) Self-report information carried forward between questionnaires (as some classes not 
asked about every time), thus risk of misclassification.  
4) Classes of AHT not considered at sub-class level.  
Interpretation  Interpretation of non-association between CCB and breast cancer, though cases where a 
positive association was found should be investigated further.  
Generalisability  Not commented on in the paper.  
Funding  National Cancer Institute funds NHS and NHS II. LRW received partial support from a NIH 
training grant.  
Abbreviations: aHR = adjusted hazard ratio, AHT = antihypertensive drug, BMI = body mass index, CCB = calcium channel blocker, CI = confidence interval, HRT = 
hormone replacement therapy.  
  





Author(s) and year of publication 
(Reference number on manuscript) 
Fitzpatrick et al. 1997 (38) 
Objectives  To investigate the epidemiologic association between calcium channel blockers and breast 
carcinoma risk.  
Methods   
Study design  Cohort study  
Setting  Selected counties in North Carolina, California, Maryland, Pennsylvania and, later, 
comprising African American participants (geographical locations not specified), United 
States.  
Study period 1989/90 through December 1994 for original cohort; 1992/93 through December 
1994 for African American cohort.  
Participants For this analysis, women 65 – 100 years included. Excluded if history of breast cancer or 
congestive heart failure at entry, if institutionalised, unable to provide informed consent, 
wheelchair bound, under hospice care, or receiving radiation or chemotherapy for cancer. 
Never users followed up from entry to censor date, users from start date (of CCB) to censor 
date. Censor at cancer hospitalisation, death or last contact with study. Unexposed becoming 
exposed could be accounted for in analysis. 
Variables  Outcome(s): incident breast cancer requiring hospitalisation.  
Exposure(s): CCB use, regardless of other drug use, duration of use or discontinuation during 
follow-up 
Potential confounder(s): age, race (African-American or other), smoking, alcohol intake, 
education, income, functional status, and self-reported diabetes, BMI.  
Potential effect modifier(s): none mentioned 
Data collection/measurement  Outcome data collected by via hospital medical records, thus non-hospitalised case data not 
included in this analysis. Event data to end of 1994 received by 20 May 1996 included in the 
analysis.  
Exposure data via interviewer-administered questionnaire, aided by transcribing details of 
drug (separated into verapamil, diltiazem, nifedipine, non-nifedipine dihydropyridine, all 
separated into immediate- or sustained-release), dose etc. from labels on boxes/bottles of 
AHTs.  
Covariate data collected via interviewer-administered questionnaire.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Cox proportional hazards used to calculate HRs. PYs began with a lag of 1 year after starting 
CCBs to allow for latency. Also modelled with 0, 6, 12 and 24-month lag period. Model 
adjusted for age, race (African-American or other), parity, and age at menopause, self-
reported diabetes. Main comparison of any CCB use to no CCB use, also CCB use to other 
AHT use. Groups not mutually exclusive. Sub-analysis for only users of HRT.  
Results  




Number of participants 3,198 women included in the analysis. Mean 5 years follow-up for original, and 2 years for 
African American cohort.  
Any CCB use: 20 events/759 cohort members/1600 PYs 
No CCB use: 55 events/2439 cohort members/10,784 PYs  
Description of study group  Mean age for CCB users of 72.9 years; 72.9 years for other AHTs and 71.9 years for non-
AHT users. Amongst CCB users, 33.4% were African American, relative to 19.7% of other 
AHT-users and 10.8% of no AHT users. Initially predominantly immediate-release CCBs, 
though this increased over the study period (1,191 PYs of immediate-release, versus 1,128 
PYs of sustained-release CCBs for the study overall).   
Outcome(s) overall  75 cases of incident breast cancer.  
Main results  CCB use versus no use [ref]  
aHR: 2.57 (95% CI 1.47-4.49)  
Other analyses  CCB use versus other AHT use [ref]  
aHR 2.91 (95% CI 1.41-6.00)  
CCB use at less than modal dose versus no CCB use [ref] 
aHR 2.29 (95% CI .56 – 9.39) 
CCB use at modal dose versus no CCB use [ref] 
aHR 1.53 (95% CI 0.7 -3.37) 
CCB use at great than nodal dose versus no CCB use [ref] 
aHR 4.42 (95% CI 1.37 – 14.27)  
CCB & oestrogen use versus no use of CCB or oestrogen [ref] 
aHR 4.48 (95% CI 1.58 – 12.75) 
Other values in this additional analysis not reported here, see table 6 in study by Fitzpatrick et 
al. (ref, 35).  
Discussion   
Limitations (author reported) 1) previous drug use prior to study not considered  
2) small number of incident cancer cases 
3) no amlodipine, nifedipine associated with excess mortality in other studies  
Interpretation  Positive association between CCB and breast cancer use found in this study warrants further 
investigation. Biologically plausible link, evidence of dose-dependence and accounting for 
confounding by investigation considered in this study. However, low number of cases means 
results should be interpreted with caution and more research is needed. 
Generalisability  Not commented upon.  
Funding  Supported “in part” via contracts from the National Heart, Lung and Blood Institute.  
Abbreviations: aHR = adjusted hazard ratio, AHT = antihypertensive drug, BMI = body mass index, CCB = calcium channel blocker, CI = confidence interval, HRT = 
hormone replacement therapy, PY = person-year.  
 
  





Author(s) and year of publication 
(Reference number on manuscript) 
Fryzek et al. 2006 (39) 
Objectives  To determine the relation between use of CCBs and ACEIs and cancer in general, updating a 
previous study by Olsen et al. (ref, 56) and Sorensen et al. (ref, 49).  
Methods   
Study design  Cohort study  
Setting  North Jutland, Denmark  
Study period from 1 January 1989 through 31 December 2002.  
Participants  Population used to form cohort were women residents of the county aged ≥50, but < 67 
years as at 1 January 1989. Excluded if cancer diagnosis prior to start of follow-up, 
excepting for non-melanoma skin cancer.  
Follow-up from date of second prescription of AHT, age of 50 years, 1 January 1990, 
whichever occurred later. Follow-up ended on first of the following events: age of 67, death, 
emigration from the country, date of diagnosis for breast cancer, or 31 December 2002. 
Variables  Outcome(s): breast cancer incidence.  
Exposure(s): ≥ 2 prescriptions for an AHT during the study period. 1989 data used to assign 
exposure status, follow-up commenced from 1990.  
Potential confounder(s): age, postmenopausal HRT use, NSAID use, number of live births, 
age at first birth.  
Potential effect modifier(s):  
Data collection/measurement  Used linked population-based databases (Central Population Register, Danish Cancer 
Registry and Pharmaco-Epidemiologic Prescription Database of North Jutland).  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Log-linear Poisson regression adjusting for confounders listed above, and by calendar period 
(1990-1995 or 1996 to 2002). All covariates except for live births and age at first birth were 
able to change during the follow-up period. Duration-response and cumulative-dose-
response (inferred from number of prescriptions) analyses conducted. Sub-analysis also by 
subclass of CCB (dihydropyridine versus non-dihydropyridine). Assume that use of AHTs 
and classes/sub-classes of AHT is relative to non-use of an AHT.  
Results  
Number of participants 49,950 women in the cohort, 19,284 classified as exposed to an AHT medication, leading to 
109,985 person-years of follow-up, average follow-up of 5.7 years (range 0 to 13 years).  
Description of study group (age, gender, 
other demographic data provided) 
Mean age at entry of 52 (range, 50 – 67); 76% in 50 – 54 year category. Of AHT users, 23% 
used a CCB (+/- other AHTs).   
Outcome(s) overall  264 cases of incident breast cancer among women ‘exposed’ to AHTs during study period 
(PYs = 109,985), number for unexposed not reported.   
Main results  Ever use of CCBs versus never use of AHTs [ref]  
aRR 0.80 (95% CI 0.59 -1.09) 




Exclusive use of CCBs versus never use of AHTs [ref] 
aRR 1.19 (95% CI 0.87 – 1.65) 
Based on number of prescription (for ever users): 
2 – 4 (61 cases of breast cancer): aRR 0.74 (95% CI 0.38 – 1.43) 
5 – 9 (40 cases) : aRR 0.85 (95% CI 0.44 – 1.64)  
10 – 19 (163 cases): aRR 0.81 (95% CI 0.55 – 1.2) 
Based on years of follow-up:  
<1 (23 cases): aRR 0.41 (95% CI 0.13 – 1.29) 
1-4 years (104 cases): aRR 0.84 (95% CI 0.54 – 1.29) 
5+ years (137 cases): aRR 0.89 (95% CI 0.57 -1.38)  
Other analyses (e.g. sub-analyses of 
subpopulations, sensitivity analyses) 
Ever use of dihydropyridines (n = 8493): 
aRR 0.85 (95% CI 0.60 - 1.20) 
Ever use of non-dihydropyridines (n = 1,113):  
aRR 0.72 (95% CI 0.42 – 1.23) 
No clear duration-response or cumulative dose-response (inferred from number of 
prescriptions) shown, see table 4 on paper by Fryzek et al. (ref, 36).  
 
The authors state that subgroup analyses with women taking HRT (as performed in the 
Fitzpatrick et al. study (ref, 35) did not support the positive association find in the other 
study.   
Discussion   
Limitations (author reported) 1) lack of history before 1989 
2) no information on BMI, age at menarche, alcohol use, physical activity 
3) Length of follow-up may limit findings, plan to continue monitoring cohort. 
Interpretation  “… this study offers no support for a relationship between any class of AHT and breast 
cancer risk” 
Generalisability  Not mentioned specifically, but mention women in general in conclusion. 
Funding  International Epidemiology Institute, Rockville, Maryland; the Ingeborg and Leo Dannins 
Foundation for Scientific Research; the Western Danish Research Forum for Health 
Sciences.  
Abbreviations: AHT = antihypertensive drug, aRR = adjusted relative risk, BMI = body mass index, CCB = calcium channel blocker, CI = confidence interval, HRT = 
hormone replacement therapy, NSAID = non-steroidal anti-inflammatory drug, PY = person-year.   
 
  





Author(s) and year of publication (Reference 
number on manuscript) 
Gonzalez-Perez et al. 2004 (40) 
Objectives  To investigate the association between the risk of breast cancer and use of 
captopril and other antihypertensive medication.  
Methods   
Study design  Nested case-control study.   
Setting  United Kingdom  
Study period January 1995 through December 2001.   
Participants (eligibility criteria, source of 
cases/controls (if applicable), define as 
matched/unmatched (if applicable)).   
Women aged 30 – 79 years between January 1995 and December 2001, enrolled 
from the first day within study of period of having at least 1-year enrolment 
with the GP and 1 year since first computer-generated prescription.  
Cohort members with a code for cancer prior to starting date and those >70 
years of age at start date and who had no data recorded during followed up time 
were excluded.  
Follow-up from start date through to recorded breast cancer, age of 80 years, 
death or the end of December 2001, whichever occurred first.  
Cases selected from the cohort, with the date of diagnosis defined as the ‘index 
date’.  
For each cohort member, a random date during the study period generated, if 
this date fell within the period contributing person-time for that cohort member, 
this person was eligible to be a control. Controls frequency-matched by age (1-
year interval), and calendar year.  
Variables  Outcome(s): incident breast cancer  
Exposure(s): prescription of an AHT, defined as current or past use.  
Potential confounder(s): information collected on history of hypertension, 
diabetes, ischaemic heart disease, cerebrovascular disease, previous breast 
lump/biopsy (≥ 1 year before index date), alcohol intake, BMI, HRT use also 
ascertained.  
Potential effect modifier(s): nil mentioned.  
Data collection/measurement  This study used the UK General Practice Research Database (GPRD).  
Outcome identified through coding on the UK GPRD, with confirmation on 
these members patient profile.  
Exposure and covariate data from the UK GPRD alone.  
Statistical methods, methods for controlling for 
confounders/effect modifiers, methods for dealing 
with missing data.  
Unconditional logistic regression used to generate odds ratio, assumed to be a 
valid estimate of the rate ratio, for use of AHTs and individual classes 
(including CCB) stratified by duration of use, relative to no use. Adjustment for: 
age, calendar year, hypertension, BMI, alcohol intake, smoking status, HRT 




use, prior breast lump/biopsy, and differing lengths of use of other AHTs. 
Duration-response analysis also conducted  
Results  
Number of participants  Cohort comprised 734, 899 women. Of these, 4,005 codes for breast cancer, 297 
of which could not be confirmed or were prevalent cases. 3,708 incident breast 
cancer cases included in this analysis.  This was compared to 20,000 controls.  
Description of study group  No age/demographic data provided besides that in eligibility criteria. Amongst 
cases, 10.1% had current or past use of CCB; this value was 10.8% amongst 
controls (respectively, 29% and 28% had a prescription for any AHT within 1 
year of index date).  
(current)CCB use < 1 year: 
63 cases; 377 controls 
CCB use 1 – 3 years: 
66 cases; 419 controls 
CCB use > 3 years:  
128 cases; 703 controls  
Past use (used ended >1 prior to index date):  
118 cases; 657 controls 
No use [ref]: 
3,333 cases; 17,844 controls 
Outcome(s) overall  Overall incidence of breast cancer of 156 per 100,000 person-years, increasing 
incidence until 60 and then plateau thereafter.  
Main results  (current) CCB use < 1 year versus no use [ref]  
aOR 0.8 (95% CI 0.6 – 1.1) 
CCB use 1 – 3 years versus no use [ref] 
aOR 0.8 (95% CI 0.6 – 1.1) 
CCB use > 3 years versus no use [ref] 
): aOR 1.0 (95% CI 0.8 – 1.2) 
Past CCB use versus no use [ref] 
aOR 0.9 (95% CI 0.8 – 1.2) 
Other analyses (e.g. sub-analyses of 
subpopulations, sensitivity analyses) 
Assume relative to no use.  
Nifedipine versus no use [ref]  
Current short (< 2 years), 36 cases, 216 controls  
aOR 0.9 (95% CI 0.6 – 1.3) 
Current long (> 2 years), 87 cases, 459 controls,  
aOR 1.1 (95% CI 0.8 – 1.4) 
Amlodipine versus no use [ref] 
Current short, 42 cases, 286 controls, aOR 0.7 (95% CI 0.5 – 1.0) 




Current long, 28 cases, 160 controls, aOR 1.0 (95% CI 0.7 – 1.5) 
Diltiazem versus no use [ref]  
Short duration, 20 cases, 137 controls, aOR 0.8 (95% CI 0.5 – 1.3) 
Long duration, 19 cases, 134 controls, aOR 0.7 (95% CI 0.4 – 1.2) 
Discussion   
Limitations (author reported) 1) Unable to account for age at menarche, family history, age at first child 
or germ line mutation. Though noted that this seems unlikely to change 
the null results.  
Interpretation  “…we did not find any association between antihypertensives and the risk of 
cancer”.  
Generalisability  No mention of generalisability.  
Funding  No funding source mentioned.  
Abbreviations: AHT = antihypertensive drug, aOR = adjusted odds ratio, BMI = body mass index, CCB = calcium channel blocker, CI = confidence interval, GP = general 
practitioner, HRT = hormone replacement therapy.  
 
  





Author(s) and year of publication 
(Reference number on 
manuscript) 
Grimaldi-Bensouda et al. 2016 (41) 
Objectives  “The primary objective … was to investigate the potential association between CCB use and risk 
for all types of cancer. The secondary objectives were to investigate the association between CCB 
and colon, breast and prostate cancers”.   
Methods   
Study design  Cohort study 
Setting  United Kingdom  
Study period 1 January 1996 through 31 December 2009.  
Participants Age 18 to 79 years, visiting GP ≥1 time(s) during study period, with > 2 years primary care and > 1 
year(s) prescription history. Patients with cancer event at any time prior to index date excluded. 
Variables  Outcome(s): Development of cancer (all types) and breast, colon or prostate cancer (separately), 
developed 6 months after index date (this was date of first CCB use (CCB cohort), date of first 
AHT (AHT cohort) or date of first CCB use for matched CCB user (matched non-CCB cohort).  
Exposure(s): CCB defined as ≥ 1 prescription during study period. For breast cancer these were 
compared to an AHT cohort (subset of non-CCB cohort formed by assigning 4 age-and sex-
matched to each CCB user within study period, who had used ≥ 1 non-CCB AHT during study 
period).  
Potential confounder(s): age, sex (both matching variables), alcohol consumption, diabetes, 
hypertension, arrhythmia, angina, or heart failure, statins, aspirin at or within 1 year of baseline, 
smoking status, BMI.  
Potential effect modifier(s): Nil specified.  
Data collection/measurement  Used data from the Clinical Practice Research Datalink and National Cancer Registration System 
for outcome, exposure and covariate data. 
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing 
with missing data.  
Conditional logistic cox-regression modelling including women cohort members only, to estimate 
HRs adjusting for age at index date, smoking status, BMI, alcohol consumption, diabetes, 
hypertension, arrhythmia, angina, heart failure, or use of statins or aspirin. ‘CCB cohort’ compared 
to ‘AHT cohort’. 
 
Results  
Number of participants 865,647 in total: 150,750 in CCB group; 557,931 in non-CCB group; 156,966 in other AHT group 
(ref for breast cancer-specific analysis).  
Women only: CCB cohort 75,794; and AHT cohort 84,697 [Ref]. 
Description of study group  Mean age for CCB cohort 61.5 years (SD 11.5) and for AHT cohort 51.4 years (SD 15.4), 50% 
male in CCB versus 46% in AHT cohort, 73.6% in CCB with hypertension at baseline versus 
29.1% in AHT (though this was adjusted for in analysis), higher proportion obese in CCB group 




versus AHT (28% versus 21%, respectively).  
Outcome(s) overall  CCB use (women only): crude rate 3.05/1,000 PYs (1,397 cases of breast cancer for 457,417 PYs 
of follow-up).   
Other AHT use (women only) [ref]: crude rate 2.32/1,000 PYs (1,194 cases of breast cancer for 
514,400 PYs of follow-up).   
Main results  aHR 0.95 (95% CI 0.87-1.04).  
Other analyses (e.g. sub-analyses 
of subpopulations, sensitivity 
analyses) 
Nil relevant  
Discussion   
Limitations (author reported)  Younger age for the AHT cohort mentioned, though this was adjusted for in the analysis.  
 Results do not apply directly to populations not covered by the UK Clinical Practice 
Research Datalink.  
Interpretation  “This…study provides strong evidence that CCB use is not associated with an increased risk of 
cancer…The analyses yielded results across all types of cancer…It is likely different results 
obtained from different countries are due to methodological rather than biological issues”. Note 
that conclusions for cancer generally, no specific conclusions for breast cancer specifically 
other than mention of results across all types of cancer.  
Generalisability  “The results of this study do not apply directly to populations not included in the CPRD network of 
physicians”. However the authors note it is likely to be generalisable to the British population.   
Funding  Innovative Medicine Initiative Joint Undertaking.    
Abbreviations: aHR = adjusted hazard ratio, AHT = antihypertensive drug, BMI = body mass index, CCB = calcium channel blocker, CI = confidence interval, HRT = 
hormone replacement therapy, NSAID = non-steroidal anti-inflammatory drug, PY = person-year, SD = standard deviation.  
  




Author(s) and year of publication 
(Reference number on manuscript) 
Hole et al. 1998 (55) 
Objectives  “To measure the rates of incident and fatal cancer in hypertensive patients taking calcium 
antagonists and to compare these with rates in three control groups”.  
Methods   
Study design  Retrospective cohort study 
Setting  Scotland 
Study period 1 January 1980 through 31 December 1995  
Participants  Patients attending the Glasgow Blood Pressure Clinic during the study period. Follow-up from 
date of first prescription for an AHT, through to diagnosis of cancer, death or 31 December 
1995, whichever comes first.  Patients receiving no treatment or known to have cancer before 
first prescription were excluded.  
Variables  Outcome(s): incident cancer (breast cancer included as one of 30 cancer sites).   
Exposure(s): first prescription for a CCB or other AHT.  
Potential confounder(s): age, sex, smoking status and year of observation.   
Potential effect modifier(s): none mentioned  
Data collection/measurement  Outcome from Scotland Cancer Registry, with co-author assigning outcome blinded to 
exposure. West of Scotland Cancer Registry used to assess the expected breast cancer 
incidence.  
Exposure data from blood pressure clinic prescription records, with co-authors blinded to 
outcome status.  
Covariate data also collected from blood pressure clinic records.  
 
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Ratio of relative risks calculated by comparing observed: expected cases for CCB users, to the 
observed: expected cases for non-CCB users. Expected case numbers adjusted for confounders 
listed above.  
Results  
Number of participants  5,207 in study population (assessing the risk of all incident cancer), 2,297 prescribed a CCB, 
2,910 prescribed another AHT. 
CCB group 
14 observed cases (23%, of 62 amongst women); 12.86 expected 
No CCB group 
17 observed cases (16%, of 109 amongst women); 22.67 expected cases 
Description of study group (age, 
gender, other demographic data 
provided) 
For study overall: mean age of women 57.4 years for those on CCBs; 48.3 years for those not.  
Proportion women aged above 70 years 13.4% for CCB group; 6.4% for no CCB group. 
Average follow-up 5 years for CCB group; 7.8 year for non CCB group.  
Outcome(s) overall   




Main results Calcium antagonist: non-calcium antagonist ratio of relative risks = 1.45. Difference no noted as 
significant with p<0.05.  
Other analyses (e.g. sub-analyses of 
subpopulations, sensitivity analyses) 
Nil relevant  
Discussion   
Limitations (author reported) 1) Risk of ascertainment bias, reduced by using same method of cancer certification 
throughout, by avoiding new searches beyond standard identification, keeping 
assessors blinded to exposure/outcome (depending on what they were assessing).  
2) Selection bias due to confounding by indication.  
Interpretation  No evidence for an increase of cancer among patients taking calcium antagonists. 
No interpretation of breast cancer result.  
Generalisability  No specific mention.  
Funding  A.F.L supported by grants from the British Heart Foundation and Tenovus-Scotland.  
Abbreviations: AHT = antihypertensive drug, CCB = calcium channel blocker, CI = confidence interval.   





Author(s) and year of publication 
(Reference number on manuscript) 
Jick et al. 1997 (56) 
Objectives  To study a large group of hypertensive patients to investigate the relation between calcium 
channel blockers and cancer.  
Methods   
Study design  Nested case-control study  
Setting  United Kingdom  
Study period based on outcome in 1995.  
Participants  Cohort, Hypertensive patients who were current users of beta-blockers alone, ACEIs alone or 
CCBs alone (all +/- diuretics) and had at least four years of continuous medical history were 
eligible. Patients with history of cancer before 1995 (except for non-melanoma skin cancer) 
were excluded. 
Cases had a first-time cancer diagnosis in 1995. Date of diagnosis considered ‘index date’.  
Controls (up to 4: 1 cases) sourced from cohort members, matched to cases by age (within 5 
years), sex and GP surgery attended.  
Variables  Outcome(s): incident cancer diagnosed in 1995 (except non-melanoma skin cancer) 
Exposure(s): exposure to CCB, ACEI, or beta-blocker (all +/- diuretic, but mutually 
exclusive of the other classes in the study) in the year prior to index date.  
Potential confounder(s): duration of hypertension, BMI, concurrent diuretic use, smoker 
status.  
Potential effect modifier(s): not mentioned 
Data collection/measurement  This study used data from the UK General Practice Research Database (GPRD). 
Outcome data planned to be confirmed via questionnaire to GP/assessment of medical 
records. However, the 32% where questionnaires were not returned were included in the 
analysis as relative risks were similar to when they were excluded.  
Exposure data information also collected about duration of exposure, daily dose (at, lower, or 
higher than mode), and whether taken once, twice or three times per day.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Conditional logistic regression comparing CCB (+/- diuretics) use to beta-blocker use, 
adjusting for potential confounders listed above. No duration-response analysis conducted for 
breast cancer specifically.  
 
Results  
Number of participants  For total study, 464 cases, with 18 excluded = 446 cases included, matched to 1,750 controls. 
Only 68% of those returned questionnaires, but as mentioned above, cases where a 
questionnaire was not returned were included in the analysis.   
For Any cancer:  
CCB, but not beta-blocker/ACEI: 178 cases; 573 controls 




Beta-blocker, but not CCB/ACEI [ref]: 183 cases; 755 controls 
 
CCB use (+/- diuretics) 
80 cases; number of controls not reported 
Beta-blocker use (+/- diuretics) 
Number of cases or controls not reported.  
Description of study group  Mean age for study overall of 71.6 years for cases; 71.3 years for controls. 79% of cases and 
76% of controls had duration of hypertension ≥ 4 years.  
Outcome(s) overall  For study overall (assessing cancer risk overall, not only breast cancer risk) 40% of cases were 
taking a CCB (+/- diuretic); relative to 33% of controls.  
Main results  CCB use versus beta-blocker use (both +/- diuretic) [ref]: 
aRR 1.32 (95% CI 0.72 – 2.41)  
Other analyses  Nil relevant to review.  
Discussion   
Limitations (author reported) 1) Only had access to records for up to 7 years before diagnosis, therefore longer-term effect 
cannot be ruled out.  
Interpretation  “We found not evidence of a material increase in the risk of any cancer casually associated 
with use of calcium-channel blockers relative to the use of beta-blockers”.  
Generalisability  Not discussed.  
Funding  Bayer AG. Boston Collaborative Drug Surveillance Program supported by grants from: Astra 
AB, Berlex Laboratories, Bayer AG, Boots Healthcare International, Glaxo Wellcome Inc, 
Ciba-Geigy Corporation, Hoechst AG, RW Johnson Pharmaceutical Research Institute, Merck 
Research Laboratories, N V Orgenan, and Pfizer Inc.  









Author(s) and year of publication 
(Reference number on manuscript) 
Lam et al. 2014 (42) conference abstract and poster presentation  
Objectives  To confirm of refute the results of Li et al. (43) showing a positive association between CCB 
use and the development of breast cancer.  
Methods   
Study design  Prospective cohort study  
Setting  United States  
Participants   Females, aged 50-70, with no history of breast cancer, categorised as ‘General patients’ (GPs) 
and coronary angiography (CV) patients. 
Participants prescribed CCBs matched with those not prescribed CCBs (1:1) based on age, race, 
tobacco, alcohol, body mass index, hypertension and follow-up time.  
Variables  Outcome(s): incident breast cancer. Secondary outcomes of incident diabetes, coronary and 
renal disease. 
Exposure(s): Prescription of a CCB.  
Potential confounder(s):;  
Potential effect modifier(s): history of other cancers, family history of breast cancer.  
 
Data collection/measurement  Outcome, exposure and covariate data extracted from Intermountain Healthcare databases 
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Multivariable cox proportional hazards regression used, adjusted for effect modifiers (above). 
Unclear if adjustment for matching criteria covariates.   
Results  
Number of participants  From conference abstract: 3,718 in total: 2,612 general patients and 1,106 CV patients.  
Description of study group  From poster presentation: disease burden generally higher amongst CCB versus non-CCB 
group. Mortality also relatively higher amongst CCB group.  
Outcome(s) overall  From conference abstract: Breast cancer predominantly developed in < 5 year of follow-up 
(64% of cases) – though maximum follow-up and cancer rate overall not specified.  
Main results  From conference abstract:  
CCB prescription versus no CCB prescription [ref] 
GP group: 
aHR of 1.58 (95% 1.10-2.26) 
CV group:  
aHR 0.51 (95% CI 0.27-0.97)  
From poster presentation:  
CCB prescription versus no CCB prescription [ref] 
GP group:  




aHR  1.71 (95% CI 1.20 – 2.44)  
CV group:  
aHR 0.68 (95% CI 0.37 – 1.25)  
Other analyses (e.g. sub-analyses of 
subpopulations, sensitivity 
analyses) 
Consistent associations for both cohorts for several secondary outcomes (incident diabetes, 
coronary and renal disease) between the two groups (data not reported here).  
From poster presentation:  
Dihydropyridine CCB prescription versus (presumably) no CCB prescription [ref] 
GP group: 
aHR of 1.78 (95% 1.17 – 2.69) 
Non-dihydropyridine CCB prescription versus (presumably) no CCB prescription [ref] 
GP group: 
aHR of 1.5 (95% 0.86 – 2.63) 
Discussion   
Limitations (author reported) None detailed.  
Interpretation  “Modest association” between CCB use and incident breast cancer observed in the general 
patient group, not reproduced in the CV patient group. These authors interpret the positive 
association as likely to represent uncorrected confounding (e.g. prescriber bias or drug 
interactions) and recommend further analysis through randomised controlled trials.  
Generalisability  Not mentioned. 
Funding  None mentioned.  
Abbreviations: aHR = adjusted hazard ratio, CCB = calcium channel blocker, CI = confidence interval.  
 
  





Author(s) and year of publication 
(Reference number on manuscript) 
Largent et al. 2010 (43) 
Objectives  “…to elucidate the association between hypertension, antihypertensive medication use, and 
breast cancer…”.  
Methods   
Study design  Prospective cohort study  
Setting  California, United States  
Study period 2000 through 31 December 2006.  
Participants  Cohort: women from California Teachers Study cohort, completing baseline survey in 1995/96, 
survey included questions on CCB from 2000/01.  
Excluded: >85 years at baseline, unknown history of hypertension or AHT use, incident breast 
cancer prior to filling in CCB-inclusive survey, unknown history of breast cancer, moved out of 
California, or who did not complete the AHT section of the questionnaire in that year. Follow-
up from date of 2000/01 surveys, incident breast cancer, death, moving away from California, 
or 31 December 2006.   
Variables  Outcome(s): incident invasive breast cancer,  
Exposure(s): AHT use (thiazide diuretics, CCB, ACEI and other antihypertensive) for ≥ 2 
months  
Potential confounder(s): race, family history of breast cancer, age at first full-term pregnancy 
and number of full-term pregnancies, hormone therapy and menopausal status, lifetime physical 
activity, diabetes, BMI, smoking history, alcohol use, hysterectomy, breastfeeding, and 
percentage of calories from fat.   
Potential effect modifier(s): none mentioned.  
Data collection/measurement  Outcome data via identified through linked-data with California Cancer Registry. 
Exposure data via 2000/01 self-administered questionnaire. 
Covariate data via baseline, self-administered, questionnaire.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Multivariable Cox-proportional hazards with person-years accumulated based on age in days, 
adjusted by confounders above and stratified by age at baseline (single age in years).  
CCB use relative to no CCB use (including those not using an AHT). 
Results  
Number of participants  73,742 included in analysis relevant to this review (of 114, 549 eligible cohort members at 
baseline for the general analysis relating to AHT use and breast cancer risk).   
CCB regular use within 2 years 
84 events/24,593 PYs 
No regular CCB use [ref] 
1,630 events/448,175 PYs 




Description of study group  Mean age at baseline of 52.8 years overall, 50.9 years for women without hypertension, and 
62.2 years for women with hypertension. However, the CCB-relevant analysis began follow-up 
~ 5 years beyond this.  A history of high blood pressure reported by 16.8% of women.  
Outcome(s) overall  For follow-up period relevant to this review, 1,714 invasive breast cancer diagnoses included.  
Main results  CCB regular use within 2 years versus no regular use [ref]: 
aRR 1.05 (95% CI 0.84 – 1.31)  
Other analyses  Nil relevant  
Discussion   
Limitations (author reported) 1) Limited information on whether hypertension was controlled by drugs.  
2) Limitation relating to collection of information at beginning of follow-up only.  
Interpretation  No specific interpretation of CCB result. Overall comment based on total cohort with respect to 
AHT use: increased risk of invasive breast cancer was observed for long-term (≥5 years) 
antihypertensive use. The authors mention the challenge of isolating the association with AHTs 
relative to any association with hypertension itself.   
Generalisability  No specific mention.  
Funding  NIH supported. 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, aRR = adjusted relative risk BMI = body mass index, CCB = calcium channel 
blocker, CI = confidence interval.  
 
  





Author(s) and year of publication 
(Reference number on manuscript) 
Leung et al. 2015 (44) 
Objectives  “To address the conflicting evidence from previous studies…to evaluate the risk of breast 
cancer associated with long-term use of antihypertensives in hypertensive women.”  
Methods   
Study design  Case-control study.  
Setting  Taiwan 
Study period 1 January 1998 and 31 December 2011. 
Participants Cases and controls selected from cohort formed of people with hypertension, taking AHTs for > 
6 months continuously during study period. Follow-up from date of diagnosis of hypertension 
during study period, until death, or 31 December 2011, whichever came first.  
Cases defined those with incident breast cancer ((ICD-9 CM codes 174.xx and 175.xx) during 
study period. Index date defined as date of breast cancer diagnosis.  
Controls (4:1 cases) from cohort with no diagnosis of breast cancer, matched for age (5-year 
categories), index data, and year of hypertension diagnosis.   
Excluded: Patients with history of breast cancer prior to prescription of AHT, or without 
continuous enrolment in National Health Insurance Program excluded.  
Variables  Outcome(s): first diagnosis of breast cancer,  
Exposure(s): treatment with AHTs (beta-blocker, CCB, ACEI, ARB) for > 6 months during 
study period  
Potential confounder(s): age, “comorbidities” at cancer diagnosis, measured in the year prior 
to cancer diagnosis, statins, HRT Rx.  
Potential effect modifier(s): none mentioned.  
Data collection/measurement  The National Health Insurance Research Database and Catastrophic Illness Patient Database 
used to assign outcome, exposure and covariate variables.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Logistic regression used to estimate crude and adjusted ORs, unclear exactly what adjusted for 
in main CCB versus no CCB use analysis. Duration – and cumulative dose-response analyses 
conducted. Additional analysis undertaken changing to AHT prescription at least 6-9 months 
before the index date. 
Results  
Number of participants 6,463 hypertensive women with breast cancer, 18,987 randomly selected controls.  
Description of study group  Mean age for controls, 61.9 (SD 10.7); 61.9 (SD 10.9) for controls.  
52.8% of cases; 48.9% controls ever-users of CCBs.  
Use of HRT cases 15.7% and controls 12.4%.   
Use of Statin cases 11.4% and controls 6.8%.   
Diabetes cases 27.3% and controls 25.3%.   
Outcome(s) overall  CCB users: 




3,411 cases; 9,290 controls  
No CCB use [ref]: 
3,052 cases; 9,697 controls 
Main results  CCB ever use versus no CCB use: 
aOR 1.09 (95% CI 1.03 – 1.16) 
Duration-response analysis versus no use [ref]:  
≤1 year: aOR* 1.05 (95% CI 0.94 – 1.16) 
1-2 years: aOR* 1.08 (95% CI 0.98 – 1.19) 
2 – 3 years: aOR* 1.09 (95% CI 0.98 – 1.22) 
>3 years: aOR* 1.11 (95% CI 1.03 – 1.19) 
Test for trend, p = 0.006 
Cumulative daily defined dose (quartiles defined in paper), versus no use [ref]: 
<Q1: aOR*1.05 (95% CI 0.96 – 1.15) 
Q1-Q2: aOR* 1.07 (95% CI 0.98 – 1.18) 
Q2-Q3: aOR*1.06 (95% CI 0.97 – 1.17) 
>=Q4: aOR* 1.16 (95% CI 1.06 – 1.28) 
*Adjusted for peripheral vascular disease, diabetes mellitus, medicines use (including HRT, 
statin, beta-blocker and ACEI): 
Other analyses  Changing date of AHT by 6 – 9 months described as not changing the result.  
Discussion   
Limitations (author reported) 1) Database contained only de-identified records 
2) Only information on frequency and classes of prescribed medications, did not provide 
clinical laboratory data/clinic information  
3) No information on risk factors: physical activity, alcohol consumption, smoking, body 
mass index, socioeconomic status, and diet. Could confound association.  
Interpretation  “…the long-term use of CCBs [or beta-1 selective blockers] is likely to be associated with 
breast cancer risk”.  
Generalisability  Not mentioned.  
Funding  “No funding or sponsorship was received for this study or publication of this article”.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, aOR = adjusted odds ratio, ARB = angiotensin II receptor blocker, BMI = 
body mass index, CCB = calcium channel blocker, CI = confidence interval, HRT = hormone replacement therapy, ICD = international classification of disease.  
 
  





Author(s) and year of publication 
(Reference number on manuscript) 
Li et al. 2003 (45) 
Objectives  “To explore whether use of CCBs and other classes of antihypertensive medications are 
associated with breast carcinoma incidence…in older women.”  
Methods   
Study design  Case-control study  
Setting  Seattle-Puget Sound Metropolitan Area, United States 
Study period for outcomes occurring 1 April 1997 through 31 May 1999.  
Participants   Elibility: women aged 65 – 79 years in these counties appearing on a list of social security 
recipients provided by the Centers for Medicare and Medicaid Services.  
Cases: eligible women diagnosed with invasive breast cancer between 1 April 1997 and 31 May 
1999, having no previous history of in situ or invasive breast carcinoma. The ‘reference date’ 
for cases was the date of diagnosis.  
Controls were matched on age, selected via the Social Security register and resided in the same 
three counties cases were identified from. For reference dates for controls were chosen to match 
an expected distribution of reference dates for cases.  
Excluded: If a history of breast cancer recorded any time other than between April 1, 1997 and 
May 31, 1999.   
Variables  Outcome(s): invasive breast cancer, 
Exposure(s): exposure to AHT (beta-blocker, CCB, ACEI and diuretics) ≥ 6 months.  
Potential confounder(s): race, income, marital status, education, age at menarche, parity, age 
at first birth, age at menopause, duration of combined oral contraceptive use, ever use of HRT, 
first-degree relative history of breast carcinoma, smoking status, average daily alcohol intake, 
BMI.  
Potential effect modifier(s): nil mentioned.  
Data collection/measurement Outcome date identified through the Cancer Surveillance system, a population-based tumour 
registry. 
Exposure and covariate data collected via participant interview. Recall enhanced by ‘life 
events calendar’ and pictures of different AHT medication.  
 
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Unconditional logistic regression, adjusted for age only, as other potential confounders did not 
change effect estimate by >10% when added one-by-one to the model. Cases/controls 
categorised as ‘never users’, ‘users’, ‘former users’ and/or ‘current users’. CCB user versus 
never AHT user. Sub-analysis restricting to only AHT users, CCB use versus non-use.  
Results  
Number of participants  975 (of 1,210, 80.6%) of eligible cases were interviewed; 1,007 (of 1,365, 73.8%) on eligible 
controls were interviewed.  




Description of study group  o Greater proportion of non-white in control group.  
o Cases were somewhat more likely than controls to have an  
o early age at menarche,  
o to be older at the time of their first birth,  
o to have undergone a hysterectomy without a bilateral oophorectomy,  
o to have a first-degree family history of breast carcinoma,  
o to be ever users of HRT,  
o to have a history of hypertension,  
o to be current or former smokers,  
o to have higher levels of alcohol consumption, and  
o to have a higher BMI.  
Other demographic and reproductive characteristics were similar 
Outcome(s) overall  Ever use of CCB: 149 (15.3%) of cases; 141 (14%) of controls.  
Never use of AHT [ref]: 446 (45.7%) cases; 490 (48.7%) controls. 
Among those used antihypertensive:  
Never used CCBs: 363 cases (out of 512); 348 controls (out of 489); 
Main results  Ever use of CCB versus no use of AHTs [ref]  
aOR 1.2 (95% CI 0.9 – 1.5).  
Duration-response analysis versus no use of AHTs [ref]:  
6 months – 5 years: aOR 1.2 (95% CI 0.8 – 1.7) 
5-15 years – aOR 1.2 (95% CI 0.8 – 1.8) 
15 years: aOR 0.6 (95% CI 0.3 – 1.3) 
Former use: aOR 2.1 (95% CI 1.0 – 4.5) 
Current use: aOR 1.1 (95% CI 0.8 – 1.5)  
 
Sub-class analysis versus no use of AHTs [ref]: 
Immediate – release: 
aOR 1.4 (95% CI 1.0 – 2.1) 
Sustained – release 
aOR 1.0 (95% CI 0.7 – 1.4) 
IR- non-DHPs, positive association with ever-use: aOR 1.6 (95% CI 1.1 – 2.5), however not 
higher for long-use, lower for former versus current users.  
Other analyses  Restriction only to ever users of AHTs:  
Ever use of CCBs versus no use of CCBs [ref] 
OR 1.0 (95% CI 0.8 – 1.3)  
Duration-response analysis, versus no use of CCBs [ref] 
6 months – 5 years: OR 1.0 (95% CI 0.7 – 1.5) 
>5 years: OR 0.9 (95% CI 0.6 – 1.3).   




Discussion   
Limitations (author reported) 1) Only able to interview 80.6% of eligible cases and 73.8% of eligible controls, therefore 
there may be some selection bias.  
2) Recall of patients relied upon to collect information.  
3) Limited to women 65-79 years, may affect generalisability of results.  
4) Large number of comparisons performed; therefore associations may be the result of 
chance.  
5) More cases than controls reported a history of hypertension.  
Interpretation  “…considering the available evidence, the finding of others and our own results indicating that 
IR CCBs may be associated with breast carcinoma incidence should be interpreted with 
caution”.  
Generalisability  Restricted to women 65-79 years, therefore results may not be applicable to younger women.  
Funding  Supported by the National Cancer Institute.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug,  aOR = adjusted odds ratio, BMI = body mass index, CCB = calcium channel 
blocker, CI = confidence interval, HRT = hormone replacement therapy.  
 
  





Author(s) and year of publication 
(Reference number on manuscript) 
Li et al. 2013 (46) 
Objectives  “To evaluate associations between use of various classes of antihypertensive medications and risk 
of invasive ductal and invasive lobular breast cancers amongst post-menopausal women”.   
Methods   
Study design  Case-control study  
Setting  Greater Seattle Metropolitan Area, United States.  
Study period for outcome between 1 January 2000 and 31 December 2008.  
Participants   Eligibility criteria: women aged 55 to 74 years diagnosed as having a primary invasive breast 
cancer between January 2000 and December 2008 identified through the Cancer Surveillance 
System (CSS), the population-based tumour registry that serves western Washington state. 
Cases eligible women with invasive lobular (ILC, ICD codes 8520, 8522, 8524), and a sample of 
~ 25% with invasive ductal breast cancer (IDC, ICD code 8500) were eligible for selection as 
cases. IDC patients frequency matched by 5-year age group to ILC patients. Reference year 
defined as year of diagnosis.   
Controls (1:1:1 ratio) identified through random digit dialling on those with Landlines, from 
eligible counties (~1.2% of those eligible did not have a landline). Controls frequency matched 
for 5-year age group to ILC case patients, county, reference year. Reference year defined by 
expected distribution for controls based on reference years for cases.  
Excluded: Women for whom there was no information regarding antihypertensive medication or 
alcohol use were excluded from the analysis, as were women without a landline telephone.  
Variables  Outcome(s): ILC or IDC forms of breast cancer  
Exposure(s): use of AHT, including diuretic, beta-blocker, CCB, ACEI, ATRA, and combination 
AHTs 
Potential confounder(s): age, race/ethnicity, education level, income, alcohol use, smoking 
status, HRT use, first-degree family history of breast cancer, parity, age at first birth, 
hypertension, hypercholesterolaemia, heart disease, BMI, recent mammography, other commonly 
used medications (lipid-lowering agents, NSAIDs, diabetes, hyperlipidaemia, depression) 
Potential effect modifier(s): nil mentioned.  
Data collection/measurement  Outcome assigned via Cancer Surveillance System and confirmed via review of pathology 
reports 
Exposure and covariate information collected via an interviewer-administered questionnaire, 
medication information transcribed from pill bottles where available and visual aids also used to 
enhance recall. 
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
Polytomous logistic regression used adjusting for age (5-year categories), reference year, county, 
race/ethnicity, and recency of alcohol use. Potential confounders other than recency of alcohol 
use did not change effect estimate by >10% when added to the model individually Women who 




missing data.  had never used any type of AHT medication were the primary reference category. Analysis also 
conducted separating into ‘current users’, ‘former users’, and ‘short-term users’. Analysis 
restricted to only users of AHTs conducted. Subclass (short, long-acting, dihydropyridine, non-
dihydropyridine), duration-response and analysis stratifying by oestrogen-receptor type (positive 
or negative) also conducted.  
Results  
Number of participants  Total cohort : 2495 eligible cases identified, 1984 (80%) were interviewed, and  1313 eligible 
controls identified, 902 (69%) were interviewed, 
Included in analysis: 891 controls (of 1,313 eligible, 68%), 905 IDC and 1,055 ILC cases 
(together, of 2,495, 79%). 
Cohort with hypertension: 360 controls, 353 IDC, 416 ILC cases.  
Description of study group Similar age distributions, income, history of hypertension (44%), heart disease and 
hypercholesterolaemia. ILC less likely to be African American, more likely to be college 
graduates, less likely to be obese, relative to IDC and controls. IDC and ILC patients more likely 
to have first-degree relative history of breast cancer, to use alcohol, to smoker, relative to 
controls. Use of HRT highest for ILC, lowest for controls.  
Outcome(s) overall  CCB use amongst full cohort:  
For IDC:  CCB current use: Cases 94 and Controls 74 
                 Non-user [Ref]: Cases 477 and Controls 456 
For ILC:  CCB User: Cases 102 and Controls 74 
                 Non-user [Ref]: Cases 556 and Controls 456 
CCB use (any duration) among Cohort with hypertension 
For IDC:  CCB current use: Cases 85 and Controls 70 
                 Non-user [Ref]: Cases 268 and Controls 290 
For ILC:  CCB User: Cases 91 and Controls 70 
                 Non-user [Ref]: Cases 325 and Controls 290 
Main results  CCB use versus never use of AHTs [ref]  
Current use:  
IDC aOR 1.3  (95% CI 0.9 – 1.8) 
ILC: aOR 1.3 (95% CI 0.9 – 1.8) 
< 5 year use:  
IDC (36 cases; 35 controls): aOR 0.9 (95% CI 0.6 – 1.5) 
ILC( 34 cases; 35 controls): aOR 0.8 (95% CI 0.5 – 1.3) 
5-9.9 year:  
IDC (28 cases; 35 control) aOR 1.2 (95% CI 0.7 – 2.2),  
ILC (43 cases; 35 controls) aOR 1.3 (95% CI 0.8 – 2.4) 
≥ 10 year:  
IDC (27 cases; 12 controls) aOR 2.4 (95% CI 1.2 – 4.9),  




ILC (31 cases: 12 controls) aOR 2.6 (95% CI 1.3 – 5.3).  
Test for trend, p = 0.01. 
Association with long-term use ≥ 10 years unaffected by oestrogen-receptor status: oestrogen 
receptor-positive breast cancer invasive ductal aOR 2.3 (95% CI 1.1 – 4.8) invasive lobular 
aOR 2.6 (95% CI 1.3 – 5.2), oestrogen receptor-negative  invasive ductal aOR 3.1 (1.1 – 8.8), 
invasive lobular not reported.   
Sub-class analysis of CCBs on table 4 of paper. 
For ≥ 10 year of long-acting CCB versus never use of AHT [ref]:  
IDC (case/controls numbers not reported) aOR 2.7 (95% CI 1.2 – 5.7) 
ILC (cases/controls numbers not reported) aOR 2.5 (95% CI 1.2 – 5.5) 
Other analyses  CCB use versus use of other AHTs (but not CCBs) [ref]  
Current use:  
IDC aOR 1.4 (95% CI 0.9 – 2.0) 
ILC aOR 1.2 (95% CI 0.8 – 1.6) 
Use < 5 year 
IDC (32 cases; 33 controls) aOR 1 (95% CI 0.6 – 1.8) 
ILC (31 cases; 33 controls) aOR 0.8 (95% CI 0.5 – 1.4) 
Use 5-9.9 years: 
IDC (23 cases; 22 controls) aOR 1.2 (95% CI 0.7 – 2.3) 
ILC (29 cases; 22 controls) aOR 1.2 (95% CI 0.7 – 2.1) 
Use ≥10 years: 
IDC (25 cases; 11 controls) aOR 2.6 (95% CI 1.2 – 5.4) 
ILC (26 cases; 11 controls) aOR 2.2 (95% CI 1.0 – 4.5)   
Discussion   
Limitations (author reported) 1) Risk of recall bias.  
2) Selection bias, lower response of controls versus cases. 80% of eligible cases 
interviewed; 69% of eligible controls. 
Interpretation  Long-term use of CCBs may be associated with an increased risk of breast cancer.   
Generalisability  Two factors increase generalisability: 1) population-based design; 2) high response rates amongst 
cases and controls.  
Funding  This study was funded by the National Cancer Institute (R01-CA105041) and the 
US Department of Defense (W81XWH-05-1-0482). 
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, aOR = adjusted odds ratio, ATRA = angiotensin II receptor antagonist, BMI 
= body mass index, CCB = calcium channel blocker, CI = confidence interval, HRT = hormone replacement therapy, ICD = international classification of disease, NSAID = 
non-steroidal anti-inflammatory drug.  
  





Author(s) and year of publication 
(Reference number on manuscript) 
Lindholm et al. 2001 (57) * 
Objectives  “…to analyse the frequency of cancer in elderly patients who participate in the ‘Swedish 
Trial in Old Patients with Hypertension 2’” 
Methods   
Study design  Randomised, controlled trial.   
Setting  Sweden.  
Recruitment from 1 September 1992 through 31 December 1998.  
Mean follow-up of 5.0 years, median of 5.3 years.  
Participants  Eligible: Patients with hypertension, defined as systolic BP ≥ 180 mmHg and/or diastolic ≥ 
105mmHg, randomly assigned to beta-blocker/diuretic, ACEI (lisinopril or enalapril), or a 
CCB (felodipine 2.5mg or 5mg, or isradipine 2.5mg or 5mg daily). Within group allocation 
was non-random. Participants seen twice a year throughout study follow-up and existing 
AHT prior to trial would be continued. Follow-up from enrolment to: diagnosis of a 3rd 
cancer, death, or end of study period, whichever occurred first 
Exclusions: contraindication to any of the study drugs, a requirement for any of the study 
drugs, orthostatic hypotension, participation in another study, severe of incapacitating illness 
or unwillingness to participate.  
Variables  Outcome(s): cancer incidence (excepting basal cell carcinoma)  
Exposure(s): randomly assigned treatment with AHTs (beta-blocker/diuretic, ACEI or 
CCB). 
Potential confounder(s): age, demographic characteristics and pre-morbid conditions.  
Potential effect modifier(s): none mentioned  
Data collection/measurement  Outcome assigned via Swedish Cancer Registry, which is populated by clinical and 
pathology/cytology reports.  
Exposure assigned at randomisation, within group allocation was non-random. Covariate 
data collected at baseline.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Standardised incidence ratios (SIR) using person-years, with 5-year age group, sex and 
calendar-year specific incidence data for the whole of Sweden used as a reference. CIs 
calculated based on a Poisson distribution. Cumulative frequency function to show 
occurrence of new cancer. Log-rank test used to calculate hazard of first cancer after 
randomised, with adjustment for death and end of follow-up.  
Results  
Number of participants  No loss to follow-up for this trial. 6,614 patients enrolled in this trial, 2,196 in the CCB arm. 
Description of study group  Mean age (overall) 76 years (range 70-84 years) at baseline, 48 in CCB group (2.2%) had a 
history of breast cancer. 192 (8.7%) had a history of any cancer. For CCB group, mean age 
75.9 years, 34% male.  




SIR overall of 0.98 (95% CI 0.76 – 1.25).  
Outcome(s) overall  Breast cancer frequency overall was 67 (19.5% of total 344 incident cancer amongst women 
in the study). Frequency of breast cancer in CCB group (women only) of 19 (observed): 
22.54 (expected). 
Main results  SIR for patients in CCB group of 0.84 (95% CI 0.51 – 1.32).  
Note outcome “essentially the same” when re-analysed excluding patients with a history of 
cancer diagnosis.  
Other analyses  Nil relevant.  
Discussion   
Limitations (author reported) 1) No adjustment for risk factors: obesity, smoking, previous smoking, alcohol, or 
protective factors like participating in a clinical trial, residence in rural areas etc.  
2) No information of any pre-existing AHTs prior to enrolment. Some patients taking 
multiple AHTs (follows from inclusion criteria); this was not adjusted for.  
3) Median follow-up relatively short at 5.3 years, cancer has long latency.  
Interpretation  “We saw no significant deviation from the expected number from any cancer type”. No 
specific interpretation of breast cancer result.   
Generalisability  No discussion in the paper.  
Funding  The study was supported by grants from Astra (AstraZeneca), Merck Sharp and Dohme, 
Sandoz (Novartis) and Zeneca (AstraZeneca). 
* STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement used for RCT to be consistent with other study data, though typically RCTs 
will report against the CONsolidated Standards of Reporting Trials (CONSORT) Statement.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, CCB = calcium channel blocker, CI = confidence interval.  
 
  





Author(s) and year of publication 
(Reference number on manuscript) 
Meier et al. 2000 (47) 
Objectives  “To explore further whether long-term use of ACE inhibitors, CCBs or beta-blockers may 
be associated with a decreased or increased risk of breast cancer…” 
Methods   
Study design  Case-control study  
Setting  United Kingdom  
Study period for outcome 1 January 1992 through 30 September 1997.  
Participants   Eligibility: women ≥ 50 years old at index date with a drug prescription history in the 
database of ≥ 3 years. 
Cases a first-time diagnosis of incident breast cancer during study period (index date is date 
of diagnosis).  
Controls (4:1 case) selected for each definite and probable breast cancer case, matched by 
age, physician practice, calendar date (index date for case), and number of years of medical 
history in the database.  
Excluded: malignancy, excepting non-melanoma skin cancer prior to breast cancer 
diagnosis were excluded. 
Variables  Outcome(s): incident breast cancer.  
Exposure(s):  AHT medication, classified as CCBs only, ACEIs only, beta-blockers only, 
mixed users (all +/-diuretics).  
Potential confounder(s): smoking status, BMI, history of alcohol abuse, previous 
hysterectomy, history of benign breast disease.  
Potential effect modifier(s):  
Data collection/measurement  Outcome, exposure and covariate data via the UK General Practice Research Database 
(GPRD). Breast cancer diagnoses classified as: confirmed (undergoing mastectomy, 
radiotherapy and/or chemotherapy with detailed clinical records) and probable (hospitalised 
at first-time diagnosis and who had some information was recoded (e.g. new tamoxifen) but 
the patient record lacked further evidence of final confirmation of the diagnosis, were 
counted as cases. When assessing outcome, exposure information was suppressed.  
Statistical methods, methods for controlling 
for confounders/effect modifiers, methods 
for dealing with missing data.  
Conditional logistic regression modelling adjusting for smoking status and BMI. CCB use 
relative to no use of AHT (except for diuretic). Users separated into current and past users. 
Duration-response, subclass analyses, as well as analysis if HRT used concurrently were 
conducted. 
Results  
Number of participants  3,706 case and 14,155 controls.  
Description of study group   Mean duration of medical history of 5.3 years (range of 3 – 14 years: 50 - 59 years: 
32%, 60 -69 years: 26%, 70 years or older: 42%). 




 >75% had >5 years of follow-up.  
Outcome(s) overall  No antihypertensive, except Thiazide [Ref]: 2567 cases and 9745 controls  
CCB use any duration: 190 cases and 735 controls 
CCB use ≥5yrs: 53 cases and 226 controls 
Main results  CCB use versus no use of CCBs/beta-blockers or ACEIs [ref]  
aOR 1.0 (95% CI 0.8 – 1.1) 
Duration of CCB use versus no use of CCBs/beta-blockers or ACEIs [ref] 
1-2 years (79 cases, 293 controls) aOR 1.0 (95% CI 0.8 – 1.3) 
3-5 years (19 cases, 75 controls) aOR 1.0 (95% CI 0.6 – 1.6) 
≥5 years (53 cases, 226 controls) aOR 0.9 (95% CI 0.7 – 1.2) 
Unknown (39 cases, 141 controls) aOR 0.7 (95% CI 0.7 – 1.5)  
Other analyses  Sub-class analysis relative to use of neither CCBs, beta-blockers or ACEIs [ref]: 
Nifedipine aOR: all 95% CI cross unity value of 1.  
Other DHPs: all 95% CI cross unity value of 1. 
Diltiazem HCl: all 95% CI cross unity value of 1. 
Verapamil HCl: all 95% CI cross unity value of 1. 
Mixed CCB use: all 95% CI cross unity value of 1. 
Use of CCBs and oestrogen replacement for ≥ 3 years (5 cases; 27 controls) aOR 0.8 (95% 
CI 0.3 – 2.0).   
Discussion   
Limitations (author reported) 1) cannot extrapolate data to long-term use  
2) Unable to control for factors such as ethnic origin, socioeconomic status, physical 
activity or diet (as not recorded in the database).  
Interpretation  This analysis does not provide evidence for an association between CCBs and breast cancer.  
Generalisability  No specific mention of generalisability, though the authors note that there are a large 
numbers of cases in this study.  
Funding  The present study was not directly funded.  
Study supported in part by Cooperative Agreement FD-U-00140501 from the U.S. Food and 
Drugs Administration. The Boston Collaborative Drug Surveillance Program is supported by 
Astra, Sodertalje, Berlex Laboratories, Glaxo Wellcome, Roche, Novartis, RW Johnson 
Pharmaceutical Research Instititute, Medeva PLC.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, aOR = adjusted odds ratio, BMI = body mass index, CCB = calcium channel 









Author(s) and year of publication 
(Reference number on manuscript) 
Michels et al. 1998 (58)  
Objectives  To investigate whether self-reported use of CCB, beta-blockers, or ACE-I; relative to the use 
of diuretics, was associated with incidence of or mortality from cancer. 
Methods   
Study design  Prospective cohort study.  
Setting  United States  
Study period 1988 through 1 May 1994.  
Participants   Cohort formed from the Nurses’ Health Study participants which was initiated in 1976 and 
includes 121,701 female registered U.S. nurses aged 30 –55 years at the time of entry. For 
the current analysis, follow-up was started from 1988 after return of a questionnaire on 
medication from the participant through to May 1, 1994, or the diagnosis of cancer or 
death, whichever occurred first. 
Excluded: Participants who were reported use of both CCB and ACE-I. Women were also 
excluded from the analysis if their year of birth, smoking status in 1988, menopausal 
status in 1988, or weight or height was unknown, or if their date of death was prior to 
1988 or not yet known. 
Variables  Outcome(s): cancer incidence and mortality. Mortality results not reported here.  
Exposure(s):  thiazide diuretics, beta-blockers, calcium channel blockers, ACEIs, or any 
combination – assessed only in 1988.  
Potential confounder(s): age, weight, height, cholesterol level, systolic and diastolic blood 
pressure, smoking, amount of current smoking, alcohol intake, regular physical activity, 
menopausal status, HRT use of >=5 years, aspirin >=5 days per month, diabetes, cancer, 
stroke, myocardial infarction, CABG, PTCA, angina pectoris, hypertension in or prior to 
1988.  
Potential effect modifier(s): none mentioned  
Data collection/measurement  Outcome self-reported via 2-yearly questionnaire and these women were contacted for study 
physicians to view hospital records, blinded to exposure information.  
Exposure assigned via responses in 1998 questionnaire without further updating.  
Covariate data collected via 2-yearly questionnaire, updated during study period.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Relative risks calculated for CCB users compared to no CCB use using pooled logistic 
regression. CCB use relative to non-use, adjusting for age, multiple drug use, self-reported 
weight, height, smoking status and mean number smoked daily for women who smoked in 
1988, alcohol intake in 1988, physical activity, menopausal status in 1988, postmenopausal 
HRT, cholesterol level, systolic and diastolic blood pressure in 1988, aspirin intake, diabetes, 
history of stroke, MI, CABG, PTCA, angina, hypertension in or prior to 1988,family history 




of breast carcinoma, history of benign breast disease, age at menarche, parity, age at first 
birth, and age at menopause.  
Results  
Number of participants  18,635 in the study population, 684 died, 502 (2.7%) lost to follow-up. 2,361 on CCB; 16,274 
not on a CCB. 107,256 person-years of data.  
Description of study group  Mean age for CCB group 58 years; 56.8 years for non-CCB group. Women prescribed CCBs 
more likely to have a history of diabetes, pulmonary disease, ischaemic heart disease, angina 
pectoris, or CABG. Women reporting use of other cardiovascular medications were more 
likely to be hypertensive (38.9% versus 70.6%).  
Outcome(s) overall  852 were newly diagnosed with cancer between 1988 and 1994, and  
335 died of cancer during this follow-up period.  
Breast cancer incidence:  
Non-user of AHT [Ref]:  304 (out of total 730 cancer incident among non-user) 
CCB user:  51 (out of total 122 cancer incident among CCB user) 
Main results  CCB use versus no CCB use [ref]:  
aRR 1.07 (95% CI 0.78 – 1.48)   
[Non-user 82,524 PYs (Ref); CCB user 11,807 PYs] 
Other analyses  Nil relevant.  
Discussion   
Limitations (author reported) 1) Self-reported medication use, however population consisted of health professionals, 
which may offset information bias resulting from this.  
2) No information on duration of use, or if use began in or before 1988.  
3) Could not ascertain what proportion of women was diagnosed with cancer prior to 
taking any medications.  
4) No dose information, could not study at a sub-class level.  
Interpretation  “…these prospective data suggest a major association between the use of calcium-channel 
blockers or the short-acting formulation and cancer incidence or cancer mortality is unlikely.” 
“Further follow-up is needed to rule out late effects of calcium channel blockers on cancer 
risk”.  
Generalisability  Not discussed.  
Funding  Supported by research grant CA 40356 from the National Cancer Institute, National Institutes 
of Health, Bethesda, Maryland. 
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, aRR = adjusted relative risk, AHT = antihypertensive drug, CABG = coronary artery bypass graft, CCB = 
calcium channel blocker, CI = confidence interval, HRT = hormone replacement therapy, MI= myocardial infarction, PTCA = percutaneous transluminal coronary 
angioplasty, PYs = person-years 
 
  





Author(s) and year of publication 
(Reference number on manuscript) 
Olsen et al. 1997 (59)  
Objectives  “…to examine the incidence of cancer in a population-based cohort of approximately 18,000 
users in a well-defined region of Denmark”.  
Methods   
Study design  Cohort study.  
Setting  North Jutland, Denmark.  
Study period 1 January 1991 through 31 December 1993.  
Mean follow-up time 1.8 years (range 0 to 3).  
Participants   Cohort members received a prescription for a CCB during the study period. Follow-up from 
date of prescription through to emigration, death, or 31 December 1993. 
Excluded: malignancy diagnosis (except non-melanoma skin cancer) prior to breast cancer 
diagnosis.  
Excluded: unable to find on prescription database or death before or on the day of CCB 
prescription.  
 
Variables  Outcome(s): cancer, excluding non-melanoma skin cancer 
Exposure(s): a prescription for a CCB 
Potential confounder(s): none mentioned 
Potential effect modifier(s): none mentioned 
Data collection/measurement  Outcome assigned via Danish Cancer Registry.  
Exposure assigned via the Pharmaco-epidemiological prescription database. 
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Number of cases observed amongst cohort compared to that expected based on data from the 
Danish Cancer Registry. This was used to calculate standardised incidence ratios (SIR). County-
specific incidence rates for all tumour categories, calculated according to sex and age (in 5-year 
groups), were applied to person-years of observation to obtain the number of cancers expected 
if the incidence rates the same as that for the general population of the county, following a 
Poisson distribution.  
Results  
Number of participants (in total and 
per group) and number lost to follow-
up (if applicable) 
17,944 patients included in the study (overall assessing cancer risk, not only breast cancer). 
17,911 included in the analysis (0.2% had died or could not be found on the prescription 
database).  
 
Description of study group  Overall, 32% < 59 years of age; 28% 60 -69 years, 29% 70 – 79 years, 11% ≥ 80 years. Overall, 
49% men, 27% on verapamil only, 41% DHPs only, 24% diltiazem only, 8% mixed use.  
Outcome(s) overall  32 breast cancer cases observed: 40.3 were expected. 
Main results SIR 0.8 (95% CI 0.5 – 1.1). 




Other analyses (e.g. sub-analyses of 
subpopulations, sensitivity analyses) 
Nil relevant.  
Discussion   
Limitations (author reported) 1) Potential for people prescribed CCBs to be in poorer health, or for cancer to aggravate 
cardiovascular disease 
2) Potential for bias through these individuals having more interaction with the health 
system  
3) Follow-up period of only 3-years 
Interpretation  No breast-cancer specific interpretation, but overall: “…our study…revealed no evidence of a 
tumour-promoting effect”.  
Generalisability  Not commented upon.  
Funding  Danish Cancer Society and Danish National Research Foundation.  
Abbreviations: CCB = calcium channel blocker, CI = confidence interval.  
  





Author(s) and year of publication 
(Reference number on manuscript) 
Pahor et al. 1996 (60) 
Objectives  “…to assess whether individuals taking calcium-channel blockers, for any indication were at 
higher risk for developing cancer than those not taking those drugs.”  
Methods   
Study design  Prospective cohort study 
 
Setting  Selected countries in Massachusetts, Iowa, Connecticut, United States.  
Study period for outcome between 1988 through 31 December 1992.  
Mean of 3.7 years of follow-up. 
Participants   Eligible: Based on the Established Populations for Epidemiologic Studies of the Elderly. 
Cohort aged ≥ 65 years at baseline in 1982, 80% of eligible population interviewed. Follow-up 
until reported cancer, death, or 31 December 1992, whichever happened first. 
Excluded: if could not link with Medicare (MEDPAR) file, reported cancer prior to study 
commencement, or taking cancer-associated medication (e.g. tamoxifen).  
Variables  Outcome(s): first cancer event  
Exposure(s): patients taking CCBs in 2 weeks before baseline interview  
Potential confounder(s): age; sex; ethnic origin; coronary heart disease; heart failure; 
hypertension; stroke; diabetes; use of beta-blockers, ACEIs, diuretics, digoxin, nitrates, 
NSAIDs, aspirin, corticosteroids, oestrogens, coumarin, smoking, alcohol, physical disability, 
BMI, number of hospital visits.  
Potential effect modifier(s):  
Data collection/measurement  Outcome assigned from 6-year follow-up questionnaire through 31 December 1992 by 
examining Medicare (MEDPAR) files (validated against a Cancer Registry in one study state).  
Exposure self-reported at baseline in 1982/83. Labels from bottles/boxes also used to transcribe 
information from prescription medication.  
Covariate data self-reported at baseline interview in 1982/83. 
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Kaplan Meier curves and cox-proportional hazards stratified by region, with CCB use relative to 
non-use, adjusted for age, sex, ethnic origin, heart failure, number of hospital admissions, 
cigarette smoking and alcohol intake, with assumption of proportionality assessed.  Indicators 
for missing data used (e.g. 1.1% had data missing on cigarette smoking).   
Results  
Number of participants  Of original >10,000 interviewed in 1982/83, 6,566 participants were still alive and interviewed 
in 1988 (baseline for this study). 298 excluded because could not link with health records. Total 
cohort for the current analysis 5052 patients: 451 CCB user and 4601 non-CCB user. 
Description of study group  For study overall: Patients taking CCBs more likely to have CV disease, diabetes, to use CV 
drugs, to be disabled, to have lower diastolic BP and to be admitted to hospital. Other 




demographic data were similar. Mean age 79 for both groups.  
Outcome(s) overall  31 breast cancer events reported (7.4% of total 420 incident cancer in this study). 
Main results  Use of CCB any duration vs non-CCB [Ref]:   
aHR 1.65 (95% CI 0.49 – 5.55) 
Other analyses  Note that for cancer overall in this study, an aHR of 1.72 (95% CI 1.27 – 2.34) was reported, 
with a positive dose-response (low, medium, high dose) – test for trend p = 0.0094.  
Discussion   
Limitations (author reported) 1) Possibility of residual confounding  
2) CCB users had higher hospitalisation rates; risk of selection bias through increased 
cancer detection.  
3) Misclassification of exposure/outcome. Exposure only assessed at baseline, cancers not 
leading to hospitalisation/death missed.  
4) Mainly short-acting CCBs used in this study. Long-acting CCBs might keep below a 
“harmful threshold”.  
Interpretation  Positive association found for cancer overall, further research should assess association. 
Overall, CCBs were associated with a general increased risk of cancer in the study population. 
Generalisability  Potentially limited generalisibility to younger patients.  
Funding  National Institute on Aging, M Pahor supported by University research grants from Italy.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, aHR = adjusted hazard ratio, AHT = antihypertensive drug, BMI = body mass index, CCB = calcium 
channel blocker, CI = confidence interval, NSAID = non-steroidal anti-inflammatory drug.  
 
  




Author(s) and year of publication 
(Reference number on manuscript) 
Poole-Wilson et al. 2006 (48) 
Objectives  To report the safety profile of nifedipine gastro-intestinal therapeutic system based on 
adverse effects reported in the ACTION trial.  
Methods   
Study design  Randomised, double blind placebo-controlled trial  
Setting  Nineteen countries, multi-centre trial.  
Mean follow-up 4.9 years.  
Participants  Inclusion: Patients aged ≥ 35 years, stable symptomatic angina pectoris requiring treatment. 
Also needed a history of myocardial infarction, proven angiographic coronary artery disease, 
positive exercise test, or perfusion defect also needed, left ventricular ejection fraction ≥ 
40%. Exclusions: heart failure, any major cardiovascular event or intervention in last 3 
months, planned angiography or intervention, known intolerance to dihydropyridines, 
valvular, pulmonary disease, unstable insulin-dependent diabetes mellitus, any 
gastrointestinal condition prohibiting use of gastro-intestinal therapeutic system, any 
condition other than coronary artery disease limiting life expectancy, hypotension, 
uncontrolled hypertension, elevated creatinine or aminotransferase levels, women could only 
participate if no risk of pregnancy. Follow-up through the pre-defined end-date, patient 
refusal, clinical reason for stopping, or need for concomitant medication incompatible with 
study medication.  
Variables  Outcome(s): multiple, site-specific cancer was one of them (in absence of pre-existing 
cancer, excepting non-melanoma skin cancers)  
Exposure(s): random assignment to nifedipine gastro-intestinal therapeutic system (GITs) 
30mg, increasing to 60mg after 6 weeks, once daily or placebo 
Potential confounder(s): age, demographic characteristics, life-style and pre-morbid 
conditions.  
Potential effect modifier(s): none mentioned  
Data collection/measurement  Outcome confirmed via pathology report and Exposure assigned as part of the trial.  
Statistical methods, methods for controlling 
for confounders/effect modifiers, methods 
for dealing with missing data.  
Incidence rate for an event by assigned treatment group was calculated as the number of 
patients with the event concerned divided by the total time ‘at risk’. Hazard ratios (HRs) 
comparing nifedipine with placebo and their 95% confidence intervals (CIs) were obtained 
by Cox proportional-hazards analysis using treatment allocation as the only covariate. No 
adjustment made.  
 
Results  
Number of participants  3,825 (of which site-specific cancer data for 3,655) in nifedipine group; 3,840 (of which 
site-specific cancer data for 3,654) in placebo group.  
Females: nifedipine groups 784 and placebo group 797. 




Description of study group  Mean age 63 years for both, ~ 80% participants male.  
Outcome(s) overall  Nifedipine GITS relative to placebo: 16 (15 female, 1 male) events versus 8 events (7 
female, 1 male) respectively. 
Main results  Hazard ratio of approximately 2.25 (based on rates reported in paper, 95% confidence 
intervals not reported, though cross unity value of 1).  
Other analyses  Nil relevant.  
Discussion   
Limitations (author reported) None reported, though see interpretation below.  
Interpretation  No specific interpretation regarding breast cancer risk. “The data on particular cancers is 
based on small numbers of cases and significant differences could represent chance 
findings”.  
Generalisability  Not discussed 
Funding  Bayer Healthcare.  
* STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement used for RCT to be consistent with other study data, though typically RCTs 
will report against the CONsolidated Standards of Reporting Trials (CONSORT) Statement.  
Abbreviations: CCB = calcium channel blocker, CI = confidence interval, HR=hazard ratio  




Author(s) and year of publication 
(Reference number on manuscript) 
Raebel et al. (49) conference abstract and conference poster. 
Objectives  Conference abstract: “To assess the relationships between CCB or ACEI use and risk of 
invasive breast cancer in postmenopausal women with <1 to 12 years CCB or ACEI use”.  
 
Conference poster: “We estimated and compared risk of incident invasive breast carcinoma 
in a large cohort of postmenopausal women with hypertension who were new users of CCB 
or angiotensin converting enzyme inhibitors (ACEI)”.  
 
Methods   
Study design  Retrospective cohort study. 
Setting  United States, 3 “Kaiser Permanente” (managed care consortium) regions.  
Study period 1997 to 30 April 2013 
Participants   Women >55 years with hypertension and enrolled > 1 year prior to cohort entry, who were 
“new users” of CCBs or ACEIs.  
Excluded: <1 year follow-up, history of breast cancer  
Variables  Outcome(s): Invasive lobular carcinoma or invasive ductal carcinoma of breast 
Exposure(s): CCB or ACEI use, who were followed up for > 1 year over study period 
(1997-2012)  
Potential confounder(s): Unclear if pre-specified. Time varying covariates were: other 
AHTs, age, BMI, hysterectomy, diabetes, alcohol, oestrogen, statins, mammography, and 
non-time varying were: region, race, education and cohort entry year.  
Potential effect modifier(s): none mentioned.  
Data sources/measurement  The Kaiser Permanente data based appears to be the source for outcome, exposure and 
covariate data.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
For conference abstract: Association assessed for each year of follow-up for 12 years using a 
“life table approach” to obtain crude HRs and a discrete survival method to obtain HRs 
adjusted for covariates mentioned above. Reference group was <1 year of CCB or ACEI 
use. 
 
For poster presentation: Cox proportional hazard regression model used. 
CCB use relative to ACEI, adjusted for age, demographic characteristics and participating 
site. 
Results  
Number of participants  Total cohort 165,807 women: CCB = 29,830 (18%); ACEI = 135,977 (82%)   
Description of study group Mean age of 68 and 67 years for CCB and ACEI users, respectively. Mean follow-4.7 years 
for CCB group, of which mean time on CCB was 2.6 years.  
Outcome(s) overall  From poster: Breast cancer outcome: CCB = 572 (1.9%); ACEI = 2,688 (2.0%) 





Main results  From conference abstract: For CCB use, with <1 year of CCB use as reference (unclear if 
ACEI users included in reference group), authors state that 95% CIs of the adjusted HRs 
cross the value of 1. Examples given in abstract of 9 years, adjusted HR = 1.09 (95% CI 0.6 
– 2) and 12 years, adjusted HR = 0.88 (95% CI 0.28-2.78).  
 
From poster presentation:  
Cox Regression Analysis 
aHR 1.02 (95% CI 0.93-1.12) [Ref ACEI] 
Discrete time survival mode 
aHR 0.91  (95% CI 0.83-1.00) [Ref ACEI] 
Other analyses  From poster presentation:  
Analysis restricting to ≥ 2 years of ACEI/CCB use:  
Cox Regression Analysis 
aHR 1.08 (95% CI 0.98-1.20) [Ref ACEI] 
Discrete time survival mode 
aHR 0.97 (95% CI 0.87-1.07) 
Discussion   
Limitations (author reported)  None mentioned.  
Interpretation   Conference abstract: “Compared to <1 year use, for CCB use to 12 years, we found 
not statistically significant increase breast cancer risk”.  
 Poster presentation: “No statistically significant increase in risk of invasive breast 
cancer among postmenopausal women with hypertension exposed to CCB 
compared ACEI.” 
Generalisability  Not discussed.  
Funding   None mentioned.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, CCB = calcium channel blocker, CI = confidence interval, HR = hazard ratio.  
 
  





Author(s) and year of publication 
(Reference number on manuscript) 
Rosenberg et al. 1998 (61)  
Objectives  “To assess whether calcium channel blocker use increases the risk of cancer overall and of 
specific cancers.”  
Methods   
Study design  Case-control study 
Setting  Baltimore, New York and Philadelphia, United States.   
Study period 1983 through 1996 
Participants  Cohort: Population was patients aged 40 – 69 years admitted to study hospitals from 1983 
to 1996.  
Cases had a primary diagnosis of cancer within 1 year of admission for cancer overall and 
for site-specific cancers for which there were ≥ 20 cases. History of prior cancer (excepting 
non-melanoma skin cancer) or concurrent cancer was excluded.  
Controls selected from patients admitted for conditions judged not to be directly related to 
antihypertensive drugs. No matching criteria reported.  
Variables  Outcome(s): primary cancer (overall) within 1 year of admission to hospital; site-specific 
cancers for which ≥20 cases were available  
Exposure(s): taking a CCB, ACEIs or beta-blocker ≥1 year prior to admission  
Potential confounder(s): age, interview year, BMI, annual visits to a physician 2 years 
before admission, race, years of education, breast cancer in a mother or sister, benign breast 
disease, age at menarche, age at first birth, parity, age at menopause, alcohol consumption, 
duration of COC use, duration of oestrogen supplementation.  
Potential effect modifier(s): none mentioned.  
Data collection/measurement  Outcome via discharge summaries/pathology reports by researchers blinded to exposure 
status.  
Exposure assigned via interview, including drug, date started, duration, and frequency of 
use (but not dose).  
Covariate data via patient interview.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
For breast cancer, female cases compared to female controls. Unconditional logistic 
regression analysis comparing CCB use to non-CCB user, controlling for confounders listed 
above, age controlled for with 5-year categories. Duration-response analysis also conducted. 
Results  
Number of participants  For study overall, 9,513 (of 9,642 available for the study) cases; 6,492 (or 8,826 available) 
controls available.  
Description of study group  For study overall, mean age of cases 56 years; 41% male. Mean age of controls 52 years; 
42% male. Mean duration of use of CCBs was 3.8 years amongst cases; 3.7 years amongst 





Outcome(s) overall  For cancer overall, amongst women, 215 cases used CCBs; 190 controls used CCBs. 
92 users of CCB developed breast cancer, relative to 190 controls (women only).  
Main results  Use of CCB relative to never use [ref]  
aRR 1.1 (95% CI 0.8 – 1.4)  
Other analyses  For use ≥5 years, beginning ≥1 year before admission:  
CCB use relative to never use [ref] (amongst 27 cases, 53 controls, women only) 
aRR 1.1 (95% CI 0.7 – 1.8)  
Use of CCBs and oestrogen supplements relative to no use [ref]:  
16 cases; 32 controls, women only.  
aRR 1.1 (95% CI 0.6 – 2.0)  
Both restricting to use ≥5 years (RR, 0.8) and those using within 5 years of admission (RR, 
1.5), both 95% CIs crossed unity.  
Discussion   
Limitations (author reported) 1) Absence of information on dose, though no duration-response effect was found. 
2) Type of CCB (e.g. immediate- versus sustained-release) was not assessed.  
3) Restriction to <70 years, whereas other studies have included older cohorts.  
Interpretation  “…the present results suggest that CCB use is unrelated to the overall risk of cancer or of 
specific cancers.” No interpretation on breast cancer result specifically.  
Generalisability  Not commented upon other than restriction to cohort < 70 years of age. 
Funding  Funding by National Cancer Institute, additional support from the US FDA. Grant from 
Bayer AG and Knoll AG.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, aRR = adjusted relative risk, BMI = body mass index, CCB = calcium 
channel blocker, CI = confidence interval.  
 
  





Author(s) and year of publication 
(Reference number on manuscript) 
Sajadieh et al. 1998 (62) * 
Objectives  “…to study the risk of cancer in relation to verapamil use”.  
Methods   
Study design  Prospective randomised double-blind, placebo-controlled trial.  
Setting  Denmark 
Study period 1985 through 31 December 1993.  
Participants   Eligibility: Multi-centre trial. Patients aged 76 years following acute myocardial infarction (MI), 
randomly assigned to verapamil 120mg three times daily or placebo in week 2 following acute 
MI. Follow-up from enrolment to December 1993. 
Excluded if: treatment with CCB, beta-blockers, uncontrolled congestive heart failure, sinoatrial 
block within last 3 days before randomisation, 2nd or 3rd degree atrioventricular block persisting 
after 3rd day of admission, hypotension or other severe disease, unwillingness to participate, or 
residence outside of the catchment area. 
Variables  Outcome(s): primary outcome was mortality and major events, this study is a secondary analysis 
assessing the risk of cancer, overall and site-specific  
Exposure(s): treatment with verapamil 120mg three times daily or placebo 
Potential confounder(s): none mentioned 
Potential effect modifier(s): none mentioned 
Data collection/measurement  Outcome assigned via Danish Cancer Registry. Exposure randomly assigned as part of the study.  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
The observed cases were compared to expected values based on sex, age year (5-year group), and 
calendar-specific (5- year group) incidence rates from the Danish Cancer Registry based on 
person-years of observation. Observed compared to expected using life table analysis, 95% CI 
assuming Poisson distribution. Differences in rate ratios used to calculate standardised incidence 
ratios (SIRs).  
Results  
Number of participants  897 in placebo; 878 in verapamil group. 10,474 person-years of follow-up.  
Female participants, 183 in placebo; 176 in verapamil treated group.   
Description of study group  No significant differences in baseline characteristics. Mean duration of treatment 15 months. 
Outcome(s) overall  Total cancer occurred 130 cases: 73 in the placebo-treated group (5,214 patient-years), and 57 in 
the verapamil-treated group (5,260 patient-years).  
Breast cancer occurred in women only, 3 cases in total: 1 placebo group; 2 verapamil group. 
Expected for both placebo and verapamil of 2.5 cases.  
Main results  SIR, placebo group:  
0.4 (95% CI  0.01–2.2) 
SIR, verapamil group: 
0.4 (95% CI 0.1 – 2.9) 




Other analyses  Nil relevant  
Discussion   
Limitations (author reported) 1) Did not have information about duration of verapamil use at time of diagnosis.  
2) No correction for smoking habits (62% current smokers) 
3) Findings in patients with coronary heart disease may not be applicable to other patient 
groups. 
Interpretation  “…no increased risks in any of the groups [of individual cancers], with only one exception [lung 
cancer]”.  
Generalisability  Findings in patients with coronary heart disease may not be applicable to other patient groups.  
Funding  Funding information not reported on this paper.  
*STROBE statement used for RCT to be consistent with other study data, though typically RCTs will report against the CONSORT Statement.  
Abbreviations: CCB = calcium channel blocker, CI = confidence interval.  
  





Author(s) and year of publication 
(Reference number on manuscript) 
Saltzman et al. 2013 (50)  
Objectives  A re-analysis of earlier cohort data (study by Fitzpatrick et al. ref 35) to assess the association 
between antihypertensive medication and breast cancer risk.  
Methods   
Study design  Prospective cohort study.  
Setting  Selected counties in North Carolina; California; Maryland; Pennsylvania and; later comprising 
African American participants (geographical locations not specified), United States.  
Study period 1989/90 through 31 December 2001 for original cohort; 1992/93 through 31 
December 2001 for African American cohort.  
Participants   Adults aged ≥65 years at recruitment. Exclusion if participants institutionalised, dependent on 
wheelchair, in hospice care, receiving radiation or chemotherapy, history of breast cancer or of 
heart failure. Follow-up from recruitment through to death, breast cancer diagnosis or end of 2001, 
whichever arrived first. 
Variables  Outcome(s): breast cancer, invasive or in situ,  
Exposure(s): AHT use (CCB, Diuretics, beta-blockers, ACEI) 
Potential confounder(s): Race, smoking, history, education and income, BMI, use of oestrogen 
replacement therapy, diabetes, age, average weekly alcohol consumption, age at menopause, waist-
hip ratio. 
Potential effect modifier(s):  
Data collection/measurement   Outcome assigned by linkage to population-based cancer registries.  
Exposure assigned by details abstracted from AHT labels during annual interview. 
Covariate data during annual interview.  
Hypertension diagnosis classified by self-report, taking AHTs, having a resting systolic BP of 
≥140mmHg, resting diastolic BP of ≥90mmHg.   
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Cox proportional hazards used to assess association. AHT use treated as a time-varying exposure. 
“Exposed time” began when first reporting AHT use and continued until end of follow-up. 
Additional analysis to assess recency of use, with “exposed” considered use within previous 2 years 
for this analysis. Analyses also repeated amongst hypertensive women using AHTs to assess for 
bias by indication. Women could be included in groups for more than one class of AHT. CCB use 
relative to AHT non-user, adjusting for potential confounders included in the model only if 
changing association by >10%. Age, average weekly alcohol consumption, age at menopause, 
waist-hip ratio were retained. No evidence of effect modification found via likelihood ratio tests.  
Results  
Number of participants  Total women cohort: 3201. Follow-up period of ~12 years. 
Non user of AHT medication = 1675 (~14,081 PYs),   
CCB user (ever) = 392 (~9,916 PYs) 




CCB use within past two years = 5,740 PYs  
Description of study group Higher proportion of women using AHTs were African American, had less high School education, 
less likely to have income >$25,000. Of non-users, higher proportion was smokers, reported 
consumption of 2 alcohol drinks per week. AHT users had higher waist – hip ratio, more likely to 
be hypertensive and have diabetes.  
Outcome(s) overall  Ever user: Breast cancer during the follow-up period was 188 
Non-user of AHT [Ref]:  Breast cancer 69 (36.7% of total breast cancer incident) 
CCB user:  Breast cancer 55 (29.3% of total breast cancer incident) 
 
Use in past 2 years: Breast cancer during the follow-up period was 143 
Non-user of AHT [Ref]:  Breast cancer 53 (37.1% of total breast cancer incident) 
CCB user:  Breast cancer 40 (28% of total breast cancer incident) 
Main results  For ever use analysis versus never AHT users [ref]: 
CCB (all types): aHR 1.1 (95% CI 0.7 – 1.6) 
CCBs (immediate-release), 24 cases: aHR 1.2 (95% CI 0.7 – 2.0) 
CCBs (sustained-release), 43 cases: aHR 1.1 (95% CI 0.7 – 1.6) 
 
Use in past 2 years versus never AHT use [ref]: 
CCB (all types), 40 cases: aHR 1.6 (95% CI 1.0 – 2.5) 
CCBs (immediate-release), 16 cases: aHR 2.4 (95% CI 1.3 – 4.5) 
CCBs (sustained-release), 28 cases: aHR 1.4 (95% CI 0.8 – 2.3) 
Other analyses  No associations between AHT use and risk of any particular breast cancer subtype (data not 
presented in the paper). Amongst women with diagnosed hypertension or taking AHTs, aHR 1.8 
(95% CI 0. 9 – 3.5) for recent use of immediate-release CCBs.  
Discussion   
Limitations (author reported) 1) Data on exposure only during, but not before cohort follow-up. Therefore, could not 
accurately assess duration-response.  
2) Limited statistical power to detect modest increase in relative risk. Due to relatively small 
sample size, the study had limited statistical power to identify more modest elevations in 
risk in the range of 20–50% and to conduct sub-analyses. 
3) People moving outside of catchment areas would have had outcome data missed.  
Interpretation  “Here, we observed that while there was some suggestion that calcium channel blockers increase 
breast cancer risk, this association appears to be confined to recent use of immediate-release 
formulations”.  
Generalisability  Not commented upon specifically.  
Funding  Part support via a pilot grant Avon Foundation for Women.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, aHR = adjusted hazard ratio, AHT = antihypertensive drug, BMI = body mass index, CCB = calcium 
channel blocker, CI = confidence interval, PYs = person-years.  










Author(s) and year of publication 
(Reference number on manuscript) 
Soldera et al. 2015 (51) conference abstract and conference presentation 
Objectives  “…to determine whether the use of CCBs is associated with an increased risk of breast cancer 
overall, and to assess whether this risk varies with cumulative duration of use”.  
Methods   
Study design  Cohort study  
Setting  United Kingdom.  
Study period to 31 December 2010.  
Participants  Women newly treated with antihypertensive drugs between 1 January 1995 and 31 December 
2009.  
No exclusion criteria listed.  
Variables  Outcome(s): new diagnosis of breast cancer  
Exposure(s): Exposure to AHT (CCB, beta-blocker, diuretics, ARB or ACEI) 
Potential confounder(s): age, smoking status, body mass index, alcohol consumption, use of 
HRT or other prescription drugs.  
Potential effect modifier(s): not specified (though arguably some confounders are more 
likely effect modifiers).  
Data collection/measurement  Outcome, exposure, covariate data collection via the UK Clinical Practice Research datalink  
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Time-dependent cox proportional hazards used to estimate HRs adjusted for listed 
confounders. CCB use considered a time-varying variable, in relation to other AHT use. 
Exposure lagged by 1 year (“for latency considerations and to minimise reverse causality”).   
Secondary analysis to see if risk varied with duration of use.  
Results  
Number of participants  273,152 women in total: 1,567,104 person-years of follow-up.  
CCB user 107,337 and Non-CCB user 165,815 [Ref].  
No mention of any loss to follow-up.  
Description of study group  Mean age (SD) for CCB users 62.6 (14.3) years; 58 (16.2) years for non-users.   
Outcome(s) overall  4,520 newly diagnosed with breast cancer (incidence rate of 2.9/1,000 person-years).  
Breast cancer event: 
CCB user : 1518 
Non-CCB user (other AHT) user: 3002 [Ref] 
Main results  Incident rate for women using a CCB: 2.8/1,000 PY 
Incident rate for women using other AHTs: 3.1/1,000 PY 
CCB versus other AHT [ref]  
aHR 0.98 (95% CI 0.92-1.04) 
Addition from conference presentation (same comparison):  
aHR  0.96 (95% CI 0.90 to 1.03) [Conventional adjustment] 




aHR  0.97 (95% CI 0.89 to 1.05) [Time-varying adjustment] 
Other analyses CCB versus other AHT [ref] 
<5 years of use: HR 0.97 (95% 0.90-1.03) 
5-10 years: HR 1.08 (95% CI 0.94-1.25) 
>10 years: HR 0.69 (95% CI 0.36-1.33) 
 
Addition from conference presentation (same comparison):  
CCB use by duration relative to Non-CCB user (p-trend = 0.25) 
< 5 years (1,302/ 431,598 PYs)   aHR 0.96 (95% CI 0.90 to 1.03) 
5 to 10 years (207/ 56,192 PYs)  aHR 1.05 (95% CI 0.90 to 1.22) 
≥ 10 years (9/ 3,978 PYs)            aHR 0.61 (95% CI 0.32 to 1.20) 
 
Analysis done by CCB type (Short / long acting), all compatible with an aHR of 1.  
Discussion   
Limitations (author reported) From conference presentation:  
 
1. Misclassification of exposure possible if noncompliance or treatment by specialist since 
prescriptions issued by general practitioners;  
2. Possibility of residual confounding  
3. Power for secondary analysis may not exclude an increased risk over 10 years of less than 
20%.  
Interpretation  “The results of this large population-based study indicate that the long-term use of CCBs is 
not associated with an increased risk of breast cancer”.  
Generalisability  Not specifically mentioned.  
Funding  None mentioned.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, aHR = adjusted hazard ratio, ARB=angiotensin receptor blocker, CCB = 
calcium channel blocker, CI = confidence interval, HRT = hormone replacement therapy, PYs = person-years, SD = standard deviation.   
  





Author(s) and year of publication 
(Reference number on manuscript) 
Sorensen et al. 2000 (52)  
Objectives  To investigate both cancer incidence and cancer mortality in an extension of a previous 
analysis of CCB users by Olsen et al. (ref 56).  
Methods   
Study design  Cohort study  
Setting  North Jutland, Denmark 
Study period 1 January 1989 through 31 December 1995.  
Participants   Exposed to CCBs, as defined by receiving ≥ 2 prescriptions during study period.  
Variables  Outcome(s): incident cancer cases and cancer deaths, excluding non-melanoma skin cancers 
excluded for analysis. Mortality also an outcome, though not reported here.  
Exposure(s): taking a CCB, defined as receiving ≥ 2 prescriptions during study period.  
Potential confounder(s): Nil  
Potential effect modifier(s):  
Data collection/measurement  Outcome assigned via the Danish Cancer Registry.  
Exposure assigned via Pharmaco-epidemiological Prescription Database, 
Statistical methods, methods for 
controlling for confounders/effect 
modifiers, methods for dealing with 
missing data.  
Number of cancer cases observed amongst cohort CCBs compared to the expected number 
based on the Danish Cancer Registry, with standardised incidence ratios (SIRs) then 
calculated assuming a Poisson distribution is followed.  
Results  
Number of participants  23,167 in cohort (73,193 person-years of follow-up); 11,726 women.  
Description of study group  Mean age for women in study group 66.4 (SD 13.4) years; mean follow-up time of 3.2 years.  
Outcome(s) overall  Breast cancer frequency during the follow-up period was 84 (18.5% of total 454 malignant 
cancer incident among women in this study). 
86.7 cases expected. 
Main results SIR of 0.97 (95% CI 0.77 – 1.20)  
Other analyses   
Discussion   
Limitations (author reported) 1) Inability to control for smoking and other confounders 
2) Lack of information of CCB use before 1989  
3) Lack of clinical detail regarding indications for use, limited duration of use and 
follow-up 
Interpretation  Not specific interpretation for breast cancer. For cancer generally, the authors observe that 
“…our large, population-based study provides no evidence of an association between use of 
calcium channel blockers and an increase in cancer incidence or mortality.”  
Generalisability  Not commented upon. 




Funding  Danish Medical Research Council (Grant 9700677). Activities of Danish Epidemiology 
Science Centre financed by a grant from the Danish National Research Foundation.  
Abbreviations: CCB = calcium channel blocker, CI = confidence interval, SD = standard deviation.  
  




Appendix E. Risk of bias assessments for included studies. Reference on main paper in parentheses.    
Assimes et al. 2008 (54)* 





Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Partially Case groups had a diagnosis of cancer, whereas the control group 
did not. Otherwise, eligibility the same for both groups.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Not applicable  Study used linked data.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
No Comparison group is appropriate, justification for thiazide 
diuretic group to reduce confounding by indication and justified 
by authors based on limited evidence of any association between 
thiazide diuretics and cancer.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Did not review study protocol, no obvious difference between 
methods and results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
No No information given that assessors were blinded to exposure, 
though using Cancer Registry should reduce the risk of 
differential misclassification.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Use of linked data improves validity and reliability of measures 
used to assess eligibility. Exposure outcomes measured using 
prescriptions as a proxy for use, cited as a study limitation. 
Outcome measure used a Cancer Registry and comorbid data 
(though it is not possible to discern exactly what conditions were 
adjusted for), utilised doctors’ files. Accuracy of registry not 
explicitly discussed but for sake of review considered as 
acceptable.  
Q7. Was length of follow-up different across 
study groups? 
Yes 14.7% of the thiazide diuretic (but not CCB), compared to 2.1% 
of CCB (but not thiazide diuretic) had total use > 7.5 years. The 
“current use” > 7.5 years was 5.8% and 1.1% for the groups 





Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Not applicable  Study utilised linked data, no mention of any loss to follow-up.  
Q9. Are there important primary outcomes 
missing from the results? 
No Not relevant to this review. 
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No Not relevant to this review. 
Q11. Are the results believable taking study 
limitations into consideration?  
Yes The use of linked data reduces the likelihood of differential 
misclassification bias. Note relatively small outcome numbers for 
different exposure groups. Note that prescription database was 
offline for 18 months, which may have led to some non-
differential misclassification.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Controls matched to cases based on entry to cohort, sex and age 
(+/- 3 years).  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Some, but not all, a priori confounders in the review protocol 
were adjusted for in statistical analysis, possible for residual 
confounding from confounders such as smoking, though probably 
less concern in this study given the null result.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation, though small numbers in CCB 
exposure group cited as one study limitation.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect outcome rather 
than a benefit outcome.  




Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Indeterminable Seem reasonable to non-statistician risk-assessor, no major 
inadequacies noted other than insufficient reporting of what 
comorbid conditions were adjusted for. Residual confounders 
(e.g. smoking) not adjusted for, survival analysis accounting for 
starting then stopping medication probably preferred, but not 
allowed by data collected.  
Abbreviation: CCB = calcium channel blocker.  
  




Azoulay et al. 2012 (33) 
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Partially  Nested case-control analysis therefore 
inclusion as case needed a cancer diagnosis, 
controls selected from those registered on the 
UK GPRD.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Not applicable  Used linked data from the GPRD database.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
No  Use of beta-blockers/diuretics seems 
reasonable for this study and helps to account 
for confounding by indication.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  No obvious differences between methods and 
results reported, study protocol not reviewed if 
it exists.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes No mention of blinding, though probably not 
an issue for this study.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Measured from GPRD information and thus 
any misclassification would be expected to be 
non-differential.  
Q7. Was length of follow-up different across 
study groups? 
No  Length of follow-up 5.5 years for both cases 
and controls.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Not applicable  No mention of loss to follow-up in the study, 
as this study used GP-linked data for a cohort 
on AHTs, would expect loss to follow-up to 
be non-differential.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  




Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Residual confounders such as race would be 
useful, however, a large population-based 
study using linked-data and valid and reliable 
measures and so believable in the context of 
evidence available. 
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Controls matched to cases based on age, sex, 
year of entry to cohort, prescription of AHT in 
2 years leading up to cohort entry and duration 
of follow-up (unsure if these were adjusted for 
in the analysis). 
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Controls matched to cases as indicated in 
question 12. Controls matched to cases based 
Several confounders adjusted for in the 
analysis, some such as race omitted.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No mention of sample size calculation, though 
assembly of a 1.2 million-person cohort is 
cited as a strength of this study.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
 Seem reasonable to non-statistician risk-
assessor and in line with many of the other 
studies in this literature. Inability to adjust for 
AHTs stopping after starting is limiting, 
though attempt to demonstrate dose-response 
is good.  




Abbreviations: AHT = antihypertensive drug, GPRD = General Practitioner Research Database.  
  




Bergman et al. 2014 (34)   
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Yes Case-control study, therefore cases had 
diagnosis of cancer, controls chosen from 
population registry. Definition of 
outcome/exposure the same for both groups.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Not applicable  Study used linked data from registries rather 
than recruiting participants.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Choice of “no continuous use” as comparator 
does introduce possibility of confounding by 
indication.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  No protocol reviewed. This study aimed to 
replicate that of Li et al. (2013, ref 43), 
followed these methods using different 
database to Li and colleagues.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes No mention of blinding, though use of cancer 
registry etc. reduces risk of differential 
misclassification bias.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Valid and reliable measures used, though 
accuracy of databases with regards to 
covariates such as level of education is not 
discussed.  
Q7. Was length of follow-up different across 
study groups? 
No Similar distribution between cases and 
controls for follow-up in this study.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Not applicable  No mention of loss to follow-up from 
registries.  




Q9. Are there important primary outcomes 
missing from the results? 
No Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Study limited by not accounting for 
confounders such as smoking, alcohol and for 
use non-continuous use as a reference group 
means that confounding by indication could be 
an issue.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Controls matched to cases based on age.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Age matching of controls to cases and 
adjusted for this in the statistical analysis. 
Potential confounders considered include age, 
education level, location of residence, and 
history of benign/malignant tumour at sites 
other than the breast. However, smoking, 
alcohol intake and other important 
confounders not adjusted for in the analysis.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. However, 
reasonably large population-based study.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Indeterminable  Seem reasonable to non-statistician risk-
assessor, similar methods to other studies 
included in the literature.  










Chang et al. 2016 (35)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same for three assembled cohorts and then a 
nested case control study within this.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Uses administrative databases and so no 
recruitment.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Yes Cohort taking AHTs and with a diagnosis of 
hypertension are appropriate sources for 
comparator group of no CCB use. That he 
cohort with a diagnosis of hypertension was 
35% smaller than that taking AHTs may 
indicate some incomplete diagnostic records, 
of AHTs used for non-hypertension 
indications (e.g. post myocardial infarction for 
angiotensin-converting enzyme inhibitors 
(ACEIs)). These other conditions were 
adjusted for in the multivariable analysis.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable.  Study protocol not reviewed. No deviation 
from protocol mentioned in the paper.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes No blinding of assessors mentioned, 
administrative data use reduces risk of 
researcher misclassification of outcome +/- 
exposure.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Administrative database used has high (~99%) 
population coverage.  




Q7. Was length of follow-up different across 
study groups? 
No  One of the matching criteria for controls was 
duration of follow-up.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Not applicable  Small loss to follow-up on 1,482 (0.19% of 
794,533) for largest cohort, no mention that 
this was differential. Smaller cohorts were a 
subset of the 794,533 cohort and so no reason 
to suspect large or differential loss to follow-
up.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms of adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Yes The collection of outcome, exposure and 
covariate data used appropriate sources, 
results seem credible in spite of study 
limitations.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Matching based on age and duration of 
follow-up from within assembled cohorts to 
select for controls.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Yes Covariates other than study drugs of interest 
added stepwise in to model, the adjusted for 
variables are comprehensive, with the 
exception of smoking which is not included.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable No sample size calculation, but large 
population-based sample. Small cases 
numbers in longer duration of follow-up 
created wider confidence intervals for adjusted 




odds ratios for these groups.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable. This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Yes Conditional logistic regression used, but 
model adjusts for a large number of potential 
confounders and the sub-cohorts assembled to 
adjust for confounding by indication is a 
strength of this study. However, the model 
doesn’t include adjustment for age and 
duration of follow-up, both matching 
variables.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, CCB = calcium channel blocker.  
  




Davis et al. 2007 (36)   
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Yes Case-control study and thus cases had cancer, 
controls did not. Otherwise 
inclusion/exclusion criteria similar due to age 
matching of controls.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Indeterminable  Controls identified through random-digit 
dialling, recruitment of cases not described in 
this study.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Main limitation of this study is that the 
questions are about details so far in the past, 
comparator group probably not ideal as they 
may have less detailed medical records/recall 
compared to cases.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Indeterminable  Attempt to blind participant to exposure of 
interest, no mention of if assessors blinded to 
outcome/exposure.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
No  Questionnaire-based design introduces issues 
with recall of drug information prior to 
diagnosis of breast cancer (for cases) and 
corresponding index date (for controls). 
Unsure how initial outcome was assessed. 
Potential for misclassification bias which may 
be differential as patients with cancer might 
have better medical recall/records relative to 
controls. Authors attempted to offset this by 
sending questionnaire one week ahead of time, 
however unsure how much this would have 





Q7. Was length of follow-up different across 
study groups? 
No  Same time had passed for cases and controls, 
those using CCBs and those not.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Partially  Authors note that death in cases group might 
be higher than for controls; this is indeed the 
case (17.1% of cases deceased; 4.2% of 
controls). Attempt to correct this by obtaining 
information on women having localised, 
regional or distant breast cancer, with the 
assumption that bias would be less for women 
with localised disease at diagnosis.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review. 
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  The use of a questionnaire to collect 
information from 5 – 18 years in the past 
introduces significant recall issue and leads to 
a question of the reliability of the exposure 
data collected. This combined with relatively 
small cases numbers lead to some question 
over the association with ever use, (aOR of 1.4 
though with 95% CI 0.9 – 1.4). Compared to 
literature using linked databases to obtain 
outcome/exposure information, this study 
design would seem of lower quality. An 
attempt is made to characterise a duration-
response relationship, though none is seen.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
Partially  Controls frequency-matched to cases based on 
5-year age groups.  




through stratification, matching, propensity 
scores)? 
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
 Matching based on age, adjusted for in the 
analysis. Information on several important 
confounders was collected, though some (e.g. 
BMI) are omitted and questionnaire-based 
design might lead to differential or non-
differential misclassification.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  Small numbers recalling medication use in 
each class cited as a study limitation; no 
sample size calculation provided in the paper.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Indeterminable  The use of conditional logistic regression is 
consistent with that of many studies in the 
literature, it would have been good to list 
adjusted for confounders on this paper rather 
than referencing a previous study.  
Abbreviations: aOR = adjusted odds ratio, CCB = calcium channel blocker, CI = confidence interval.  
  




Devore et al. 2015 (37)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same for all entering the cohort study.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same for all entering the cohort study.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Having past/never use as comparator group for 
analysis introduces the risk of confounding by 
indication. The authors do address this by 
performing a secondary analysis restricting 
only to participants with hypertension.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol, if there is one, not reviewed.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes Not mentioned that assessors were blinded to 
exposure information. That all self-reported 
cases of breast cancer ended up being included 
in the analysis (due to an accuracy of self-
report data > 98%), this lack of blinding is 
probably not an important study limitation.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  There were issues in this study with imputing 
data for CCBs and ACEIs backwards for the 
NHS II cohort and where it was assumed that 
AHT were continuing through years in which 
questionnaires did not capture this 
information. Outcome data seemed 
reasonable; the authors tested the accuracy of 
self-report prior to deciding that all self-report 
cases would be included in the analysis. Some 
potential issues for recall for both exposure 




and confounders – though one would expect 
this to be a non-differential bias.  
Q7. Was length of follow-up different across 
study groups? 
No  Length of follow-up was the same for both 
groups.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Not applicable  Follow-up quoted as >90% for each cohort, no 
mention of different loss to follow-up between 
CCB users and past/never users.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  The study is based on a large population-based 
cohort. The outcome data is quite well sourced 
and a strength of this study is accounting for 
many potential confounders, though the 
authors acknowledge a limitation of this 
observational study is that residual 
confounding may be present. The major 
limiting issue for this study is that exposure 
data was reasonably inconsistently collected, 
though given the comparator group is 
past/never use perhaps this would not affect 
results significantly. The choice of past/never 
use as the comparator group introduces the 
risk of confounding by indication. That a null 
result was found might decrease the 
importance of these limitations, another 
strength is that it follows from previous work 
with the same cohort (Michels et al. 1998).  




Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  A lot of confounders were adjusted for in the 
analysis, a strength of this study. Restricting 
an analysis to only participants with 
hypertension helps to assess confounding by 
indication.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size, though this is a large 
population-based cohort study. Numbers were 
high compared to other studies.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable.  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Use of cox-proportional hazards seems more 
appropriate than other studies where logistic 
regression was used (though these were 
limited by the data available). No adjustment 
for multiple comparisons. NHS and NHS II 
data appropriately analysed separately.  
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, AHT = antihypertensive drug, CCB = calcium channel blocker, NHS = 
Nurses’ Health Study.  
  




Fitzpatrick et al. 1997 (38)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same for both.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same for both  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
No  Compares to both non-CCB users and other 
AHT users, not sure whether non-mutually 
exclusive nature of the groups is an issue.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Protocol for study not reviewed.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes Not mentioned that assessors blinded to 
exposure data.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  Use of bottle labels by interviewers improves 
the assignment of exposure data; outcome data 
would miss those cases not attending hospital. 
Data on other covariates collected by 
questionnaire, complemented with clinical 
data such as blood pressure measurement.  
Q7. Was length of follow-up different across 
study groups? 
No  No reason to think that length of follow-up 
was different.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Indeterminable  Number lost to follow-up not noted on the 
study, no mention of differential loss to 
follow-up.  
Q9. Are there important primary outcomes 
missing from the results? 
No Not relevant to this review 
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
No not relevant to this review  




intervention/exposure missing from the 
results? 
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  This study reports a positive association 
between the use of CCBs and breast cancer. 
However, some associations reported have 
small case numbers, there is not a clear dose-
response relationship shown. Immediate-
release CCBs were more prevalent at the 
beginning of the cohort, compared to the end 
and these were not differentiated in the 
analysis from sustained-release formulations. 
As other studies also found that immediate-
release CCBs, but not SR CCBs were 
associated with incident breast cancer, perhaps 
aggregating these together is not appropriate.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Most a prior confounders in this review 
adjusted for in the analysis. HRT use is 
considered in a separate stratified analysis, 
though with small outcome cases numbers.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation, though small 
incident cancer numbers cited as a study 
limitation.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess Partially Not entirely clear how the covariates 




the main harm or adverse effect outcomes 
inadequate?  
eventually adjusted for in the final model are 
chosen, choice of Cox-proportional hazards 
seems consistent with techniques used in other 
studies and appropriate to the data.  
Abbreviations: AHT = antihypertensive drug, CCB = calcium channel blocker, HRT = hormone replacement therapy, SR = sustained-release.  
  




Fryzek et al. 2006 (39)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same for all groups  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Not applicable  Using population registries, recruitment not 
necessary.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Comparison to non-users of AHTs may 
introduce risk of confounding by indication.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, methods match 
results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes No mention of blinding of assessor to 
exposure, though outcome data read from the 
Danish Cancer Registry, reducing the risk of 
misclassification bias.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Population-based registries used for this study. 
The Danish Cancer Registry’s accuracy is 
commented upon with a reference, the 
prescription database and Central Population 
Registry are not explicitly commented on 
regarding their accuracy, though would expect 
any misclassification bias to be non-
differential.  
Q7. Was length of follow-up different across 
study groups? 
No Length of follow-up not mentioned as 
different between the two groups.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No No loss to follow-up mentioned, emigration 
numbers not reported so cannot assess if they 
were different between the groups.  




Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially Some confounders are omitted. However, used 
of 3 linked populations registries, assessment 
of number of prescription-response and 
separation of dihydropyridine and non-DHP 
drugs are strengths of this study. It would have 
been interesting to see separation of 
immediate – and sustained-release 
formulation.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Information on BMI, age at menarche, alcohol 
use and physical activity was not available, 
ideally these would be adjusted for in an 
analysis in cases of uneven distribution 
between groups.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. However, this is a 
large, population-based study extending a 
previous cohort analysis.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable.  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
No  Statistical methods seem appropriate to the 
data available; separation into immediate-




inadequate?  release and SR formulations would have been 
useful, acknowledging the risk of multiple 
comparisons leading to spurious results.  
Abbreviations: AHT = antihypertensive drug, DHP = dihydropyridine.  
  




Gonzalez-Perez et al. 2004 (40)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Yes Nested case-control study, therefore cases had 
incident breast cancer, controls selected by 
matching to cases.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No   
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Compared to no CCB use, though with 
adjustment for other AHTs. Analyses also 
adjusted to hypertension.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
No  No mention of blinding of outcome assessors.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Used GPRD for outcome, exposure 
information and covariate data, thus if there is 
misclassification likely to be non-differential. 
Authors mention that several studies have 
been conducted reinforcing the completeness 
of the GPRD.  
Q7. Was length of follow-up different across 
study groups? 
No   
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No  Loss to follow-up not mentioned as an issue.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review  
Q10.  Are any important harms or adverse No  Not relevant to this review. 




events that may be a consequence of the 
intervention/exposure missing from the 
results? 
Q11. Are the results believable taking study 
limitations into consideration?  
Yes Seems to be good ascertainment of outcome, 
exposure data, analysis of duration-response 
effect and disaggregation by different drugs 
within the CCB class, adjustment for the 
majority of important confounders including 
hypertension, to account for confounding by 
indication.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Frequency matching of cases to controls based 
on age and calendar year of entry.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Authors cite as a limitation unable to collect 
information on age at menarche, family 
history, and age at first child or germ line 
mutation.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample-size calculation. Large population-
based study.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Changing from unexposed to exposed does not 
seem to have been accounted for, though 
whether this is likely to change the results 
seems unclear.  
Abbreviations: AHT = antihypertensive drug, CCB = calcium channel blocker, GPRD = General Practitioner Research Database.  
  




Grimaldi-Bensouda et al. 2016 (43)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No   
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Uses linked data, no recruitment.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Yes Comparison to users of other AHTs is 
appropriate to account for confounding by 
indication (note hypertension also adjusted for 
in the analysis).  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes No mention of blinding of assessors in the 
abstract or conference presentation.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Indeterminable  Outcome and exposure variables from 
population-based registries, source of 
covariate data not clear but seems reasonable 
to assume these were sourced from the 
Clinical Practice Research Datalink. 
Q7. Was length of follow-up different across 
study groups? 
No  No mention of different length of follow-up.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No  No mention of loss to follow-up, or 
differential loss to follow-up.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review 
Q10.  Are any important harms or adverse No  Not relevant to this review 




events that may be a consequence of the 
intervention/exposure missing from the 
results? 
Q11. Are the results believable taking study 
limitations into consideration?  
Yes Sourcing of data seems appropriate, 
comparator group probably appropriate, for 
cancer overall a duration-response analysis is 
provided, though not for breast cancer 
specifically.   
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Mentions that this is a “matched-cohort” 
study, by sex and age.   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially Use of HRT not adjusted for in analysis, other 
non a priori to this review confounders such as 
age at menarche, parity, also not adjusted for. 
However, adjustment for hypertension and 
several other medical conditions is 
appropriate. 
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation, however this is a 
large population-based study.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Yes Seem appropriate to data available, adjusted 
confounders decided based on previous 
findings as risk factors for cancer.  
Abbreviation: AHT = antihypertensive drug.  
  




Hole et al. 1998 (55)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  CCB group and non CCB group (but other 
AHTs) are both sourced from a Glasgow 
Hypertension Clinic, both compared to age 
and year of observation adjusted West of 
Scotland population-based registry data.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Not applicable.  Retrospective analysis and so no recruitment, 
just use of patient records.   
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Yes Assuming that any increased cancer risk due 
to hypertension is evenly spread between the 
CCB and non-CCB group, then the 
comparison between the groups is reasonable. 
However, the selection of population-based 
controls may mean that any increase in 
observed cancers over expected is not only 
attributable to treatment and if, for example, 
the level of hypertension control is worse in 
the CCB, relative to the non-CCB group, then 
this could be an issue.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable.  Study protocol not reviewed, methods 
correlated with reported results.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
No Co-author assigning outcome (incident cancer) 
blinded to exposure (CCB or non-CCB). 
Treatment classified by co-authors blinded to 
outcome status.  
 
Q6. Were valid and reliable measures, 
implemented consistently across all study 
Partially  Reliability of outcome measurement depends 
upon the reliability of coding in the database 




participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
used, the authors note that these data quality 
for inclusion in ‘Cancer Incidence in Five 
Continents’, “…the only accepted publication 
on the incidence of cancer”. Authors comment 
that no further searches for cancer beyond 
registry amongst clinic patients were 
conducted, in an attempt to reduce differential 
misclassification. Exposure data sourced from 
the Glasgow Blood Pressure Clinic, no 
comment by the authors of the reliability of 
these records. Limited confounding data 
collected, age and year of observation, expect 
to be accurate.  
Q7. Was length of follow-up different across 
study groups? 
Yes For CCB group average follow-up was 5 
years, for non-CCB group it was 7.8 years.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Indeterminable  Unclear if loss to follow-up is differential for 
this study, no sensitivity analyses performed 
to assess impact if there was.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this study 
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this study  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially For the portion relevant to this review, the 
case numbers are small and thus it is difficult 
to draw firm conclusions. The comparison of 
blood pressure clinic patients to population-
based controls (with only limited adjustment) 
introduces issues of potential bias to the study. 
Q12. Any attempt to balance the allocation Partially  Adjustment for age important given difference 




between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
in mean ages between the groups.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
No  Limited adjustment for confounding in this 
study.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable.  No sample size calculation for study overall. 
Small numbers of incident breast cancer in 
both the CCB (14 cases) and non-CCB groups 
(17 cases).  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  The comparison to population-based controls 
introduces issues that limit the study results 
and don’t seem to be fully accounted for in the 
statistical analysis. Adjustment for multiple 
testing using the Bonferroni correction.  
Abbreviations: AHT = antihypertensive drug, CCB = calcium channel blocker.  
  




Jick et al. 1997 (56)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Partially  Cases had a diagnosis of cancer; controls did 
not. Otherwise eligibility criteria similar.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Partially  Cases were contacted via questionnaire to 
confirm cancer diagnosis and those not 
confirming were excluded from the analysis, 
whereas controls were not contacted as part of 
the study (database records reviewed only). 
However, as only 68% of these questionnaires 
returned 
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Comparison to beta-blocker group addresses 
confounding by indication (at least partially) 
those the veracity of the relative risk relies 
upon beta-blockers themselves having a low 
risk of breast cancer.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed. Change to 
include cases not returning a questionnaire to 
confirm diagnosis justified by relative risks 
being similar when they were included to 
when they were excluded.   
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Indeterminable  No information about blinding of assessors.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  Outcome, exposure and covariate data from 
population-based registries. Issue with 
questionnaire being used to confirm diagnosis 
addressed by removing this step in the 
analysis. However 18 people who did return 
questionnaires were excluded, thus some risk 
of selection bias introduced.   
Q7. Was length of follow-up different across Indeterminable  No mention of different length of follow-up 




study groups? between the groups. 
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No Registry-based study and thus expect limited 
loss to follow-up. However, no mention of 
high or differential loss to follow-up or 
sensitivity analysis to address this.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review  
Q11. Are the results believable taking study 
limitations into consideration?  
Yes The use of linked databases to collect all 
outcome, exposure and covariate data. Thus 
any misclassification would be expected to be 
limited and non-differential. Small selection 
bias introduced by excluding some cases that 
returned a questionnaire probably does not 
markedly affect results.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Controls matched to cases based on age, sex 
and GP practice attended.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Yes Matching of controls to cases (as above) and 
adjustment for smoking, BMI, duration of 
hypertension and diuretic use. However, 
confounders such as alcohol use not adjusted 
for. Confounding by indication addressed by 
having beta-blockers as a reference group, 
unless level of control of hypertension is 
different between these groups.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
Indeterminable  No sample size calculation, adjusted RR for 
breast cancer based on 80 incident cases.  




or more between groups in at least one 
primary outcome measure? 
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Yes Conditional logistic regression used, with all 
potential confounders being included in the 
final model. Stratification by duration of use 
and dose performed for cancer overall (not 
clear trend), though not for breast cancer 
specifically.  
Abbreviations: BMI = body mass index, GP = general practitioner.  
  




Lam et al. 2014 (42) * conference abstract and presentation *  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Partially  Cases had incident breast cancer; controls did 
not. Otherwise eligibility appears the same.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Not applicable  Population-based registry and patients thus not 
recruited.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Selection of matched controls not on a CCB 
introduces risk of confounding by indication. 
However, matching controls to cases based on 
hypertension reduces the importance of this.   
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable.  Study protocol not reviewed, methods appear 
to match results but note assessment based 
upon conference abstract and poster.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Indeterminable.  No information provided.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  Limited information on outcome, exposure, 
and covariate allocation – used registry-based 
information and thus would expect any 
misclassification to be non-differential (except 
in case of missing data/more detailed data e.g. 
for the CV group).  
Q7. Was length of follow-up different across 
study groups? 
Indeterminable No information on any length of follow-up.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Indeterminable  Matching of controls to cases by follow-up 
time.   
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse No  Not relevant to this review.  




events that may be a consequence of the 
intervention/exposure missing from the 
results? 
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Issues with potential confounding by 
indication, selection of two different groups of 
patients makes for interesting comparison, 
though those undergoing coronary 
angiography are at particular risk of residual 
confounding. Attempt to replicate a previous 
study, not compelling evidence of an 
association.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Matching based on age, race, tobacco, alcohol, 
BMI and follow-up time.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Adjustment for history of other cancers, 
family history of breast cancer. Assume also 
adjustment to matching covariates, though this 
is not mentioned. Some confounders such as 
use of HRT not adjusted for.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation, numbers of 
incident breast cancer not reported, just 
relative risks.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Yes Use of cox-proportional hazards allows 
adjustment for length of exposure, adjustment 
for several confounders.  
Abbreviation: CCB = calcium channel blocker.  
  




Largent et al. 2010 (43)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same for both groups.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same for both groups.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  “No regular use” comparator introduces risk 
of confounding by indication.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, methods match 
results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Indeterminable  No information on blinding provided.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  Outcome data verification adequate, authors 
quote 99% accuracy for the population-based 
registry used. Confounder data seems to be 
from baseline questionnaire (1995-96) rather 
than from 2001-01 where exposure data are 
sourced. Thus a risk those confounder 
characteristics have changed in the interim. 
Unclear if all of these data were collected in 
each subsequent survey. Self-report of 
exposure data also, risk of recall bias. 
Q7. Was length of follow-up different across 
study groups? 
Indeterminable  Not mentioned if length of follow-up was 
different for comparator groups.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Yes Cox-proportional hazards analysis addresses 
any differential loss to follow-up.  




Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  No relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  The collection of exposure and confounding 
data is less reliable than population-based 
databases, though self-report of exposure data 
does potentially reduce issues of prescription 
as a proxy for taking the drugs (a problem 
when using the prescription databases). The 
outcome allocation is reliable. 
Misclassification of exposure would likely be 
non-differential, though confounding variables 
may be more/less accurately reported by 
patients with hypertension relative to those 
without 
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Yes Age-stratified analysis adjusted for a large 
range of confounders. No adjustment for 
hypertension (or level of control) and 
comparator of ‘no regular use’ introduces risk 
of confounding by indication, though less 
important given null result.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. 84 breast cancer 
cases in the CCB group.  




Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  No duration-response, dose-response analysis, 
but otherwise statistical methods are adequate.  
Abbreviation: CCB = calcium channel blocker.  
  




Leung et al. 2015 (44)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Partially  Cases had a diagnosis of incident breast 
cancer, controls did not. Otherwise eligibility 
criteria the same.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Not applicable.  Study utilised population-based databases.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Yes Given participants were only hypertensive 
patients.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, methods match 
the reported results.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
No  No mention of blinding of assessors.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Outcome, exposure and confounding variables 
collected from a population-based database.  
Q7. Was length of follow-up different across 
study groups? 
Indeterminable  No mention of different loss to follow-up.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Indeterminable  No mention of differential or high loss to 
follow-up, not adjustment in sensitivity 
analysis.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse No  Not relevant to this review  




events that may be a consequence of the 
intervention/exposure missing from the 
results? 
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Main limitation is that the variables adjusted 
for in the analysis are not clarified in the 
study, residual confounders such as alcohol 
use, BMI may be important given that the 
bottom of the 95% CI for the adjusted analysis 
is close to unity. Dose-response analysis 
strengthens cases for a true association with 
these data. 
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Controls matched to cases based on age, index 
data and year of hypertension.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Residual confounding (e.g. by BMI, alcohol 
etc. as highlighted by the authors).  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. A large number of 
cases taking a CCB.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Model covariates unclear for the main 
analysis. Duration-response analysis is 
helpful, though more detailed data would 
allow correction for differential follow-up 
time.  




Abbreviations: BMI = body mass index, CCB = calcium channel blocker, CI = confidence interval.  
  




Li et al. 2003 (45)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Partially  Cases had incident breast cancer and controls 
did not. Otherwise selection criteria were the 
same.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same 
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Risk of confounding by indication, though 
sub-analysis restricting to “ever users” of 
AHTs in an attempt to explore this.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable. Study protocol not reviewed.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes No information provided on blinding of 
assessors.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  Outcome data linked to population-based 
registries. Exposure based on interview, with 
visual aids to enhance recall. Confounders 
also collected via interview. Note that 80.6% 
of eligible cases and 73.8% of controls were 
interviewed, introducing risk of selection bias.  
Q7. Was length of follow-up different across 
study groups? 
Indeterminable  No indication that length of follow-up was 
different.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Indeterminable  Note differences in response to take part in 
study, in Q6. No adjustment for this.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to review 
Q10.  Are any important harms or adverse No  Not relevant to review 




events that may be a consequence of the 
intervention/exposure missing from the 
results? 
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Issues with multiple comparisons, some 
potential selection bias, misclassification due 
to recall limitations etc. This study focussed 
mainly on IR CCBs, which are no longer 
commonly used. Age adjustment only could 
introduce issues, as collectively potential 
confounders may have had a marked impact 
(i.e. above the 10% mentioned by the co-
authors for individual covariates) on the 
associations reported.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Matching of controls to cases based upon age 
and location.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
No  Omitted from analyses (other than age) as 
found to impact association by <10%, when 
added to model individually.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. 149 cases were 
“ever users” of a CCB.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Adjustment for potential confounders seems to 
be limited; age-adjustment only may not be 
sufficient for this analysis.  




Abbreviations: AHT = antihypertensive drug, CCB = calcium channel blocker.  
  




Li et al. 2013 (46)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Partially  Cases have incident invasive ductal or 
invasive lobular breast cancer; controls do not.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Yes Cases identified by population-based cancer 
registry, controls identified via random digit 
dialling.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Use of “never use” of an AHT as the reference 
group could introduce a risk of confounding 
by indication. However, this was explored in 
an additional analysis, with similar results to 
that seen with the original reference group.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, however, 
methods described match the results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes No indication of blinding of assessors.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  Outcome data used population-based 
registries, with reclassification of type as 
necessary based upon review of pathology 
records. Exposure data relied on self-report by 
participant, introducing risk of recall bias. 
Tablet bottles/boxes and visual aids used to 
enhance recall. Potential confounder 
covariates collected by interview, thus again 
risk of recall bias.  
Q7. Was length of follow-up different across 
study groups? 
Indeterminable No mention of different length of follow-up. 
Duration-response analysis would partly 
correct for any difference.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
No Differential response rate for this case-control 
study listed as a study limitation and may 




assessed (through sensitivity analysis or other 
adjustment method)? 
introduce some bias. 
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Concern with adding potential confounders to 
model changing association by >10%, as 
combination of several confounders adjusted 
for in the model may have impacted results. 
Case numbers are relatively small (e.g. 27 
ductal; 31 lobular) for the >=10 year sub-
analysis.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Controls frequency matched for 5-year age 
group to ILC case patients, statistical analysis 
methods also mentions matching by county 
and by reference year. 
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Concerns noted in Q11 regarding 
parsimonious model used by authors in this 
study. Addition of further covariates may have 
affected the strength of the association 
reported.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. Total 94 ductal 
and 102 lobular cases amongst CCB ever 
users for this study.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess Partially  Issues noted with adding each potential 




the main harm or adverse effect outcomes 
inadequate?  
confounder to model individually to see if 
relative risks alter by >10%, residual 
confounding may present an issue in this 
analysis. No corrections for multiple testing.  
Abbreviations: AHT = antihypertensive drug, CCB = calcium channel blocker.  
  




Lindholm et al. 2001 (57)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same for all groups.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same for all groups  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Comparison to general population to calculate 
SIR may make confounding by indication an 
issue.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, methods 
described match results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Indeterminable  Double-blinded.   
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Use of cancer registry to assess endpoint 
reduces risk of non-differential 
misclassification.  
Q7. Was length of follow-up different across 
study groups? 
No  This is accounted for in the analysis.   
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No  Loss to follow-up not assessed through 
sensitivity analysis, analysis is intention-to-
treat. 77% of CCB group was still taking CCB 
as assigned after 4 years in the trial.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse No  Not relevant to this review.  




events that may be a consequence of the 
intervention/exposure missing from the 
results? 
Q11. Are the results believable taking study 
limitations into consideration?  
Yes Though small case numbers and inability to 
adjust for potential confounders such as 
smoking may limit analysis. This is, for 
example, if the smoking prevalence is higher 
amongst the CCB group relative to the general 
Danish population. Latency is also a potential 
issue here given reasonably short length of 
follow-up.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Randomisation helps to reduce bias, though 
there are some potential issues in differences 
between trial participants and the general 
population that don’t seem to have been 
adjusted for in these authors’ analysis.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation provided. Only 19 
observed breast cancer cases during the trial.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  It may have been useful to compare 
randomised groups to one another, rather than 
comparing to the general Danish population 
via SIRs.  
Abbreviation: SIR = standardised incidence ratio.  









Meier et al. 2000 (47)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Partially  Cases had incident breast cancer; controls did 
not. Otherwise eligibility criteria are the same.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Not applicable.  Use of population-based registry (the UK 
GPRD).  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Selection of no AHT use as the reference 
group introduces the risk of confounding by 
indication.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, methods 
described correspond to results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes No information on blinding, though use of 
population-based registry reduces risk of 
differential misclassification.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially.  Use of population-based registries to assess 
outcome, exposure, and potential confounders 
are reliable measures. Assumes that 
prescription is a proxy for use. ‘Definite’ and 
‘probable’ cases included seems reasonable 
and tested via sample of probable cases for 
which confirmation was requested.  
Q7. Was length of follow-up different across 
study groups? 
No  Mean follow-up of 5.3 years, no mention of 
differential length of follow-up. More than 
75% of case and control groups had follow-up 
> 5 years.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No  Population-based registry and thus expect loss 
to follow-up to be low. No mention of 
differential/high loss to follow-up and no 
adjustment for this.  




Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Yes Outcome, exposure and confounding data are 
sourced from the same, and a reliable source. 
Exploration of the effect of several 
confounders (though not those such as 
socioeconomic status) available via the 
GPRD. 190 cases in the CCB group and 
exploration of duration-response and 
individual CCBs subclasses are strengths of 
this study. Limited by relatively short follow-
up.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Yes Controls matched by age, physician practice, 
calendar date (index date for case), and 
number of years of medical history in the 
database.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Exploration of the impact of several 
confounders on the association between CCBs 
and breast cancer explored, though only 
smoking and BMI included in final model. 
Authors report that adding further covariates 
to the model (in multivariate models, assume 
several added simultaneously to model) did 
not “materially change” association.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation, 190 cases in the 
CCB group.  




Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
 Seem adequate, though no correction for 
multiple testing.  
Abbreviations: AHT = antihypertensive drug, BMI = body mass index, CCB = calcium channel blocker, GPRD = General Practitioner Research 
Database.  
  




Michels et al. 1998 (58)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No   
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Comparison to women using ‘other 
cardiovascular drugs’ could introduce bias in 
women for each group having different 
patterns of morbidity, may be related to 
differential risk of cancer.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, methods 
described match results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
No  Physicians confirming outcome blinded to 
exposure information.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  Outcome data self-reported with confirmation 
by physician. Exposure data self-reported in 
1988 and not updated beyond this. The 
authors’ report that 57% of those using CCBs 
in 1988 were still reported this use in 1994. 
Recall bias may be reduced by this cohort 
being made up of nurses, however, change in 
pattern of drug use or duration of use could 
not be adjusted for. In 1988 CCBs primarily 
immediate-release. Covariate data self-
reported and updated 2-yearly via 
questionnaire.  
Q7. Was length of follow-up different across 
study groups? 
No No reported difference in length of follow-up.  




Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No  No mention of differential/high loss to follow-
up, no exploration through sensitivity analysis.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Main issue with this study is that the exposure 
is assigned at baseline. Recall bias is also an 
issue given self-reporting of exposure data and 
potential confounders. Multiple confounders 
are adjusted for in this analysis. No 
exploration of dose- or duration-response and 
timeframe means that CCBs under study 
would be mainly immediate-release, rather 
than majority sustained-release in 
contemporary practice.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Multiple self-reported potential confounders 
adjusted for in the analysis, omission of some 
(e.g. socioeconomic status) but otherwise 
adequate (acknowledging potential drawbacks 
of self-reported data).  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
Indeterminable  No sample size calculation; 51 incident breast 
cancer cases amongst 11,807 person-years of 




or more between groups in at least one 
primary outcome measure? 
CCB use; 304 breast cancer cases amongst 
82,524 non-CCB users.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable.  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Incorporation of person-years of follow-up 
helps to reduce the impact of loss to follow-
up, adjustment for multiple confounders in the 
analysis. Main limitation in this study of 
assignment of exposure at baseline without 
review during study cannot be rectified 
through statistical analysis.  
Abbreviations: CCB = calcium channel blocker.  
  




Olsen et al. 1997 (59)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
Not applicable  Population-based database used for identifying 
participants.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially Population-based comparator group introduces 
bias if people on a CCB are less well/ have 
more interaction with the health system (and 
therefore more opportunities for diagnosis of 
cancer). Age-adjustment probably doesn’t 
address this adequately.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable.  Study protocol not reviewed. Methods 
described match results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
No  No mention of blinding of assessors, though 
assignment of outcome and exposure has low 
vulnerability to selection bias.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Use of population-based registries to assign 
outcome and exposure reduces risk of 
differential misclassification. No exploration 
of covariates in this study.  
Q7. Was length of follow-up different across 
study groups? 
No  No mention of different length of follow-up.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No  Use of population-based registries makes risk 
of loss to follow-up low, not mentioned that 
there is high/differential loss to follow-up and 
no sensitivity analysis for this.  




Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this study  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this study 
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Limitation of this study is risk of bias due to 
confounding, including confounding by 
indication.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Partially  SIRs calculated with expected case numbers 
adjusted for age and county.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
No  Limited adjustment for potential confounders 
in this analysis. 
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. 31 breast cancer 
cases included in this analysis.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Residual confounders not accounted for in this 
analysis. Null results makes this less of an 
issue, though could still affect the association.  
Abbreviation: CCB = calcium channel blocker.  
  




Pahor et al. 1996 (60)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same 
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Comparison to non-CCB users introduces the 
risk of confounding by indication; note that 
81.7% of those taking CCBs had hypertension, 
relative to 90% in the CCB group.   
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, if it exists, 
methods described match the results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes No mention of blinding of assessors.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  Outcome data assigned by reviewing 
Medicare Provider files, the validity of this 
assessed by comparing to Iowa’s Cancer 
Registry. Exposure data self-reported at 
baseline, interviewer aided by asking for tablet 
bottle/boxes. Covariate data, including self-
report of comorbidities and measurement of 
clinical indicators such as blood pressure 
taken as baseline. Self-reported data 
susceptible to recall bias.  
Q7. Was length of follow-up different across 
study groups? 
No  No indication of differential loss to follow-up, 
average follow-up of 3.7 years.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
Indeterminable  No reported high/differential loss to follow-
up.  





Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Issue with assignment of exposure and 
covariates at baseline being carried through on 
the Kaplan-Meier curves. Positive association 
for CCB and breast cancer crosses unity, but 
has low numbers. Timeframe of study means 
likely to be majority data for immediate-
release CCB.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
Partially  Stratification by region in the analysis.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Stratification by region, age, ethnic origin, 
heart failure, number of hospital admissions, 
cigarette smoking, alcohol intake and 
oestrogen use. Residual confounders such as 
BMI, socioeconomic status not adjusted for in 
this analysis. No adjustment for level of blood 
pressure control in this majority hypertensive 
population.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
 No sample size calculation. There are 31 
events amongst CCB and non-CCB users in 
this cohort, total cancers among CCB users in 
this study 47 (therefore estimated 4 cases of 
breast cancer among users in this study).  
Q15. Are the statistical methods used to assess Not applicable.  This review is assessing a harm/adverse effect 




the primary benefit outcomes inadequate?  outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Seems adequate, though limited scope with 
small cases number for breast cancer analysis. 
Carrying forward exposure data through 
survival analysis could be problematic if 
people stop taking CCBs during the study.  
Abbreviations: BMI = body mass index, CCB = calcium channel blocker.  
  




Poole-Wilson et al. 2006 (48)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same for both groups.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same for both groups.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Yes Reasonable assuming sufficient equipoise with 
treatment at the time to justify a placebo 
control.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed. Methods 
described match results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Indeterminable  Double-blinded.   
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Examination of pathology reports seems 
reasonable assuming undertaken by a 
competent person. If assessors unblinded, 
potential risk of ascertainment bias.  
Q7. Was length of follow-up different across 
study groups? 
No  No evidence of different length of follow-up 
between groups.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Not applicable  Analysis appears to be intention-to-treat.  
Q9. Are there important primary outcomes 
missing from the results? 
No Not relevant to this review.  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
No  Not relevant to this review.  




intervention/exposure missing from the 
results? 
Q11. Are the results believable taking study 
limitations into consideration?  
Yes However, small case numbers reported.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
No  No correction for confounding.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable. No sample size calculation provided in the 
reviewed paper.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Seem reasonable and correction for person-
time in study to calculate hazard ratio is a 
strength. However, a 95% confidence interval 
would be useful.  
 
  




Raebel et al. 2015 (49) *conference abstract and presentation *  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  No difference in selection criteria for 
compared groups, though which groups are 
compared is not entirely clear from the 
conference abstract.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  No recruitment, insurance database used.  
Q3.  Is the selection of the comparison group 
inappropriate, afar taking into account 
feasibility and ethical considerations? 
Indeterminable  The authors indicate that the reference was 
<1-year use, though not clear if angiotensin-
converting enzyme inhibitors (ACEIs) and 
calcium channel blockers (CCBs) part of 
cohort assessed separately (one would assume 
that there is some crossover, with some cohort 
members taking both agents).  
 
Based on the poster presentation, comparator 
is reference is users of ACEIs, this is an 
appropriate comparator.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable Study protocol not mentioned.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Indeterminable  Not mentioned in this conference abstract or 
presentation.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes The use of an insurance database for exposure, 
outcome and covariate data seems appropriate, 
though no information about this health 
information system accuracy is provided.  




Q7. Was length of follow-up different across 
study groups? 
Indeterminable  Unsure if reference group (<1 year of use) 
stopped taking CCBs or were followed up for 
less time on average than those taking CCBs 
for a longer period of time.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
Indeterminable  No mention of any loss to follow-up. 
Retrospective cohort assembled.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review.  
Q10.  Are any important harms of adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review.  
Q11. Are the results believable taking study 
limitations into consideration?  
Indeterminable.  Full study results were unable to be published 
in this conference abstract, full appraisal of 
data not possible.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No  None mentioned.  
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Smoking not adjusted for, assessing users of 
CCBs +/- ACEIs only likely reduces the risk 
of confounding by indication.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable.  No sample size calculation, though large 
cohort assembled of 165,807 women. Cases 
numbers of incident breast cancer not 
reported. Stratification by single years of 
follow-up may reduce the preciseness of 




hazard ratio point estimates.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable.  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Indeterminable. This depends on whether follow-up time 
differed between groups. Questions around 
whether mortality was higher for reference 








Rosenberg et al. 1998 (61)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
Yes Cases had incident cancer, controls had 
conditions not judged to be related to 
antihypertensive drugs. This could introduce 
some bias between cases and controls. 
Controls are hospital-based.  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Both recruited on admission to study hospitals 
between 1983 and 1996.  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Comparison to never use could introduce 
confounding by indication. In a sub-analysis 
CCB use was compared to use of beta-
blockers, but this was for cancer generally 
rather than breast cancer specifically.   
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed. Methods 
described match results reported. Sub-analysis 
with beta-blocker comparison doesn’t seem to 
be a priori, however, not relevant to breast 
cancer outcome.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
No  Assessors allocating disease were blinded to 
exposure status.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Partially  Outcome, exposure and covariates obtained by 
interviewers on admission to hospital, risk of 
recall bias. Hospital-based cases/controls may 
limit generalisibilty of data to general 
population.  
Q7. Was length of follow-up different across 
study groups? 
No  No indication of differential length of follow-
up 
Q8.  In cases of high loss to follow-up (or No  Data collected at baseline therefore loss to 




differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
follow-up is not an issue.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review 
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Interview collection of data at baseline, and 
that these are people admitted to hospital are 
important limitations of this study. Blinding of 
outcome assessors to exposure is a strength.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially The most important missing confounder is 
smoking status.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. 92 breast cancer 
cases amongst CCB users.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
No  Statistical analysis seems adequate, though 
some confounding not accounted for, CCB 
considered as a class for breast cancer 




analysis, short latency period accounted for by 
requiring >=1 year before admission for AHT 
use.  
Abbreviations: AHT = antihypertensive drug, CCB = calcium channel blocker.  
  




Sajadieh et al. 1999 (62)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same for both groups 
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same for both groups 
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Yes Reasonable assuming sufficient equipoise for 
trial question to justify placebo.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, methods 
described match results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Indeterminable  Double-blinded.   
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Use of cancer registry to assign outcome 
should reduce risk of misclassification, 
exposure assignment undertaken at random. 
Q7. Was length of follow-up different across 
study groups? 
No  No evidence of differential length of follow-
up 
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No  Analysis appears to be intention-to-treat. N 
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
No  Not relevant to this review 




intervention/exposure missing from the 
results? 
Q11. Are the results believable taking study 
limitations into consideration?  
Yes However, small patient numbers and use of 
thrice daily dosing verapamil limit relevance 
to contemporary practice.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
No  No confounders assessed for in analysis. Risk 
factors, medical conditions, age, sex, reported 
in the trial appear to be reasonably evenly 
spread between the groups.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculations, though note 
small case numbers reported.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Reporting of SIRs limits comparison between 
placebo and active groups. However, small 
case numbers probably means that this is 
unimportant to overall study interpretation as 
relevant to this review.  
 
  




Saltzman et al. 2013 (50)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  For main analysis restriction to never use of 
AHTs, however sub analysis restricting to 
women diagnosed with hypertension.  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed, however 
methods described match results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Indeterminable  No information that interviewers are blinded 
to exposure/outcome (would not make sense 
that they are).  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
 Linked data are used to assign outcome via 
cancer registries. Exposure and covariates data 
are collected during interview, with 
measurement of blood pressure during 
interview. Assignment of hypertensive status 
by self-report, taking AHTs, or by clinical 
measurement.  
Q7. Was length of follow-up different across 
study groups? 
No  No indication of differential length of follow-
up. Comment by authors that people moving 
outside catchment area would not be included 
amongst outcome data.  
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No No high/differential loss to follow-up reported 
or tested in sensitivity analysis.  




Q9. Are there important primary outcomes 
missing from the results? 
No Not relevant to this review 
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review 
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Main result is for immediate-release CCBs, 
may have limited relevance to contemporary 
practice.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially Multiple confounders added to model to see if 
estimate changed by >10%, excluded if not 
changing by >10% alone.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation, 55 cases amongst 
all CCB use.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Issue with adding individual covariates to 
model and assessing change (rather than 
together) which could mean residual 
confounding is retained in the model. No 
adjustment for multiple testing.  
Abbreviations: AHT = antihypertensive drug, CCB = calcium channel blocker.  
  




Soldera et al. 2015 (51) *conference abstract and presentation *  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same  
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No Same 
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Yes Comparator of other AHTs helps to address 
confounding by indication improves 
comparability but may limit generalisability 
(though that latter probably doesn’t matter).  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed. Limited methods 
and results due to conference 
abstract/presentation format, however methods 
described match results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
No  No indication, use of population-based 
registries makes this unimportant.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Use of population-based registries amongst 
AHT users is reliable and consistently used in 
this study.  
Q7. Was length of follow-up different across 
study groups? 
Indeterminable  No indication of differential length of follow-
up 
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
adjustment method)? 
No No indication of differential/high loss to 
follow-up or sensitivity analysis for this.  
Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review 




Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially Large, population-based study appears to 
adjust for several relevant confounders. Risk 
of residual confounding if comparator groups 
different in regards, for example, to 
socioeconomic status. Abstract/presentation 
format limits information available to critique.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
Partially  Some confounders, e.g. socioeconomic 
status/ethnicity omitted. However 
confounding by indication reduced by study 
design.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. However this is a 
large population-based study.  
Q15. Are the statistical methods used to assess 
the primary benefit outcomes inadequate?  
Not applicable  This review is assessing a harm/adverse effect 
outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Introduction of latency and hazard analysis is 
adequate and appropriate to these data.  
Abbreviation: AHT = antihypertensive drug.  
  




Sorensen et al. 2000 (52)  
Question to assess the risk of bias  Assessment (yes, partially, no, 
indeterminable, not applicable)  
Evidence/Comments  
Q1. Do the inclusion/exclusion criteria vary 
across the comparison groups of the study? 
No  Same 
Q2. Does the strategy for recruiting 
participants into the study differ across 
groups? 
No  Same  
Q3.  Is the selection of the comparison group 
inappropriate, after taking into account 
feasibility and ethical considerations? 
Partially  Comparison to Danish General Population 
may not be appropriate if the characteristics of 
those taking CCBs differ from the general 
population (i.e. more hypertension, different 
distribution of cancer-related risk factors such 
as smoking).  
Q4. Does the study fail to account for 
variations in the execution of the study from 
the proposed protocol? 
Indeterminable  Study protocol not reviewed. Methods 
described correspond to results reported.  
Q5. Was the outcome assessor not blinded to 
the intervention or exposure of participants? 
Yes Not highly relevant to this study design, no 
information of any blinding of assessors 
provided.  
Q6. Were valid and reliable measures, 
implemented consistently across all study 
participants used to assess inclusion/exclusion 
criteria, intervention/exposure outcomes, 
participants health benefits and harms, and 
confounding? 
Yes Use of population-based registries utilising 
linked data means that measures are reliable; 
any misclassification bias would be expected 
to be non-differential.  
Q7. Was length of follow-up different across 
study groups? 
Not applicable  Mean follow-up time for 3.2 years, assume 
that calculation of SIRs considered expected 
cancer incidence over this length of follow-up. 
Q8.  In cases of high loss to follow-up (or 
differential loss to follow-up), was the impact 
assessed (through sensitivity analysis or other 
Not applicable  See question 7.  





Q9. Are there important primary outcomes 
missing from the results? 
No  Not relevant to this review  
Q10.  Are any important harms or adverse 
events that may be a consequence of the 
intervention/exposure missing from the 
results? 
No  Not relevant to this review  
Q11. Are the results believable taking study 
limitations into consideration?  
Partially  Non-adjustment for potential confounders is 
an issue with this study design. Furthermore, 
incident cancer over the 3.2 years of follow-up 
were 84, so relatively small numbers to 
calculate SIR. This study was unable to assess 
exposure prior to 1989, and the study period 
means that immediate-release CCBs probably 
predominate. No dose/duration-response 
analysis, or breakdown of CCB class into 
subclasses.  
Q12. Any attempt to balance the allocation 
between the groups or match groups (e.g. 
through stratification, matching, propensity 
scores)? 
No   
Q13. Were the important confounding 
variables taken into account in the design 
and/or analysis (e.g. through matching, 
stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as 
instrumental variables)?  
No  SIR would adjust for age, though other 
confounders not accounted or in this analysis.  
Q14. Is the sample size sufficiently large to 
detect a clinically significant difference of 5% 
or more between groups in at least one 
primary outcome measure? 
Indeterminable  No sample size calculation. This study had 84 
cases of incident breast cancer amongst a 
cohort of 11,726 women.  
Q15. Are the statistical methods used to assess Not applicable  This review is assessing a harm/adverse effect 




the primary benefit outcomes inadequate?  outcome rather than a benefit outcome. 
Q16. Are the statistical methods used to assess 
the main harm or adverse effect outcomes 
inadequate?  
Partially  Calculation of SIRs as a measure of relative 
effect leaves the possibility of differences 
between the cohort members taking CCBs and 
the general population (e.g. confounding by 
indication). This is less important given null 
result of this study.  
Abbreviations: CCB = calcium channel blocker, SIR = standardised incidence ratio.  
  




Appendix F Quality assessments 
Table 1. Non-randomised studies with quality assessment using the Newcastle-Ottawa Scale.(1)   
Study author(s) and 
year of publication 
(reference on 
manuscript) 
Study design  Number of stars assigned  Total 
  Selection Comparability 1, 2 Exposure/Outcome3  
Assimes et al. 2008 (54) Nested case-control 3 2 3 8 
Azoulay et al. 2012 (33) Nested case-control  3 2 3 8 
Bergman et al. 2014 (34) Case-control  3 1 3 7 
Chang et al. 2016 (35) Nested case-control  3 1 (2 for versus AHT 
part) 
3 7 (8 for AHT part) 
Davis & Mirick 2007 (36) Case-control 4 1 1 7 
Devore et al. 2015 (37) Cohort 4 1 2 7 
Fitzpatrick et al. 1997 (38) Cohort 4 1 1 6 
Fryzek et al. 2006 (39) Cohort 4 1 3 8 




4 1 3 8 
Grimaldi-Bensouda 2016 
et al. (41) 
Cohort  
 
4 2 3 9 
Hole et al. 1998 (55) Retrospective, cohort  3 1 3 8 
Jick et al. 1997 (56) Nested case-control 3 2 3 8 
Lam et al. 2014 (42) Prospective, cohort 
 
4 1 2 7 
Largent et al. 2010 (43) Prospective, cohort  2 1 3 6 
Leung et al. 2015 (44) Case-control 3 2 3 8 
Li et al. 2003 (45) Case-control 4 1 (2 for versus AHT 
part) 
2 7 (8 for AHT part) 
Li et al. 2013 (46) Case-control 4 1 (2 for to versus AHT 
part) 
2 7(8 for AHT part) 
Meier et al. 2000  Case-control 4 1 3 8 
Michels et al. 1998 (58) Prospective, cohort  2 1 3 6 




Olsen et al. 1997 (59) Cohort  4 1 2 7 
Pahor et al. 1996  (60) Prospective, cohort  4 1 2 7 
Raebel et al. 2015 (49) Retrospective, cohort 4 1 (2 for main analysis) 3 8 (9 for main analysis) 
Rosenberg et al. 1998 (61) Case-control 2 1 3 6 
Saltzman et al. 2013 (50) Prospective, cohort 4 1 3 8 
Soldera et al. 2015 (51) Cohort 
 
4 2 3 9 
Sorensen et al. 2000 (52) Cohort 
 
3 1 3 7 
1= most important factor selected as hypertension/use of antihypertensive drugs, or an only hypertensive cohort (i.e. controlling for 
‘confounding by indication’). 
2. For adequate follow-up period criterion, this was set at study period of 5 years.   
3 = exposure for case-control and outcome for cohort studies. 
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1. Lack of allocation concealment, lack of blinding, large loss to follow-up or early cessation of trial/selective reporting outcomes considered. 
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